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Abstract
N eurom uscular disorders, which associate with muscle degeneration, are not rare and 
affect millions o f  people worldwide. The impacts o f  such disorders vary from gradual 
loss o f  mobility and independence to severe disability and death, and therefore 
m illions o f  patients suffer from them at every stage o f their life. Because, there is 
currently no treatment o f  any form o f  such disorders, this study was aimed to develop 
a novel treatm ent for such disorders.
For a long time it has been known that Insulin-like Growth Factor (IGF-I) influences 
several cellular processes, including proliferation, differentiation, repair and 
maintenance. Like m any genes, the IGF-I gene can be spliced to produce several 
isoforms, and in hum an muscle, it expresses at least two main isoforms which are a 
liver type, systemic form (IGF-I Ea) and an autocrine / paracrine form (IGF-I Ec). 
This second isoform has been named the Mechano Growth Factor (MGF) because o f  
its mechanosensitivity.
The in vitro and in vivo effects o f  these two splice variants o f the IGF-I gene were 
investigated in this study. In vitro roles o f  two splice variants o f  the gene were studied 
by the proliferation / differentiation effects o f  two alternative splice isoforms o f the 
gene in animal muscle cell lines (mouse C2C12 and rat L6 E9). Proliferation /
differentiation assays were carried out using human primary cell cultures from 
biopsied muscles from congenital muscular dystrophy (CMD), fascioscapulohumeral 
m uscular dystrophy (FSHD) and amyotrophic lateral sclerosis (ALS) patients as well 
as from healthy volunteers. Human primary muscle cells were treated with IGF-I Ea 
(long r  IGF-I) and MGF E domain peptides, and immunocytochemistry techniques 
with Desmin, DAPI and FITC markers were used to detect proliferation state o f 
myogenic commitment. The CPK and BCA protein assays were also used to 
determ ine the differentiation state following such peptide treatments. The results 
showed that MGF significantly increased muscle stem (satellite) cell proliferation in 
both animal and human muscles, both in healthy and in severe muscle wasting 
disorders. E dom ain o f  MGF dramatically increased proliferation in progenitor cell in 
CMD (68%), FSHD (74% ) and ALS (49%) primary cultures. The results also 
confirmed that the M GF had no effect on myotube formation but that it increases 
myoblast progenitor cell proliferation, whilst systemic IGF-I peptide (IGF-I Ea) 
increased cell differentiation and facilitated myotube formation.
The effects o f two IGF-I splice variants in muscle fibre growth were also studied in 
relation to Duchenne M uscular Dystrophy (DMD) by in vivo gene transfer method 
using the mdx mouse model. Such effects were investigated in both young and old 
mdx mice TA muscles by intramuscular injection o f cDNAs in plasmid vectors 
pcD NA 3.1NT/GFP. Maximum muscle tetanic contractile force was measured to 
determine the changes o f  muscle strength at 21 days after gene injection. The results 
showed that cDNA o f  MGF dramatically increased muscle fibre strength in young 
mdx mice (37 %) in only 3 weeks time. The MGF also increased muscle strength and
i v
mass in the older mdx mice but to a moderate level (11%). In mdx mice, the changes 
in gene expressions o f  satellite cell markers (M yoD and myogenin) were determined 
by quantitative real-time reverse transcriptase PCR, 21 days after injection o f the gene 
constructs into TA muscle comparing with TA muscle o f untreated leg. The results 
showed that MGF had an effect in satellite cell activation, and it activated quiescent 
satellite cells in mdx mice.
This study showed that MGF has a significant effect in both in vitro and in vivo 
m odels, which were used in relation to treatment o f  muscle degeneration in DMD, 
CM D, FSHD and ALS. The study also showed that MGF has considerable potential 
to use as a therapeutic agent to treat muscle degeneration in such neuromuscular 
disorders.
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Chapter 1 • Part 1:
1.1 Introduction
1.1 Introduction
The impacts o f  musculoskeletal / neuromuscular diseases and the conditions, which 
associate with m uscle wasting / weakness / loss, worldwide are enormous. The 
musculoskeletal / neurom uscular diseases and conditions vary from gradual loss o f 
mobility and independence to severe disability and death: and loss o f  work hours. The 
treatment o f  such diseases and conditions cost in the order o f 250 billion US dollars 
per year (Goldspink and Noble, 2006). All muscular / neuromuscular disorders 
characterised by m uscle wasting and weakness, and they affect human beings (both 
sexes, males and females) at every stage o f life: in their infancy, childhood, 
adolescence, adulthood, and also in their lates years. In addition, during the aging, 
mammals lose up to a third o f  their skeletal muscle mass and strength (Barton-Davis 
et al, 1998). Furthermore, the aged population in the developed world is continuing to 
expand.
The neurom uscular disorders including muscular dystrophies are not rare. The 
incidence o f neurom uscular disorders in general is 1 in every 1,000 births, (those o f 
muscular dystrophies are almost 1 in every 2000) (http://www.distrofia- 
mexico.org/diadm/ingles.htm). According to this rate, currently, there might be more
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than 6 millions patients with neuromuscular disorders worldwide. These problems are 
seen worldwide, with no country or region being an exception. World Health 
Organisation and others predict that some o f  these diseases and conditions will 
increase dram atically in the next two decades (Goldspink and Noble, 2006). However, 
now, there is no effective treatment o f  any form o f such disorders and conditions. 
Therefore, it seems that the treatment for such muscle conditions associated with 
neuromuscular / m usculoskeletal disorders / diseases will be more important in the 
near future, and it will thus be given high priority. Thus, the aim o f  this study was to 
attempt a novel gene therapy application for treating muscle degeneration in such 
disorders.
On the other hand, it is known that that IGF-I has very important roles in cell and 
tissue development and growth, including proliferation, differentiation, repair and 
maintenance, in m any tissues, especially in skeletal muscle in many species. Like 
many genes, the IGF-I gene can be spliced to produce several isoforms, and in human 
skeletal muscle, it expresses at least two main isoforms which are a liver type, 
systemic form (IGF-I Ea) and an autocrine / paracrine form (IGF-I Ec / MGF). The 
recent publications strongly suggest that one o f IGF-I isoforms, MGF, has a crucial 
role in tissue growth and repair, particularly in skeletal muscle in mice and rabbits. 
Such studies show that MGF acts as a general repair factor. These splicing variants o f 
the IGF-I gene were therefore used in this study as gene therapy agents.
The experiments in this study were designed to two main parts: in vitro cell culture 
model and in vivo gene transfer method using the mdx mouse model. In in vitro cell
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culture experiments, the roles o f  the isoforms o f  IGF-I gene in cell proliferation and 
different were investigated in different mammalian skeletal muscle cells (mouse, rat 
and human) with and without different neuromuscular disorders such as CMD, FSHD 
and ALS.
In in vivo animal experiments o f the study were separated into two parts after 
injecting cDNAs constructs o f IGF-I splice variants into TA muscles o f  mdx mouse, 
which is a mouse model o f  human Duchenne M uscular Dystrophy (DMD). In the first 
part, the effects o f  two IGF-I splice variants in muscle fibre growth were investigated 
in order to study the roles o f  such variants in DMD as gene therapy agents.
The damaged or degenerated muscles need extra nuclei o f the muscle satellite (stem) 
cells for regeneration and repair. All muscular / neuromuscular disorders are 
characterised by m uscle wasting and weakness. It is apparent that activation o f the 
quiescent satellite cells and providing extra nuclei is crucial for treating such 
disorders. The second part o f  in vivo animal model experiments was therefore 
designed for investigating the roles o f such variants in satellite cell activation. The 
changes in gene expression and mRNA transcripts o f satellite cell markers (MyoD 
and myogenin) were determined by quantitative real-time R-T PCR.
The in vitro data o f  this study clearly showed that MGF increased cell proliferation 
dramatically both in healthy and degenerative muscle cells. The in vivo data showed 
that MGF increased muscle fibre growth in DMD by increasing muscle force. The 
study also showed that MGF activated satellite cells. Thrawout this study, in vitro and
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in vivo data strongly suggested that MGF might be suitable as a therapeutic agent to 
treat muscle degeneration in neuromuscular disorders, such as DMD, CMD, FSHD 
and ALS as well as other wasting conditions. Thus, gene therapy applications using 
MGF transfer into skeletal muscle could therefore be an effective technique.
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Chapter 1 - Part 2:
1.2 Background Information and
Literature Review
1.2.1 Muscle
In nature, motion is one o f  the basic phenomena o f  life. In many animals muscle 
tissue has a crucial role in this motion and is involved in life sustaining processes such 
as respiration. In human and most animals, muscle accounts for about 40% o f the 
body mass and although there are relatively few diseases o f muscle, those, which 
affect muscle mass and muscle function are usually life threatening (Goldspink and 
Hansen. 1993, Emery and Muntoni, 2003).
The human body has three types o f muscle tissues, which differ in function and form: 
skeletal muscle, cardiac muscle and smooth muscle. The skeletal muscle cells are 
long, cylindrical, cross-striated and multinucleate. They are organised into muscles 
that are responsible for the gross and fine movements o f limbs and the maintenance o f 
the body position and posture. The cardiac muscle cells are short, branched, cross- 
striated and usually with a single nucleus. They are confined to the heart and are 
rhythmically contractile. The smooth muscle cells are spindle-shaped, non-striated
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and with a single, central nucleus. They are mainly found in vascular system, 
digestive tract and in uterus. (Martini, 2001; Tortora and Grabowski, 2003).
1.2.1.1 The skeletal muscle
1.2.1.1.1 The structure of skeletal muscle
The skeletal muscle tissue is composed o f  bundles o f  multinucleated muscle cells, 
called muscle fibers or myofibres, which are surrounded by a plasma membrane 
(sarcolemma). They are very different from that o f mononucleated cells. They are 10 
to 100 pm in diam eter and from a few millimetres to several centimetres long. They 
contain up to several thousand nuclei derived from the fusing o f myoblasts in fatal 
and postnatal life. Each muscle cell (myofibre) is packed with bundles o f thick 
(myosin) and thin (actin) filaments, and organised into myofibrils.
As can be seen from Figure 1.1, myofibrils are subdivided into A bands (dark bands) 
and I bands (light bands). A bands are bisected by H zone, and M line, a dark line, and 
I bands are bisected by Z disk or Z line, a different dark line. The segment between 
two Z disks is termed a sarcomere, and consists o f two halves o f  an I band and an A 
band. The sarcom ere is the structural and functional unit o f skeletal muscle. Each 
sarcomere contains two types o f filaments, thick filaments (myosin II) and thin 
filaments (a-actin). (Lodish et al, 2001).
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Bundle o f -----------
muscle fibers
Single muscle fiber 
(cell)
Z line
I band A
Thick filaments 
(myosin)
Thin filaments 
(actin)
OS Hm
I band
Figure 1.1: Skeletal muscle structure. (Taken from the web page at
http://fajerpc. magnet.fsu. edu/Education/2010/Lectures/3 7 Muscle System Jiles/imageO I O.jpg)
1.2.1.1.2 Contraction mechanism of skeletal muscle
Skeletal muscles contract according to the sliding-filament theory, proposed by Hugh 
Huxley in 1954 (Huxley and Hanson, 1954). According to this theory, the thin (actin) 
filaments slide on the thick (myosin) filaments so that the actin and myosin filaments
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overlap to a greater degree. In a relaxed muscle fiber, the thick and thin filaments 
overlap just slightly. However, when muscle fibers are stimulated by the nervous 
system, cross-bridges latch on to myosin binding sites on actin in the thin filaments, 
and sliding filament mechanism starts (Marieb, 2001).
The stimulations (the action potential) reaches to muscle fibers by the axon of a motor 
neuron. The stimulation activates calcium ion (Ca2+) channels on the axon. At the 
neuromuscular junction, the acetylcholine (ACh) was released by the synaptic 
terminal, binding to receptors on sarcolemma. The action potential reaches to 
sarcoplasmic reticulum through the T tubule. The sarcoplasmic reticulum releases 
stored Ca2+, increases Ca2+ concentrations of the sarcoplasma in and around the 
sarcomeres. Ca2+ binds to troponin C on the thin filaments of the myofibrils, 
activating the troponin-tropomyosin complex, and exposes active sites on the thin 
filaments. When myosin heads bind to active sites myosin cross bridges form and the 
contraction begins (Martini, 2001).
The binding site is powered by the hydrolysis of ATP. The myosin, which is bound to 
ATP, binds to the newly binding sites on the thin filaments, and then hydrolyses ATP 
to release ADP and an inorganic phosphate (Pi), providing energy to deliver a power 
(working) stroke. The releasing of ADP and Pi causes the myosin head to turn. 
Myosin is now bound in the strong binding sites. This event produces filament 
sliding, pulling the Z bands towards each other, and also shortens the sarcomere and 
the I band, which are shown in Figure 1.1 (Martini, 2001).
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When the action potential ceases Ach is removed by acetylcholinesterase (AchE). The 
sarcoplasmic reticulum reabsorbs Ca2+, and the concentrations of Ca2+ in the 
sarcoplasm decreases. When Ca2+ concentration comes to normal resting levels, the 
troponin-tropomyosin complex returns to its normal position. This event re-covers the 
active sites and prevents further cross-bridge interaction. Without cross-bridge 
interactions, no more sliding can occur, and then the contraction ceases. Finally, 
muscle relaxation takes place, and muscle returns passively to resting length position 
(Martini, 2001).
1.2.1.1.3 Embryologic origin of muscle tissue
Muscle is a derivation of mesodermal cells. All vertebrate skeletal muscles (apart 
from head and neck muscles) are derived from mesodermal precursor cells originating 
from the embryonic somites (epithelial spheres of paraximal mesoderm) 
(Buckingham, 2001; Buckingham et al, 2003; Parker et al, 2003; Zhao and Hoffman, 
2004; Charge and Rudnicki, 2004). The limb muscles, which are among the cells used 
in in vitro part of this study, arise from myogenic precursors located in the somites 
(lateral half / dorsal part of the somites), particularly leg muscles originate from 
somites 26-33 (Valasek et al, 2005). The limb muscles are also are innervated by 
spinal nerves (Yu et al, 2002). On the other hand, the muscles of the head and cervical 
region, including cranial, neck and face muscles, are originated in the somitomeres, 
which are from the branchial arch region of the early embryo (Larsen, 1998; Carlson, 
1999; Buckingham et al, 2003). For instance, the craniofacial masseter muscles, 
which again are amongst the cells used in this study, are derived from the sixth cranial 
somitomere and innervated by cranial nerves (Noden et al, 1999; Buckingham, 2001;
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Yu et al, 2002). In brief, while the somites are differentiated into lower body muscles, 
the somitomeres are differentiated into the head and neck muscles.
1.2.1.1.4 The differences among skeletal muscles
Along with the differences of the embryologic origins, there are also some 
anatomical, physiological, biochemical, functional, compositional differences 
between muscles, muscle groups and muscle regions. A big diversity in fiber-types, 
and motor tasks among such muscles / groups / regions is seen (Korfage et al, 2005a; 
Korfage et al, 2005b). Large differences in fibre-type composition were observed 
among individuals, individual muscles, muscle groups and muscle regions (e.g., jaw 
muscles and limb muscles). For instance, the jaw muscles are quite active during a 
large variety of motor task, including mastication, biting, speech, and swallowing. 
(Korfage et al 2000; Korfage et al, 2005a; Korfage et al, 2005b).
1.2.1.1.5 The Myogenesis of Skeletal Muscle
The mature skeletal muscle fiber is a complex multinucleated cell. Up to this stage, 
the mammalian skeletal myogenesis proceeds thraw three stages: (a) the 
determination of muscle progenitor cells, (b) proliferation, and then (c) differentiation 
into mature muscle.
Initially, somites, which are collections of embryonic mesodermal cells, transform 
into myoblasts. These myogenic progenitor cells undergo mitotic divisions 
(proliferation), become postmitotic myoblasts due to the action of a set of 
transcription factors such as myogenin and MyoD (Davis et al, 1987; Goldspink and
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Hansen, 1993; Hawke and Garry, 2001; Dhawan and Rando, 2005) and growth factors 
such as fibroblast growth factor (FGF) and transforming growth factor (TGF) 
(Carlson, 1999; Carlson, 2003; Dhawan and Rando, 2005). Further details about other 
transcription factors and growth factors, which have roles in myogenesis, can be 
found in other related sections of this thesis.
Postmitotic myoblasts differentiate into multinucleated myotubes by cellular fusion. 
The myotubes contain many nuclei but share a common cytoplasm. Subsequent to the 
fusion into myotubes, there is no further mitotic division of the muscle cells. The 
myotubes then develop into myofibres after innervation and attachment to the 
skeleton. This is the final stage o f  skeletal muscle differentiation.
In the course o f adult muscle fiber growth, the extra nuclei are derived from satellite 
cells. There are residual mononucleated myoblasts, which take up positions between 
the muscle fibers and basal lamina. The myoblasts fuse to multinucleated myotubes 
and then to the muscle fibers.
Satellite cell Myoblasts Myotube Myofibre
Figure 1.2: Myogenesis of Skeletal Muscle
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1.2.1.16 Gene Expression in the skeletal muscle
Different gene families are involved in skeletal muscle development and functions: 
these include the myogenic regulatory factors (MRF), growth factors and the 
structural genes, e.g.: myosin heavy chain genes (MHC) and myogenic genes. For 
instance, MRFs initiates the terminal myogenic differentiation program by 
upregulating the genes such as those encoding myosin heavy chain, creatine kinase 
and sarcomeric actin proteins (Dhawan and Rando, 2005).
MHC isoforms expressed in skeletal muscles are encoded by a multigene family and 
are expressed in different developmental stages and fiber types. In humans and mice, 
skeletal myosin heavy chain (MHC) genes are clustered on chromosome 17p and 11 
(Weiss et al, 1999).
The different molecular motors are encoded by different myosin heavy chain 
isogenes. These isogenes comprise a family of separate genes. The regulation and 
switching of different myosin heavy chain isogenes play a role during growth and 
adaptation in skeletal muscle (Goldspink, 1998).
The first skeletal muscle fibers to form in vertebrate embryos appear in the somitic 
myotome. There are fast and slow myosin heavy chain mRNA transcripts within 
myotomal fibers. Firstly, the embryonic fast myosin heavy chain isoform is expressed, 
and then the slow myosin heavy chains 1 and 3, and slow myosin heavy chain 2 
(Sacks et al, 2003). The myogenic regulator factor genes play an important part in 
muscle development. One of these is MyoD. The MyoD gene plays a key role in
30
muscle development. Other genes such as Myf5, myogenin and Mrf4 are also 
involved in the development (Lodish et al, 2001).
1.2.1.2 Satellite cells
Investigations of adult mammalian organs have revealed tissue specific progenitor 
cells in almost every tissue (Sun et al, 2003). These progenitor cells are involved in 
normal tissue turnover and repair while some others undergo self-renewal. They are 
mostly multipotent progenitor cells, that is, cells capable of different lineages under 
certain conditions (Lakshmipathy and Verfaillie, 2005). Therefore, most of them can 
also be considered as stem cells (Weismann, 2000). In muscle tissue, such stem cells 
are the satellite cells (Partridge, 2004); in other words, the satellite cells are the 
primary stem cells in adult skeletal muscle (Collins and Partridge, 2005). The satellite 
cells provide a reserve capacity to add to or to replace the nuclei in differentiated 
muscle fibres.
The satellite cells are characterized by their location, lineage markers such as Pax-7, 
myogenin, MyoD and others, myogenic potential and ability to change in response to 
extrinsic and intrinsic signals including exercise, muscle damage, increased workload, 
electrical stimuli and degenerative muscle diseases (Dhawan and Rando, 2005; 
Goldspink, 2005).
Satellite cells have long been considered a distinct myogenic lineage responsible for 
postnatal growth, hypertrophy, regeneration, repair, and maintenance of the skeletal 
muscle (Dhawan and Rando, 2005; Seale et al, 2000). The skeletal muscle satellite
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cells were first described in frog muscles in 1961 (Mauro, 1961; Katz, 1961) and then 
identified in adult avian and mammalian muscle (Schultz, 1976; Armand et al, 1983). 
They are thought to be the main source of new myonuclei in postnatal muscle (Moss 
and Leblond, 1971).
The numbers of satellite cells are very low in vivo (Dhawan and Rando, 2005). In the 
first few weeks after birth, the number of satellite cells in a rodent declines from about 
30% to less than 5%. However, in adults, the number remains almost constant 
although the satellite cells numbers per fiber differ in fast-twitch and slow-twitch 
fibres (Schultz and McCormick, 1994).
For a while now, a debate about the reason of the low number of satellite cells has 
been going on. The debate concerns the question whether there is a considerable 
decline in satellite cell numbers with age, or a functional decline in their activation 
rather than a true loss o f such cell number until very old age (Conboy et al, 2003; 
Dhawan and Rando, 2005).
1.2.1.2.1 The molecular mechanism of satellite cell quiescence, activation 
and self-renewal I replenishment
Every myofibre is associated with a number of satellite cells. In normal (healthy) 
adult muscle, satellite cells are mitotically quiescent, and become activated to divide 
in response to signals from exercise, muscle damage and/or increased workload and 
degenerative muscle diseases. Subsequent to the division, activated satellite cells 
become fusion competent myoblasts, they then differentiate into multinucleated
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myotubes (Dhawan and Rando, 2005), and finally incorporate into mature muscle 
fibres as post-mitotic myonuclei (Biscoff, 1994).
1.2.1.2.2 Satellite cell quiescence
Some evidence suggests that the satellite cell quiescent state is under active 
transcriptional control (Yusuf and Fruman, 2003). The quiescent satellite cells express 
various proteins, which are also used for the identification and purification of such 
cells. Some of these markers are CD34 (Beauchamp et al, 2000), M-cadherin 
(Beauchamp et al, 2000), Pax-7 (Seale et al, 2000), syndecan-3, syndecan-4 and c-met 
(Comelison et al, 2001). Myostatin is also expressed in quiescent satellite cells and 
McCroskery et al suggest that myostatin might actively promote the quiescence 
(McCroskery et al, 2003). Epigenetic mechanism and cytoskeleton might also play a 
role in the satellite cell quiescence (Dhawan and Rando, 2005). Grigoryev et al 
suggest that epigenetic mechanism induce and maintain quiescence in other lineages 
(Grigoryev et al, 2004; Dhawan and Rando, 2005). Grigoryev et al showed that major 
changes in epigenetic chromatin markers in centomeric heterochromatin and non- 
centomeric chromatin go with the reactivation of quiescent T-lymphocytes from 
mouse spleen. They examined the levels and intranuclear localization of major histone 
modifications and non-histone heterochromatin proteins in quiescent and reactivated 
mouse spleen lymphocytes. According to authors, reciprocal changes in the locations 
of these two proteins were observed in activated lymphocytes and cultured mouse 
fibroblasts induced into quiescence (Grigoryev et al, 2004). On the other hand, 
Dhawan and Helfman suggest that the cytoskeleton is a key regulator of proliferation: 
perturbation of microfilament-dependent signalling system in culture leads to
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reversible quiescence (Dhawan and Helfman, 2004, Dhawan and Rando, 2005). 
Dhawan and Rando also suggest that the core program of quiescence is probably 
conserved, and might be important in the maintenance of satellite cell quiescence 
(Dhawan and Rando, 2005).
1.2.1.2.3 Satellite cell activation
The satellite cell activation is a multi-step process. The localisation of the satellite 
cells and the communication between myofibres and satellite cells are very important 
for the maintenance of quiescence. Therefore, any disturbance of the satellite cell 
environment can lead to its activation (Dhawan and Rando, 2005). When quiescent 
satellite cells receive an activating signal, they exit from the quiescent state and go to 
the transition from Go to Gi phase of the cell cycle. After entering into their first 
cycle, they proceed thraw a highly proliferative intermediate progenitor stage and thus 
become intermediate progenitors. The intermediate progenitor stage is strongly 
regulated by the Notch signalling pathway (Conboy and Rando, 2002). These 
progenitors can be characterized by declining CD34 and high levels of Pax3 and 
Pax7. The progenitors then exit from this progenitor stage and progress to the fusion -  
competent myoblast stage and express Desmin (Dhawan and Rando, 2005). The 
myoblasts then progress to the fusion for myogenic differentiation stage, and become 
multinucleated myotubes. Finally myotubes differentiate into mature muscle fibres.
To sum up, the following factors and pathways have been identified as playing 
significant roles in satellite cell activation: signal transduction pathways, including 
expressing of c-met, syndecan-3, syndecan-4 and CXCR4; hepatocyte growth factor
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(HGF) -  c-met pathway; fibroblast growth factor (FGF) family pathway; and also, as 
mentioned above, the Notch signalling pathway (Dhawan and Rando, 2005).
1.2.1.2.4 Satellite cell replenishment and return to quiescence
Some intermediate progenitors do not progress into myoblast stage, and myogenic 
lineage. They remain in this progenitor stage until they return to quiescence as 
renewed satellite cells. Although the molecular mechanism o f satellite cell 
replenishment remains unclear, there are some scenarios, such as the Numb scenario. 
The Numb is a Notch signalling inhibitor. For the Numb scenario, the daughter that 
inherits Numb, the signalling inhibitor, progresses along myogenic lineage and 
become myoblast; on the other hand, a daughter that does not inherit Numb returns to 
quiescence (Dhawan and Rando, 2005).
Quiescent satellite cell
/
/  I \
 Activated satellite cell Int. progenitors Myoblasts
Myoblasts Myotubes /  9 /  /$ #/ Sat. cells & myofibres
Figure 1.3: Satellite cell quiescence, activation, proliferation, differentiation and selfrenewal.
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1.2.2 Growth Factors
Growth factors (GFs) are one o f the major regulators o f postnatal body growth. Some 
growth factors and hormones, such as Insulin-like Growth Factors (IGFs), Fibroblast 
Growth Factor (FGF), Transforming Growth Factor (TGF), and Thyroid Hormone, 
are involved in muscle cell proliferation and/or differentiation (Goldspink et al, 1993). 
Growth Factors are proteins that bind to receptors on the cell surface, with the primary 
result o f  activating cellular proliferation and/or differentiation, and are essential to 
growth and repair. Some growth factors are quite versatile, stimulating cellular 
division in num erous different cell types, while others are specific to a particular cell- 
type depending upon the dose.
There is a range o f  these growth factors in serum, including Hepatocyte Growth 
Factor (HGF), Epidermal Growth Factor (EGF), Erythropoietin (Epo), Fibroblast 
Growth Factor (FGF), Interleukins, Nerve Growth Factor (NGF), Platelet Derived 
Growth Factor (PDGF), Transforming Growth Factor (TGF), Tumor Necrosis Factors 
(TNF), Vascular Endothelial Growth Factor (VEGF).
1.2.2.1 Insulin-like Growth Factor System
The Insulin-like Growth Factor (IGF) system is a highly conserved signal system for 
the control o f embryonic and postnatal development in vertebrates. In mammals, IGFs 
act thrawout the body and are regulated by a system o f receptors, binding proteins, 
proteases and binding protein related proteins. The IGF system is a large family. It has 
two ligands (IGF-I and IGF-II), two high - affinity cell surface receptors (IGF1R and 
IGF2R), at least six high -  affinity IGF binding proteins (IGFBP-1, IGFBP-2, IGFBP-
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3, IGFBP-4, IGFBP-5, IGFBP-6), at least nine low -  affinity binding protein related 
proteins (IGFBP -  rPl to IGFBP -  rP9) and multiple binding protein proteases. Figure 
1.4 shows the components of IGF system.
High-affinity IGF binders
150k0a complex  ^30kDa complex
IGFBP-1 IGFBP-2 IGFBP-3 IGFBP-4 IGFBP-5 IGFBP-6
Low -affinity  IGF b in d e rs  
B
IGFBP-rPs
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IGFBP IGFBP proteolysed 'A
fragments IGF-I / IGF-Iproteases M 6P,
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Extracellular
Intracellular
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Type I IGF 
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Type II IGF 
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Figure 1.4: IGF System. Abrr: IGF-I and IGF-II: IGF I and II: IGFBP: IGF binding protein, 
IGFBP-rP: IGF binding protein related protein and M6P: Mannose - 6 - Phosphate, a: a 
subunit o f IGF-IR: fi: p  subunit of IGF-IR. A: IGF binding proteins, B: IGFBP related 
proteins, C: Proteases, D: IGF-I and/or IGF-II, E: IGF receptors (A dapted from Hw a et al, 
1999).
1.2.2.1.1 The historical background of IGF system
The Insulin-like Growth Factors (IGF) were first identified in 1957, when W. Salmon 
and W. Daughaday reported a serum factor(s) that mediated cartilage sulfation and the 
bone growth activity o f growth hormone (GH). This factor was therefore termed the 
“sulfation factor” and was produced by hepatic cells after exposure to GH (Salmon 
and Daughaday, 1957). Nearly a decade later, in 1966, the factors were renamed as 
nonsuppresible insulin-like activity I / II (NSILA I/II)- (Froesch et al, 1966). Then, in
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the early 1970s, Dulak and Temin renamed them as multiplication-stimulating activity 
(MSA) (Dulak and Temin, 1973). During this period, Daughaday renamed them again 
as somatomedins (Daughaday, et al, 1972). In the 1970’s, it was discovered that both 
factors, NSILA and Somatomedin, might be very similar to insulin. Similarity to 
insulin was to be proven in the late 1970s, and based on this finding, the factor was 
finally renamed insulin-like growth factor I (IGF-I) (Rinderknecht and Humbel, 
1978a) and a short while later, insulin-like growth factor II (IGF-II) (Rinderknecht 
and Humbel, 1978b).
In addition to Insulin-like growth factors, in the early 1970s, it was also found that 
IGF-I competed for binding insulin receptors (Hintz et al, 1972). In 1975, it was 
suggested that at least two more receptors (apart from the insulin receptor) existed 
(Megyesi et al, 1975). In 1980, type I and type II insulin-like growth factor receptors 
(IGF-IR and IGF-IIR) were discovered (Rechler et al, 1980), and then the molecular 
sizes o f  all three receptors (IR, IGFIR and IGFIIR) were determined in the early 
1980s (M assague and Czech, 1982). More recently, the binding proteins o f IGFs 
(IGFBPs) were found (Jones and Clemmons, 1995).
1.2.2.1.2 IGF Receptors
IGF-I and IGF-II ligands interact with various cell surface receptors that particularly 
recognise and bind the IGFs. There are two known receptors in IGF system: IGF-I 
receptor -IGF-IR- (also known type 1 IGF receptor), and IGF-II receptor -IGF-IIR- 
(also known type 2 IGF receptor or cation -  independent mannose-6-phosphate 
receptor -M-6-PR-). IGF-IR has IGF mediated signalling functions, whereas IGF-IIR
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has currently no known IGF signalling function (Jones et al, 1995). Each receptor is 
the product of a unique gene (Jones and Clemmons, 1995).
1.2.2.1.2.1 Type 1 IGF receptor (IGF-IR)
IGF-IR binds both IGF-I and IGF-II with high affinity. This receptor has been 
identified in essentially all tissues except liver, and virtually all of the biological 
activities of the IGFs result from binding to the type 1 receptor. IGF-IR (and also IR) 
is a transmembrane tyrosine kinase receptor. It has two extracellular a subunits and 
two membrane spanning p subunits which form a P-a- a-p arrangement (Figure 1.5). 
As can be seen from Figure 1.5, the major ligand binding determinants are located 
within the a  subunits and the intrinsic tyrosine kinase domain is located in the 
cytoplasmic part o f the P subunits (Denley et al, 2005, Adams et al, 2000).
a  subunits
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Figure 1.5: IGF-I receptor
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1.2.2.1.2.2 Type 2 IGF receptor (IGF-IIR)
IGF-IIR binds IGF-II with high affinity but binds IGF-I with very low affinity and 
does not bind insulin (Denley et al, 2005). IGF-IIR has no intrinsic signalling 
transduction capability. It appears primarily to be involved in clearance and 
degradation o f  IGF-II. This is also the cation-independent mannose-6-phosphate 
receptor used for targeting mannosylated enzymes to lysosomes (Denley et al, 2005).
1.2.2.1.2.3 Insulin (IR) and hybrid (IGF-IR/IR) receptors:
The insulin receptors -IR - (IR-A and IR-B) and hybrid IGF and insulin receptors 
(IGF-IR/IR) can also interact with IGFs, but insulin receptors (IRs) bind IGF-I with 
100-fold lower affinity than insulin. The insulin receptor has two isoforms: insulin 
receptor exon 11 +ve (IR-B) and insulin receptor exon 11 -v e  (IR-A). IR-B has low 
affinity for the IGFs. High concentrations o f IGF may stimulate insulin signalling 
thraw this receptor. However, it has recently been discovered that IGF-II binds to IR- 
A with high affinity (D enley et al, 2005; Pandini et al, 2002).
1.2.2.1.3 IGF Binding Proteins (IGFBPs)
IGF Binding Proteins (IGFBPs) are a family o f  at least six circulating proteins 
(designated IGFBP-1 to IGFBP-6) which bind IGF-I and IGF-II with high affinity, 
therefore, they can also be called high affinity IGF binders (Hwa et al, 1999). In 
circulation, IGFBPs are carrier proteins for IGFs. In circulation, over 99 % o f IGFs 
are in complex with a member o f the IGFBP family, particularly with IGFBP-3; and 
less than 1% o f IGFs circulate in an unassociated form (Furstenberger and Senn,
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2002). In plasma, more than 90 % o f  circulating IGFs are bound to IGFBP-3 and 
IGFBP-3 I ALS complex (Fiirstenberger and Senn, 2002).
IGFBPs control distribution, function and activity o f the IGFs in various cells, tissues 
and body fluids by binding them. For high affinity IGF binding, both N- and C- 
terminal regions o f  IGFBPs are required; whereas in bindings IGFs with low affinity, 
they require just one o f  them, either N- or C- terminals. IGFBP-3 and IGFBP-5 can 
form a ternary complex with IGFs and acid labile subunit (ALS) (Denley et al, 2005, 
Hwa et al, 1999).
IGFBPs coordinate and regulate the biologic activity o f IGFs in several ways, such as,
a) To transport IGFs in plasma to deliver them to tissues; and to control their 
diffusions and effluxes from the vascular space; and therefore they determine 
physiological concentrations o f IGFs;
b) To increase the half life o f IGFs in circulation (less than 10 minutes to 12- 
15 hours) and to regulate clearance o f  the IGFs;
c) To modulate, inhibit, potentiate or facilitate actions o f IGFs and interactions 
o f IGFs with their receptors;
d) To provide specific binding sites for the IGFs in extracellular and 
pericellular space (Russo et al, 2005; Jones and Clemmons, 1995).
IGFBPs functions are site-specific. Until recently, it was thought that they act just by 
the sequestration o f  the IGF peptides, by preventing receptor interactions. However, 
there is increasing evidence that IGFBPs, such as IGFBP-3 and IGFBP-5, have also
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independent functions, even in intracellular actions (Davies et al, 2006; Duan and Xu, 
2005; Clemmons, 1998).
The mature peptides o f  IGFBPs are between 216 and 289 amino acids, and 24 and 43- 
45 kDa. Their concentrations are various. The concentrations o f IGFBP-2, 4, 5 and 6 
in serum are around 2-15 nM. But, that o f  IGFBP-3 in serum is quite high (about 100 
nM) and that o f  IGFBP-1 in serum is very low (relatively constant).
Although the liver is the major source o f  circulating IGFs, IGFBPs and ALS, most 
cell types produce one or more members o f the IGFBP family. Hepatocytes synthesize 
IGFBP-1, IGFBP-2, IGFBP-4 and ALS; and hepatic Kupffer cells synthesize IGFBP- 
2 and IGFBP-3. Again, IGFBP-3, IGFBP-4 and IGFBP-6 are expressed in vascular 
smooth muscle cells, while IGFBP-4 and IGFBP-5 are produced by a wide range o f 
osteoblast cells.
1.2.2.1.4 IGFBP related Proteins (IGFBP-rPs)
There are also 9 other binding proteins (designated IGFBP-rP-1 to IGFBP-rP-9) 
which bind IGFs with low affinity because they bind IGFs by just their N- terminal. 
The biologic activities o f  the IGFBP-rPs are currently unclear.
Although there are six binding proteins, some scientists have been suggesting seven 
binding proteins, including IGFBP-7. IGFBP-7 has been also called Mac25. Today, it 
is quite clear that IGFBP-7 is one o f the IGFBP related proteins (IGFBP-rPl), and not 
that o f  IGFBPs.
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The IGFBP-rPI (previously termed as Mac25 and IGFBP-7) has been independently 
cloned in various cellular systems, and thus has been previously identified as IGFBP- 
7 (Haugk et al, 2000; Oh et al, 1996), Mac25 (Swisshelm et al, 1995; Murphy et al,
1993) and is a tumour-derived adhesion factor (Akaogi et al, 1996), and also a 
prostacylin-stimulation factor (Yamauchi et al, 1994).
1.2.2.1.4 IGFBP Specific Proteases
In IGF system, there are also a range o f  IGFBP specific proteases including prostate- 
specific antigen (PSA), matrix metalloproteases, cathepsin, thrombin and serine 
proteases. Today, there is increasing evidence that IGFBP specific proteases are 
involved in the regulation o f  IGFBP functions and turnover. IGFBPs are cleaved at 
specific sites by those proteases. Following limited proteolysis, IGFBPs exhibit a 
reduced affinity for IGFs and some IGFBP fragments appear to have IGF independent 
activity (Baxter, 2000).
1.2.2.1.5 IGF Ligands
The IGF system has two ligands: IGF-I and IGF-II (Figure 1.6). Those two Insulin­
like Growth Factors, IGF-I and IGF-II, are both growth-promoting peptides. IGF-I 
and IGF-II, are single chain polypeptides, respectively 70 and 67 amino acids in 
length, w ith a highly conserved amino acid sequence, and complicated and conserved 
gene structures (W oelfle et al, 2005; Stewart and Rotwein, 1996; Daughaday and 
Rotwein, 1989; Rinderknecht and Humbel, 1978a; Rinderknecht and Humbel, 1978b). 
The mature peptides o f  IGF-I and IGF-II (70 and 67 amino acids) are very similar
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among mammals, birds and amphibians (Russo et al, 2005; Perfetti et al, 1994; Koval 
et al, 1994; Kajimato and Rotwein, 1991; Chan et al, 1990; Shimatsu and Rotwein, 
1987; Zapf and Froesch, 1986). Each of these IGFs has a number of variant forms, 
resulting from the use o f alternative gene promoters and alternative splicing. IGFs are 
structurally related to insulin and are in a class o f peptides that have a structure similar 
to proinsulin (insulin-like effects). The mature IGFs consist of B, C, A and D 
domains. Structurally, both IGFs resemble insulin in having two chains connected by 
disulfide bonds. Large parts of the sequences within the A and B domains are 
homologous to the A (a) and B (p) chain of human proinsulin. This sequence 
homology with insulin is 43 % for IGF-I and 41 % for IGF-II (Duan, 2005). Although 
IGFs and insulin are closely related in primary sequences and biologic activity, the 
IGFs are main growth factors for nearly all tissues in the body, whereas insulin 
predominantly regulates glucose uptake and cellular metabolism.
IG F -I IG F -II
Figure 1.6: IGF ligands, IGF-I and IGF-II.
IGF-I is one of the main growth factors that stimulates protein synthesis in almost all 
tissues including muscle tissue. It is also one of the main regulators of tissue mass 
during early life (McKoy et al, 1999; Daughaday et al, 1972). IGF-I is the primary
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mediator involved in the response o f  cells to growth hormone (GH). IGF-I plays a 
critical role in normal body growth. It induces cellular activities, including cell 
growth, differentiation, migration, and mitosis (Stewart and Rotwein, 1996); and has 
autocrine and paracrine activities in addition to the endocrine activities.
1.2.2.1.5.1 IGF-II
Human IGF-II gene has been localised on the short arm o f chromosome 11 (11 p 15). 
IGF-II consists o f  67 amino acids residue with a molecular mass o f 7.47 kDa. It is 
also a single chain polypeptide. The amino acid sequence o f IGF-II molecule is 62 % 
identical to IGF-I (Dupont and Holzenberger, 2003; Fiirstenberger and Senn, 2002; 
Rinderknecht and Humbel, 1978b). The IGF-II gene has 10 exons, including 4 leader 
exons, 1 alternative exon and 3 common (mature) protein-coding exons. The IGF-II 
gene has also 4 promoters ( p i -4) and these precede the common coding exons 7, 8 
and 9 exons (Rinderknecht and Humbel, 1978b).
In general, IGF-II acts as an embryonic and foetal growth factor, whereas IGF-I acts 
as a postnatal and adult growth factor. IGF-II plays a fundamental role in embryonic 
and foetal development (Davies et al, 2006). Although, in humans, IGF-II also 
expresses in the postnatal period and is produced in various tissues thrawout life, its 
role in the postnatal period seems to be less important. The serum concentration o f 
IGF-II is considerably higher than IGF-I (IGF-II: 400-600 ng/ml, IGF-I: 100-200 
ng/ml) (Dupont and Holzenberger, 2003).
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1.2.2.1.5.2 IGF-I
1.2.2.1.5.2.1 The Biochemical Structure and Expression of IGF-I gene
The human IGF-I gene has been localised on the long arm of chromosome 12 (12q22- 
12q24) (Brissenden et al, 1984) and human IGF-I cDNA was first characterised by 
Jansen et al. in 1983 (Jansen et al, 1983). Although human mature IGF-I peptide is a 
70 amino acid single-chained polypeptide and its size is just 7.65 kDa, its gene has 
over 100 kb o f genomic DNA (Tricoli et al, 1984). In humans, the expression of the 
IGF-I gene leads to the production of three different sizes of mRNA at 1.1, 1.3 and 
7.6 kilo bases (Rotwein, 1984). As it was mentioned above, the IGF-I is organised 
into four peptide domains: B, C, A, and D.
As can be seen from Figure 1.7, the IGF-I gene has 6 exons, four of which are 
alternatively spliced (Smith et al, 2002). Although they do not alter the structure of the 
mature peptide, the alternative splices generate different precursor peptides. Different 
tissues produce IGF-I for autocrine and paracrine actions (Stewart and Rotwein, 
1996). Exons 1 and 2 are promoter exons derived from different transcription start 
sites. Exons 5 and 6 are subject to a complex alternative splicing pattern. Exon 4 
usually splices to exon 6 but sometimes it splices to exon 5, representing 10% of IGF-I 
transcripts. A minor isoform results from splicing of exons 4 and 5, and from an 
alternative 5' splice site in exon 5 to exon 6. (Smith et al, 2002)
Figure I .7: IGF-I gene.
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IGF-I is synthesised in the liver systemically. In addition, both IGF-I and IGF-II are 
expressed in many non-hepatic tissues. Particularly during exercise, the major source 
o f circulating IGF-I is skeletal muscle (Goldspink and Yang, 2004). Thus, IGFs are 
expressed both systemically and locally and therefore, they have endocrine and 
autocrine / paracrine actions (LeRoith et al, 2001).
IGF-I expression is affected at many levels including gene transcription, splicing, 
translation and secretion. IGF-I expression is also affected by hormonal (GH), 
(Bichell et al, 1992; Meton et al, 1999), nutritional (Thissen et al, 1994), tissue- 
specific and developm ental factors (Russo et al, 2005; Dupont and Holzenberger, 
2003; Sara and Carlsson-Skwirut, 1994). The IGF-I has multiple isoforms that have 
specific functions and at least six main iso forms expressed by human muscle: Classes 
I and II IGF-I Ea, and IGF-I Eb and IGF-I Ec (MGF).
1.2.2.1.5.2.2 The Biological Actions of IGF-I
Insulin-like growth factor - I is an anabolic and mitogenic peptide. For a long time, a 
substantial amount o f  research showed that IGF-I plays a key role in growth and 
development (Jones and Clemmons, 1995; Stewart and Rotwein 1996; Dupont and 
Holzenberger, 2003), and has tissue - specific multifunction, involving several cellular 
processes including tissue proliferation (Jones and Clemmons, 1995; Stewart and 
Rotwein 1996), differentiation (Florini and Magri, 1989; Jones and Clemmons, 1995; 
Stewart and Rotwein 1996), maintenance (Yang et al, 1997) and repair (Adams, 1998; 
Goldspink and Yang, 2004) in almost all tissues including muscle, brain, nerve, bone, 
mammary glands, cartilage, pancreas, ovary, skin and fat tissues (Jones and
47
Clemmons, 1995; Stewart and Rotwein, 1996; Dupont and Holzenberger, 2003); and 
has autocrine and paracrine activities in addition to the endocrine activities.
IGF-I is not just produced by different tissues, but it also has different functions in 
different organ systems o f  the body, including the muscular, the digestive and gastro­
intestinal, the reproductive, the cardiovascular, and also peripheral and central 
nervous systems. IGF-I has some anabolic effects such as the stimulation o f the 
synthesis o f glycogen, lipids and proteins. It also increases glucose metabolism in 
adipose tissue and inhibits lipolysis (Reece et al, 1994).
It is currently quite clear that IGF-I and some other IGF system components have also 
key roles in the cell cycle (Furlanetto et al, 1994), aging (Dupont and Holzenberger, 
2003; Goodman-Gruen and Connor, 1997), lifespan (Dupont and Holzenberger,
2003), migration, mitosis (Stewart et al, 1996), apoptosis (Fiirstenberger and Senn, 
2002; Baxter, 2001) and cancer development (Davies et al, 2006; Fiirstenberger and 
Senn, 2002).
The mitogenic effects o f  IGF-I arise as a result o f  increased DNA synthesis. IGF-I 
upregulates the expression o f cyclin D1 (Gi cyclin), cyclin B1 (G2 cyclin) and cyclin- 
dependent kinases such as cdc2 and cdck2 (Furlanetto et al, 1994).
Serum IGF-I levels decrease with age (Goodman-Gruen and Connor, 1997). In 
postnatal and childhood period, until puberty, IGF-I levels increase slowly. During 
puberty, the increase dramatically rises and after puberty, the levels o f IGF-I begins to
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decrease slowly until old age. In elderly men and women, this level is very low 
(Goodman-Gruen and Connor, 1997).
Several studies have also suggested that the insulin / IGF signalling pathway may 
control body size and longevity in invertebrates (Gems and Partridge, 2001), and the 
growth hormone/IGF-I signalling axis may perform the same function in mammals 
(Bonkowski et al, 2006). Because, reduced calorie restriction extends longevity in 
organisms ranging from yeast to mammals. Mutations affecting somatotropic, insulin, 
or homologous signaling pathways can increase life span in worms, flies, and mice, 
and there is considerable evidence that reduced secretion o f insulin-like growth factor 
I and insulin are among the mechanisms that mediate the effects o f calorie restriction 
on aging and longevity in mammals. (Bonkowski et al, 2006). Those studies have 
shown that insulin/IGF signalling is a key regulator o f lifespan in both nematodes and 
flies (Dupont and Holzenberger, 2003).
1.2.2.1.5.2.3 IGF system and Cancer
For a while, numerous studies have shown that there is a link between serum 
concentrations o f  IGF-I and different IGFBPs, particularly IGFBP-3, (with an 
increased risk o f  breast, prostate, colorectal and lung cancers). Many studies have 
shown that high levels o f  IGF-I and low levels o f IGFBP-3 predict increased cancer 
risk (Fiirstenberger and Senn, 2002). The action o f IGF-I is predominantly mediated 
thraw the type I IGF receptor (IGF1R). IGF1R is also involved in several oncogenic 
transformation processes (Davies et al, 2006; Fiirstenberger and Senn, 2002).
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1.2.2.1.5.2.4 IGF system and Apoptosis
The IGFs also have a cellular action to inhibit cell death in certain situations 
(Haunstetter and Izumo, 1998). This action has been shown particularly in 
haematopoietic cells (W illiams et al, 1990; Jones and Clemmons, 1995). An 
increasing number o f  studies have shown the anti-apoptotic effect o f IGF-I and IGF 
system. In brief, IGF-I inhibits apoptosis by increased expression o f the bcl-xL 
(Parrizas and LeRoith, 1997).
1.2.2.1.5.2.5 IGF-I gene and its alternative splicing 
1.2.2.1.5.2.5.1 Alternative Splicing
After the discovery o f  exons and introns in the Adenovirus hexon gene in 1977 
(Sambrook, 1977), it was proposed that different combination o f exons could be 
spliced together to produce different mRNA isoforms o f a gene. This was therefore 
termed as alternative splicing (Gilbert, 1978).
In the beginning o f  the 1980s, alternative splicing was shown in several genes, and in 
the 1990s, it was estimated that 5% o f genes might have alternative splicing (Sharp, 
1994). Since then, the estimates o f the percentage o f  alternative splicing in human 
genes have increased dramatically. In recent years, different research groups 
estimated the percentage o f alternative splicing in human genes as follows: 22 % 
(Croft et al, 2000), 35 % (Miranov et al, 1999), 38 % (Brett et al, 2000), 42 % 
(Modrek et al, 2001), 55 % (Kan et al, 2001), at least 59 % (Int Hum Gen Seq Co. 
2001), up to 60% (Modrek and Lee, 2002), more than 75 % (Lynch, 2004; Johnson et 
al, 2003) and finally, 80 % (Lee and Wang, 2005).
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Although some genes have limited numbers of alternative splicing, some genes have a 
huge number of alternative splicing. For instance, alternative splicing o f dystrophin 
gene generates at least 16 different alternative transcripts (Sironi et al, 2002). On the 
other hand, the combinatorial alternative splicing of different exons of the neurexin 
gene generate up to 40,000 different isoforms (Modrek and Lee, 2002; Graveley, 
2001). At present, current studies indicate that primary transcripts from more than 80 
% of all human genes undergo alternative splicing, generating a great number o f 
protein isoforms (Lee and Wang, 2005). As can be seen below, similar to most of the 
genes, IGF-I gene also has different alternative splice variants in different conditions 
and tissues.
1.2.2.1.5.2.5.2 Alternative splicing of IGF-I
As explained before, the IGF-I gene has 6 exons, four of which are alternatively 
spliced (Gilmour, 1994; Smith et al, 2002), while the other two are common exons 
(exons 3 and 4) which encode mature IGF-I. The structure of human IGF-I gene and 
its alternative ways o f splicing are shown in Figure 1.8.
1 - ® ~
V
5’ UTR Mature IGF-I (A-D) E Domain
Figure 1.8: Human genomic IGF-I gene and its alternative splice variants ways
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Exons 1 and 2 are alternative leader exons (Gilmour, 1994; Goldspink and Yang, 
2004) with transcription start sites. Exons 1 and 2 are differently spliced to the 
common exon 3 and produce class 1 and class 2 IGF-I mRNA transcripts (Goldspink 
and Yang, 2004; Welle et al, 1993). Exons 3 and 4 code the mature IGF-I (B, C, A, 
and D domains) as well as the first 16 amino acids of the E domain. Exons 5 and 6 
code the alternative parts of the E domain and because of a reading frame shifts in the 
splicing of IGF-I Ec (MGF) (Goldspink and Yang, 2004). There is also a change in 
the coding.
Alternative splicing and / or inclusion of exons lead to a family of IGF-I mRNAs 
which all encode the same mature IGF-I; but they differ in sequences 3’. Exons 1 and 
2, which are 5’ leader exons, lead to two different sets of transcripts: Class 1 and 
Class 2. Classes 1 and 2 alternative splicing of IGF-I gene is shown in Fig. 1.9.
B i l l * ] — G O -
Class 1 - b -k n r  —
Mechanical signals 
including excercise 
and cell damage
-B-ftEZD-CZD-HI -0- 
49 bp insert
IGF-I Ea 
IGF-I Eb 
IGF-I EC (MGF)
m m — ] —3’ Human IGF-I
Hormonal signals (GH)
Class 2 l l ll M  II 1
-□H -iniM ZO —I-
IG PI Ea 
IGF-I Eb 
IGF-I EC (MGF)
49 bp insert
Figure 1.9: Human genomic IGF-I gene and its alternative splice variants expressed in 
skeletal muscle.
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As can be seen from Figure 1.9, Classes 1 and 2 alternative splicing of the primary 
IGF-I transcripts result in at least six different IGF-I mRNAs. These are: Class 1 IGF- 
I Ea (exons 1, 3, 4 and 6), class 1 Eb (exons 1, 3, 4 and 5), class 1 Ec (exons 1, 3, 4, 5 
and 6); class 2 Ea (exons 1, 3, 4 and 6), class 2 Eb (exons 1, 3, 4 and 5) and class 2 Ec 
(exons 1, 3, 4, 5 and 6) (Goldspink and Yang, 2004).
1.2.2.1.5.2.5.3 ProlGF-l proteins
The 3’ alternative splicing of IGF-I gene leads to three different proIGF-I proteins, 
which are, proIGF-IEa, proIGF-IEb and proIGF-IEc. ProIGF-IEb is the longest 
peptide which has 147 amino acid residues. ProIGF-IEa is the shortest peptide and has 
105 amino acid residues. IGF-IEc has 110 amino acid residues. All three proteins 
share a common mature IGF-I peptide, which has 70 amino acid residues, as well as 
the 16 amino acids sequence at N-terminal part of the E domain (Goldspink and Yang, 
2004). The different proIGF-I peptides can be seen from Figure 1.10.
Mature peptide 70 aa E domain
,------------------ A \ r  >>
ProIGF-I Ea (105 aa)
ProIGF-I Eb (147 aa)
ProIGF-I Ec (110 aa)
Figure 1.10: ProIGF-I proteins
n
n
16 aa
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1.2.2.1.5.2.5.4 The Alternative Splicing of IGF-I in Muscle Tissue
For a long time, it had been known that IGF-I was produced by the liver under the 
influence o f  growth hormone (GH). It is now realised that IGF-I is not just expressed 
by liver tissue, but also by many other tissues in the body, including muscle tissue. It 
is now known that IGF-I exists as different forms o f alternative splice variants, each 
o f  which has a different physiological action (Goldspink and Yang, 2004).
The skeletal muscle is a highly complex and heterogeneous plastic tissue which is 
capable o f  regenerating itself and o f remarkable adaptation in response to various 
stimuli including exercise. For a long time, it has been known that when a muscle is 
exercised, that particular muscle undergoes an increase in mass, but not all muscles o f 
the body. On the other hand, for sometime, it has been noted that IGF-I is up- 
regulated by skeletal muscle during exercise, and therefore, the expression o f the 
mRNA o f IGF-I increases as a result o f  exercise (DeVol et al, 1990; Czerwinski et al,
1994). Furthermore, Brahm et al showed that the exercise increased the circulating 
levels o f IGF-I. They showed that during extensive exercise, the large part o f the 
circulating IGF-I is derived from muscle, not by liver (Brahm et al, 1997). As well as 
skeletal muscle, IGF-I is also expressed by cardiac and smooth muscle (Goldspink 
and Yang, 2004).
Some recent studies have shown that at least two splice variants o f the IGF-I gene are 
expressed by skeletal muscle including human and animal muscles. The first isoform 
o f IGF-I is IGF-I Ea. This is expressed by muscles, even at rest. The IGF-I Ea is 
similar to the liver or the systemic / the hepatic endocrine type o f IGF-I and has a
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general anabolic action. Although the IGF-I Ea splice variant is expressed even in 
resting muscle, it is also expressed by active muscle, in response to mechanical 
stimuli including exercise. The first splice variant o f IGF-I has several abbreviations 
such as IGF-I Ea, L.IGF-I, m.IGF-I (Yang et al, 1996; McKoy et al, 1999; Hameed et 
al, 2003; Goldspink and Yang 2004).
The second isoform is expressed in muscle, only in response to mechanical activity. It 
was cloned by Yang et al (1996) in rabbit tibialis anterior muscles when subjected to 
an electrical stimulation, stretch and immobilisation model (Yang et al, 1996). This 
isoform was classified as IGF-IEb in rats and IGF-IEc in humans. This was termed as 
Mechano Growth Factor (MGF) in the literature because o f the mechanosensitivity o f 
its expression. The M GF is generated in muscle subjected to stretch and overload 
(Yang et al, 1996; M cKoy et al, 1999; Hameed et al, 2003; Goldspink and Yang 
2004).
According to Aperghis and Goldspink, muscle does not express only class 1 splice 
variants o f IGF-I mainly in response to mechanical activity, but it also expresses class 
2 variants (Goldspink and Yang, 2004). Adams’ group showed that those two splice 
variants’ expression kinetics are different with each other. Their research shows that 
the MGF is expressed earlier than IGF-I Ea (Haddad and Adams, 2002). Following 
muscle damage, firstly the MGF is produced. It lasts a day or so, and then MGF 
expression starts declining as IGF-I Ea increases. IGF-I Ea stays for much longer (Hill 
and Goldspink, 2003).
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1.2.2.1.5.2.5.5 The Alternative Splicing of the IGF-I Gene in Neuronal Tissue
The alternative splicing o f the IGF-I in neuronal tissue is similar to muscle tissue. 
Both isoforms, IGF-I Ea, and MGF, are expressed in brain and spinal cord. Aperghis 
et al showed that MGF has neuroprotective effects (Aperghis et al, 2004). CNS also 
express N-terminal truncated IGF-I iso form, des-N -(l-3) (Ballard et al, 1987; Szabo et 
al, 1988; Carlsson-Skwirut et al, 1989).
1.2.2.1.5.2.5.6 The Alternative Splicing of the IGF-I Gene in Other Tissues
The liver is the main source o f the circulating IGF-I. Different alternative splice 
variants o f IGF-I gene (IGF-I Ea, Eb and Ec) were first detected in the liver tissue. 
The cDNA o f  liver IGF-I (L.IGF-I or IGF-I Ea) was first reported in 1983 (Jansen et 
al, 1983). The second splice variant was expressed in human liver is IGF-I Eb, and it 
was detected in 1986 by Rotwein (Rotwein, 1984). The third variant, IGF-I Ec, was 
reported by Chew et al in liver cells in 1995 (Chew et al, 1995).
1.2.2.1.5.2.5.7 Mechano Growth Factor (MGF)
15 years ago, Professor Goldspink’s group showed that when the mature rabbit tibialis 
anterior (TA) muscle was electrically stimulated while held in the stretched position 
by plaster cast immobilization, muscle mass was increased by 35% just in 7 days 
(Goldspink et al, 1992). The group found considerably increased RNA in the stretched 
/ stimulated muscle, not in the resting control one. They then detected a RNA 
transcript from stretched / stimulated muscle using different oligonucleotides primers 
and RT-PCR. When the group analysed the sequence, they saw that it was derived 
from the IGF-I gene by alternative splicing (Yang et al, 1996). The newly discovered
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alternative splice variant had a different carboxyl peptide sequence and E-domain to 
liver type o f IGF-I and therefore it was differentiated from the systemic / liver type o f 
IGF-I (IGF-I Ea). The new splice variant has been classified as IGF-IEb in rats and 
IGF-IEc in humans. Because o f the confusion in terminology and its 
mechanosensitivity it was called Mechano Growth Factor (MGF).
As can been seen from Figure 1.9, alongside the common exons 3 and 4, the MGF 
differs by the inclusion o f 49 bp insert in humans, and (52 bp insert in rats) from the 
first part o f the exon 5 o f the E domain o f IGF-I gene. Neither 49 nor 52 bp are 
multiples o f 3. Therefore, the 3’ RNA sequence encodes for a different C-terminal 
peptide sequence than that the liver type o f IGF-I (Goldspink and Yang, 2004).
It has been shown in a recent C2C12 cell culture study that the systemic or liver type 
IGF-I (IGF-I Ea) activates differentiation into myotubes, whereas the MGF activates 
proliferation, and prevent differentiation by remaining in the mononucleated state. It 
has been also suggested that MGF has a role in the activation o f satellite cells (Yang 
and Golspink, 2002).
Furthermore, a very recent human muscle exercise study has shown that high 
resistance exercise results in MGF mRNA in the young, but not in the elderly 
(Hameed et al, 2003). The molecular weight o f MGF is 5 kDa and is expected to have 
a shorter half -  life than the liver IGF-I’s which are stabilized by binding proteins. 
Therefore the half-life o f  MGF is less than 10 minutes. The MGF is likely to act in an
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autocrine/paracrine mode o f  action rather than a systemic endocrine one (Hameed et 
al, 2002).
1.2.2.1.5.2.6 Therapeutic implications of IGF-I and IGF system
Our knowledge o f  IGF system has increased substantially in recent years due to the 
developments in molecular and cellular biology. We can now easily measure 
circulating levels o f  the members o f the IGF system in order to understand the 
possibly pathophysiological changes in certain clinical situations. We also now have 
an opportunity to identify the genetic alterations as the underlying cause o f such 
situations. The human beings with a variety o f  illnesses and different disorders have 
altered circulating IGF-I and IGFBPs levels (Pozo et al, 2005). Numerous studies 
have shown that these levels change in many diseases and disorders. The data 
provided from the circulating levels o f  IGFs bring about a new approach for treatment 
o f such clinical situations. So far, many therapeutic implications o f the components o f 
the IGF system have been applied to many clinical situations. Particularly using 
recombinant human IGF-I (rhIGF-I) or recombinant human IGF-I/IGFBP-3 complex 
has opened the potential for therapy for a wide range o f  pathological conditions 
(Savage et al, 2004). Therefore, the potential therapeutic applications o f IGF system 
are very broad. Studies have shown that IGF system does have some therapeutic 
effects, in one way or another, on several human diseases, ranging from 
neuromuscular or neurodegenerative diseases to growth disorders; from malignancy to 
diabetes (Monzavi and Cohen, 2002; Savage et al, 2004, Russo et al 2005). The 
following disorders have either been already treated in some way with the products o f 
IGF systems attempt this has been carried out mainly using animal models:
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• Traumatic / hypoxic or ischemic muscle and neuronal tissue damages including 
skeletal and cardiac muscle, peripheral and central nerve damages, MI, stroke, 
neuropathies, spinal cord injuries, brain ischemia. (Gluckman et al, 1992; Guan et al 
1993; Sharma et al, 1998; Guan et al, 2003; Goldspink and Yang, 2004; Cortes et al, 
2005; Dluzniewska et al, 2005; Russo et al, 2005);
• Neuromuscular disorders, including myopathies, muscular dystrophies and ALS 
(Singleton and Feldman, 2001; Mitchell et al, 2002; Kaspar et al, 2005; Russo et al, 
2005; Wilczak and Keyser, 2005);
• Neurodegenerative diseases, including ALS, Alzheimer, Multiple Sclerosis and 
Cerebellar ataxia (Dore et al, 2000; Gasparini and Xu, 2003; Watson and Craft, 2003; 
Carro and Torres-Aleman, 2004; Russo et al, 2005; Kaspar et al, 2005; Wilczak and 
Keyser, 2005);
• Growth disorders, including IGF-I gene defects, Growth Hormone Deficiency 
(GHD), Growth Hormone Insensitivity Syndrome (GHIS or Laron syndrome), 
Acromegaly, Idiopathic short stature (ISS) (Monzavi and Cohen, 2002; Savage et al,
2004);
• Endocrinal diseases, including type I and II diabetes, insulin resistance syndrome 
(Zenobi et al, 1992; Cheetham et al 1995; Thrailkill, 2000; Monzavi and Cohen 2002; 
Savage et al, 2004);
• Bone diseases, including osteoporosis (Rosen and Poliak 1999);
• C hronic inflammatory and nutritional disorders, including chronic inflammatory 
bowel diseases, Crohn’s Disease and Chronic Juvenile Arthritis (Savage et al, 2004);
• Different types of cancer, including breast, prostate, colorectal, lung cancers 
(Monzavi and Cohen 2002).
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1.2.3 Degenerative Muscle Disorders
1.2.3.1 Muscular Dystrophies
Muscular dystrophies (MDs) are a group o f  neuromuscular disorders which vary in 
their pathology and inheritance patterns. At least 30 different muscular dystrophy 
forms have been identified to date (Vainzof and Zatz, 2003). They all are inherited 
myogenic disorders characterised by progressive muscle wasting and weaknesses o f 
variable distribution and severity. They share a set o f clinical and pathological 
characteristics but vary in severity and inheritance pattern, and molecular defect. 
Muscular dystrophies are caused by loss o f the linkage between the extracellular 
matrix and the actin cytoskeleton (Laval and Bushby, 2004). The most common form 
o f M D ’s is Duchenne muscular dystrophy (DMD). DMD affects 1 in 3500 live male 
births (O ’Brien and Kunkel, 2001).
Nine major forms o f MDs are as follows: Myotonic muscular dystrophy (MMD, also 
known as Steinert's Disease), Congenital muscular dystrophy (CMD), Duchenne 
Muscular Dystrophy (DMD, also known as Pseudohypertrophic), Becker muscular 
dystrophy (BMD), Emery-Dreifuss muscular dystrophy (EDMD), Distal muscular 
dystrophy (DD -  Miyoshi MD), Facioscapulohumeral dystrophy (FSHD or FSH, also 
known as Landouzy-Dejerine), Oculopharyngeal muscular dystrophy (OPMD), Limb- 
girdle muscular dystrophy (LGMD) (Emery, 2002). Figure 1.11 shows the affected 
muscles in six different types o f muscular dystrophy.
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Figure 1.11: Muscle weakness in different types o f dystrophies. Shaded areas are the affected 
muscles. A: Duchenne and Becker, B: Emery-Dreifuss, C: Limb-Girdle, D: 
Fascioscapulohumeral, E: Distal and F: Oculopharyngeal. Taken from Emery, 2002)
The genetics o f many types o f muscular dystrophies have now been known in details. 
Different forms o f MDs have different pathology and inheritance patterns. Therefore, 
the gene loci and protein defects in the commonest forms o f muscular dystrophies 
vary. These are shown in Table 1.1.
Congenital MD (AR) 6q a 2-Laminin (merosin)
Congenital MD (AR) 12q Laminin receptor (a-integrin)
Congenital MD (AR) 9q Fekutin (Fukuyama dystrophy)
Congenital MD (AR) 1P Selenoprotein N1 (rigid spine syndrome)
Congenital MD (AR) 1p Glycosyltransferase (muscle -  eye -  brain disease)
Duchenne and Becker MD (XR) Xp21 Dystrophin
Emery -  Dreifuss MD (XR) Xq28 Emerin
Emery -  Dreifuss MD (AD/AR) iq Lamin A / C
Distal MD (AD) 14q,2q Not known
Distal MD (AR) 2p Dysferlin
Facioscapulohumeral MD (AD) 4q Not known
Oculopharyngeal MD (AD) 14q Poly (A) -  binding protein 2 (PAB 2)
Limb -  girdle MD (AD)
1 A 5q Myotilin
1 B 1 q Lamin N  C
1 C 3p Caveolin 3
1 D 6q Not known
1 E 7q Not known
1 F 2q Not known
Limb -  girdle MD (AR)
2 A 15q Calpain - 3
2 B 2p Dysferlin
2 C 13q y- sarcoglycan
2 D 17q a-sarcoglycan (adhalin)
2 E 4q p- sarcoglycan
2 F 5q 5-sarcoglycan
2 G 17q Telethonin
2 H 9q Not known
2 I 19q Fekutin-related protein
2J 2q Titin
Table 1.1: Gene loci and protein defects in the commonest forms o f muscular dystrophies. 
Abbr: AR: Autosomal recessive, AD: autosomal dominant, XR: X- linked recessive. (Adapted 
from Emery, A. E. H., 2002; and Bogdanovich et al, 2004)
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The different forms o f muscular dystrophy vary in their pathology and inheritance 
patterns. For instance, congenital muscular dystrophy is an autosomal recessively 
inherited disorder that presents hypotonia and weakness o f muscles. It has several 
different forms. Some, such as Fukuyama muscular dystrophy, occur with mental 
retardation and some transpire without it. The congenital muscular dystrophies are 
caused by the absence o f certain proteins such as merosin, laminin and fekutin in birth 
or within the first few months o f life (Emery, 2002). It is seen in severe and early 
contractures (shortening or shrinking o f muscles that cause joint problems). On the 
other hand, Duchenne Muscular Dystrophy (DMD) and its milder allelic variant, 
Becker muscular dystrophy (BMD) are X linked recessive disorders. DMD is caused 
by the absence o f  dystrophin protein that is encoded by the dystrophin gene which is 
the largest mammalian gene known. When some mutations, such as several types o f 
deletions and other rearrangements, occur in the gene, the dystrophin protein cannot 
be translated, except in the BMD where dystrophin protein is truncated. Figure 1.12 
shows the molecular pathologies o f different forms o f MDs.
1.2.3.1.1 Dystrophin and Dystrophin Associated Protein Complexes
The dystrophin gene (dys) within Xp21 is the largest identified mammalian gene, 
which spans approximately 2.6 Mb o f genomic sequence and occupies almost 2% of 
X chromosome, and nearly 0.05 % o f entire human genome (Bogdanovich et al, 
2004). The gene consists o f 79 exons and the corresponding 14 kb dystrophin 
transcript is expressed in skeletal, cardiac and smooth muscle, with lower levels in 
brain. In normal muscle, dystrophin gene encodes a 427 kDa dystrophin protein 
composed o f 3685 amino acid residues. The dystrophin protein localises to the
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cytoplasmic surface o f  sarcolemma and is enriched membrane o f neuromuscular 
junction (Kapsa et al, 2003; Bogdanovich et al, 2004).
The dystrophin protein is organised into four structural domains: (a) The amino- 
terminal acting binding domain, (b) a central rod domain, (c) cystein-rich domain, and 
(d) a carboxy-terminal domain. The N-terminal o f dystrophin binds actin filaments o f 
cytoskeleton. The rod domain is the majority o f the protein. The cystein-rich domain 
binds intracellular calcium and ZZ domain. Finally, the C-terminal o f  dystrophin 
binds some dystrophin associated proteins such as dystrobrevin, syntrophin. and P- 
dystroglycan.
The dystrophin is located beneath the muscle sarcolemma associated with a 
membrane-spanning protein complex that connects the cytoskeleton to the basal 
lamina. The protein complex associated with dystrophin is therefore o f key 
importance in the pathogenesis o f the muscular dystrophies. Mutations in different 
components o f the dystrophin associated protein complex (DAPC) cause different 
forms o f MDs (see Table 1.1 and the Figure 1.12). The a-Dystroglycan is an 
extracellular component o f DAPC and is linked to the sarcolemma by interaction with 
a trans-membrane complex consists muscle specific P-dystroglycan and sarcoglycan 
complex (a, p, 5, and y sarcoglycans). The cytoplasmic tail o f the P-dystroglycan 
binds the dystrophin. The a-Dystroglycan also binds components o f extracellular 
matrix, including laminin, biglycan, agrin, and perlecan.
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Figure 1.12: Muscular dystrophies and the membrane associated proteins. The figure shows 
the location of different membrane and enzymatic proteins associated with muscular 
dystrophies. Diseases are shown in boxes. The figure in a circle shows Golgi complex and 
related proteins and diseases. Abbr: MDC and CMD: Congenital muscular dystrophy, 
LGMD: Limb-Girdle muscular dystrophy, DMD: Duchenne muscular dystrophy, BMD: 
Becker muscular dystrophy. (The figure is taken from Dalkilic and Kunkel, 2003, by kind 
permission o f Dr Isin Dalkilic from Neoromuscular Disease Project in MGH of Harvard 
University).
1.2.3.1.2 Duchenne I Becker I Muscular Dystrophy (DMD I BMD)
Duchenne muscular dystrophy (DMD) is a X-linked fatal progressive muscle wasting 
disorder that affects only male children (females are the carrier). With an incidence of 
~ 1 in 3,500 male new bom, it is the most common muscular dystrophy and one o f the 
most common fatal hereditary disorders.
DMD was first described by Edward Meryon in 1851 (Meryon, 1851), and then its 
clinical and muscle histology was detailed by Duchenne a decade later in 1861
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(Duchenne, 1861), and Gowers in 1879 (Gowers, 1879). In spite o f this, the molecular 
basis o f the disease was not determined until 1986 (Kunkel et al, 1986a; Kunkel et al, 
1986b; Koenig et al, 1987). The entire 14-kb cDNA o f DMD gene was fully cloned 
and sequenced and the encoded protein was named dystrophin in 1988 (Koenig et al, 
1988).
DMD is the most common form o f muscular dystrophy in children and affects only 
boys. The affected boys appear normal at birth. First clinical symptoms o f the disease 
develop between ages o f  2 and 6. These include a delay in walking, difficulties in 
climbing stairs and a wadding gait (Dubowitz, 1978). A typical behavioural 
adaptation (G ow er’s sign) is that patients use their arms to “climb” up their own 
thighs, when changing from a lying to a standing position. The muscles decrease in 
size and grow weaker over time though they may appear larger. Calf muscles show a 
marked pseudo hypertrophy while all proximal muscles become progressively 
weaker. Disease progression varies, but many sufferers need a wheelchair by the age 
o f 12. In most cases, the arms, legs, and spine become progressively deformed. Some 
sufferers are mildly retarded. Severe breathing and heart problems mark the later 
stages o f the disease. The most DMD patients die from respiratory or cardiac failure 
in the early 20s (in some rare cases in the early 30s).
Becker muscular dystrophy (BMD) is quite similar to Duchenne muscular dystrophy, 
but the difference is that the disease is much milder than DMD. The symptoms appear 
later and progress more slowly. It affects 1 in every 20,000 new bom boys (van 
Deutekom and van Ommen, 2003). BMD usually appears between the ages o f 2 and 
16 but can also appear as late as age o f  25. Like DMD, it affects only males and
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causes heart problems. Even though the clinical symptoms are similar to DMD, they 
are significantly delayed. Disease severity varies. Sufferers can usually walk into their 
30s and live further into adulthood. Some BMD patients even remain ambulant until 
old age (England et al, 1990).
The main pathological problem in DMD and/or BMD is the mutations in the gene 
encoding dystrophin protein. The mutations in DMD and/or BMD result in the 
absence or the severe reduction o f the dystrophin protein. The dystrophin protein is 
completely absent from the sarcolemma in muscles from DMD patients and some 
animal models, including the mdx mouse and GRMD dog. On the other hand, in 
BMD patients, dystrophin protein still exists but it is internally truncated. Therefore, 
the dystrophin protein has semi function (and milder phenotype).
Dystrophin also plays a role in the brain. This role is not sufficiently understood 
currently, but the absence o f dystrophin in DMD may result in a mild cognitive 
impairment (Blake and Kroger, 2000; Mehler, 2000).
The progressive nature o f  the disease results from the inability o f the affected muscle 
to efficiently replace damaged muscle fibres. This is mainly due to an exhaustion o f 
the potential to regenerate fibres from muscle progenitor cells, in concert with the 
gradual replacement o f muscle fibres by connective tissue (Reimann et al, 2000). An 
useful, although unspecific diagnostic marker, even before the onset o f a clinical 
phenotype, is the strongly increased serum creatine phosphokinease activity. The 
histological hallmarks o f the disease in skeletal muscle are: fibre size variation, cluster 
o f necrotic fibres, central nuclei in regenerating fibres, fibrosis and infiltration o f
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macrophages and CD4+ lymphocytes (Gorospe et al, 1990; McDouall et al, 1990; 
Blake et al, 2002).
A definite diagnosis for DMD is based either on the absence o f dystrophin protein in a 
muscle biopsy or on the molecular identification o f a mutation in the dystrophin gene. 
About 65% o f dystrophin mutations are large deletions which occur preferentially at 
two mutation “hot spots” and 5% o f these are large duplications (Koenig et al, 1989). 
The remaining 30% which is distributed over the whole gene are point mutations or 
small-scale deletions/duplications, including 18% o f nonsense mutations, 8% small 
deletions or insertions, and the remaining are splice site mutations, and missense 
mutations (Roberts et al, 1994). According to the “reading frame theory” (Monaco et 
al, 1988) a deletion or duplication causing a frame shift leads to a premature 
termination o f translation.
The resulting dystrophin protein is truncated, not functional, and due to low mRNA 
and protein stability only present at very low levels. Patients with such mutations 
develop DMD. Surprisingly, even these patients show a small subset o f dystrophin 
positive fibres. The occurrence o f  so-called revertant fibres is directly associated with 
the nature o f mutation in individual patients. While some mutations allow revertant 
fibres, others do not. A natural exon skipping mechanism was proposed to be the 
underlying molecular mechanism. Overall, revertant fibres are detected in 
approximately 50% o f DMD patients and account for 0.2 -  4 % o f the total number o f 
muscle fibres (Burrow et al, 1991; Nicholson et al, 1993).
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In BMD, the mutations usually cause the loss o f  a small, non-essential part o f the 
molecule while the reading frame stays intact. In BMD, the deletions mainly occur 
from exon 13 (Sitnik et al, 1997) or 17 (England et al, 1990) to 48 (Bogdanovich et al, 
2004). This deletion allows the expression o f smaller dystrophin protein. The resulting 
dystrophin could have varying degrees o f  functionality, depending on the size and the 
position o f the deleted sequence. This is reflected by the wide spectrum o f the clinical 
severity o f BMD patients. Female carriers are not or only mildly affected because 
they are normally able to compensate the defect via the functional dystrophin copy on 
their second X chromosome.
Current treatment options for DMD and BMD are very limited. No effective 
pharmacological treatment is available so far, while supportive therapies like artificial 
ventilation have moderately prolonged patient’s survival but offer no permanent cure 
(Scheuerbrandt, 1998). The recent therapeutic applications for Duchenne / Becker 
Muscular dystrophies can be seen in 1.5.1.8.
1.2.3.1.3 Congenital Muscular Dystrophy (CMD)
Congenital muscular dystrophies (CMD) are a heterogeneous group o f autosomal 
recessively inherited disorders, which present with hypotonia, muscle weakness and 
contractures, associated with dystrophic changes on skeletal muscle biopsy (Sellick et 
al, 2005). CMDs have several different forms with different gene defects such as 
Ulrich CMD (21q22.3 and 2q37). Walker-Warburg Syndrome (9q34.1), Muscle-eye- 
brain disease (Iq32-q34) and Fukuyama muscular dystrophy (19q 13.3) with and 
without mental retardation and with geographic high-incidence foci (Tubridy et al,
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2001; Emery, 2002; Kirchner and Bonnemann, 2004). Most recently, another CMD 
locus was identified on 4pl6 .3  by using a high-density SNP array (Sellick et al, 2005). 
CMDs are caused by the absence o f  some extracellular matrix proteins such as a2- 
laminin (merosin), a  integrin, fekutin, glycosyltransferase and selenoprotein N 1 in 
birth or within the first few months o f life (M ukheijee and Mittal, 2004). Therefore a 
proportion o f children with CMD show an absence or a marked deficiency in a 
merosin which divides CMD into 2 groups, merosin-negative and merosin-positive 
(Tome et al, 1994). In CMD, it is associated with severe and early contractures 
(shortening or shrinking o f muscle that causes joint problems). Unfortunately, there is 
no effective treatment for any form o f CMD (Emery, 2002; Kirchner and Bonnemann, 
2004).
1.2.3.1.4 Facioscapulohumeral Dystrophy (FSHD)
Facioscapulohumeral dystrophy (FSHD) is an autosomal dominant muscle disorder 
characterised by progressive weakness and wasting o f facial, scapulohumeral, anterior 
tibial, pelvic and pectoral-girdle and upper arm muscles including retinal vascular 
disease, sensory hearing loss and in severe cases some with detectable abnormalities 
o f the CNS (M ukherjee and Mittal, 2004). FSHD is the third most common inherited 
muscular disorder after Duchenne muscular dystrophy and myotonic dystrophy 
(Fitzsimons, 1999; Upadhyaya and Cooper, 2002; Topler and Gabellini, 2004; 
Yamanaka et al, 2004); and the estimated prevalence is 1 in 20,000 (Fitzsimons, 1999; 
Kissel, 1999). A deletion has been found in the subtelomeric region o f chromosome 
4q35 (Fitzsimons, 1999; Upadhyaya and Cooper, 2002; Topler and Gabellini, 2004; 
Yamanaka et al, 2004) and at least 95% o f families with FSHD show linkage to such
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deletion (Pradhan, 2003). FSHD currently has no effective treatment (Fitzsimons, 
1999).
1.2.3.1.5 Emery-Dreifuss Muscular Dystrophy (EDMD)
Emery-Dreifuss M uscular Dystrophy (EDMD) appears from childhood to early teens. 
The symptoms are weakness and wasting o f shoulder, upper arm and shin muscles. 
Joint deformities and frequent cardiac complications are also common. The disease 
usually progresses slowly. EDMD is X-linked recessive (females are carriers) and 
defective proteins are emerin and lamin A/C.
1.2.3.1.6 Limb-Girdle Muscular Dystrophy (LGMD)
Limb-Girdle M uscular Dystrophies (LGMD) are also a diverse group o f muscle- 
wasting disorders, and they characteristically affect the large muscles o f the pelvic 
and shoulder girdles (Laval and Bushby, 2004). LGMDs are autosomal recessive, or 
X-linked recessive disorders, and appears from childhood to middle age. Defective 
proteins o f LGMDs vary. Some o f these are myotilin, lamin A/C, laminin-alpha2, 
collagen VI, caveolin 3, calpain-3, dysferlin, a, p, y and 6 sarcoglycans, titin, 
telethonin or myotilin, fekutin-related protein and E3-ubiquitin ligase.
To date, five autosomal dominant and ten autosomal recessive forms o f limb-girdle 
muscular dystrophies have been identified: the first four forms o f AR LGMDs are the 
sarcoglycanopathies (LGMD2C - y- sarcoglycan, 2D - a-sarcoglycan / adhalin, 2E - p- 
sarcoglycan and 2F - 8-sarcoglycan). The other forms are LGMD2A (calpain 3), 
LGMD2B and Miyoshi myopathy (dysferlin - 2p31), LGMD2G (telethonin),
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LGMD2H (9q31-11), and LGMD2I (Fekutin-related protein - 19q 13.3) and LGMD2J 
(Titin) (Vainzof et al, 2001; Emery, 2002; and Bogdanovich et al, 2004). On the other 
hand, Myotonic Dystrophy (MMD), Oculopharyngeal Muscular Dystrophy (OPMD) 
and Distal Muscular Dystrophy (DD), all are autosomal dominant disorders.
1.2.3.1.7 Animal models for Muscular Dystrophies
Animal models have provided valuable clues to understand o f DMD pathogenesis and 
offer a good opportunity for the development and testing o f therapeutic approaches 
(Allamand and Campbell, 2000). Several species o f animals have been identified in 
which mutations in the dystrophin gene (in murine, canine and feline) lead to the 
absence o f dystrophin and to development o f dystrophy with varying degrees o f 
severity. Some o f  these are as follows:
1.2.3.1.7.1 The mdx mouse
The most commonly used animal model o f DMD is C57Bl/10ScSn mdx (murine 
dystrophy x-linked) mouse (Bulfield et al, 1984). A point mutation in the dystrophin 
gene (nonsense mutation in exon 23, in position 3185) results in a premature stop 
codon (CAA - > TAA) (Sicinski et al, 1989). The mice have a small number o f 
revertant fibres (about 1%). Although the mdx is a genetic and biochemical 
homologue o f the DMD, it has a milder phenotype. The clinical phenotype o f the mdx 
mice is much more benign than in human DMD patients (Gillis, 1999). Therefore, 
these animals have a nearly normal life expectancy and move normally at old ages. 
Typical features o f regenerated muscles o f mdx mice are centrally located nuclei. 
Under normal conditions nuclei return to the periphery o f the muscle fibre after a
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regeneration process is completed. In mdx muscles very high levels o f central nuclei 
were observed over the entire lifespan. Central nucleation is an easily measurable and 
well accepted indicator o f  muscle pathology in mdx mice.
There are also some other murine models o f  DMD, such as dy/dy mouse (C57B1/6 J -  
dy2J) and mdx/utm (dystrophin and utrophin deficient) mouse and several different 
immunodeflcient strains o f  mouse (Collins and Morgan, 2003). On the other hand, 
some other murine models o f  different muscular dystrophies are also available, such 
as, dysferlin deficient C57BL/10.SJL-Dysf mouse (von der Hagen et al, 2005).
1.2.3.1.7.2 The GRMD dog
There are several dog models o f  DMD such as Golden Retriever (Cooper et al, 1988), 
Rotweiller (Partridge, 1991) and the German short-haired pointer (Schatzberg et al, 
1999). O f these, the Golden Retriever Muscular Dystrophy (GRMD) dog has been the 
most extensively studied and best characterised animal model o f DMD. GRMD is 
caused by a point mutation in consensus splice acceptor in the introns 6 o f canine 
dystrophin gene. The mutation results in the deletion o f exon from the mRNA thereby 
introducing a frame shift which leads to a premature stop codon. The mutation is 
3 ’splice-site point mutation in introns 6 (in position 739-2a). Affected pups gain 
weight slower than unaffected siblings. The affected dogs generally die within days or 
months (Cooper et al, 1988). The GRMD dogs are a good model for DMD because of 
their severe clinical phenotypes, their large size and the accompanying 
histopathological progression (Howell et al, 1997; Cozzi et al, 2001).
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1.2.3.1.7.3 The HFMD cat
There is also a dystrophin deficient cat: Hypertrophic feline muscular dystrophy 
(HFMD) cat. (Carpenter et al, 1989; Gaschen and Burgunder, 2001; Collins and 
Morgan, 2003). Hypertrophy is the most notable effect in affected animal. An 
abnormal gait and some necrosis are present but the overall phenotype is benign. 
Affected cats also suffer from cardiomyopathy (Gaschen et al, 1999). The mutations 
o f HFMD cat is deletion o f  Dp427m and Dp427p promoter regions.
Although there are currently no primate models o f dystrophin deficiency, some non­
mammalian and invertebrae models o f  disease are available for research, such as 
zebrafish (Chambers et al, 2001; Rubinstein 2003), the nematode C. elegans 
(Baumeister and Ge, 2002) and the sea urchin (Neuman et al, 2001).
1.2.3.1.8 Therapeutic Approaches for Muscular Dystrophies
M uscular dystrophies, particularly DMD, affect hundreds o f thousands patients 
worldwide. Because no effective treatment is available, great efforts are underway to 
develop a cure. Once an effective approach is established to one o f these, it might be 
applicable with modification in large numbers o f other heritable diseases. Because of 
the complexity o f muscular dystrophies, an optimal therapeutic approach can be 
targeted all genetic (mutations in genes), biochemical (absence o f proteins), cellular 
(myofibre necrosis), tissue (reduction o f  myofibre size and number), functional (loss 
o f muscular function) and clinical levels o f the physiopathological changes including 
paresis and paralysis, column deformities, and cardio-respiratory insufficiencies.
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Until now, many different strategies have been studied and developed to treat 
muscular dystrophies. The majority o f  these various therapeutic strategies have been 
for DMD over the years. Therefore, it will mainly concentrate on the potential 
therapies for DMD. Such therapeutic strategies have been studied and developed on 
mainly dystrophin deficient animal models o f  DMD, particularly on mdx mice. 
However, many DMD human clinical trials are currently ongoing.
Different levels o f  progress for these different therapeutic strategies have been 
achieved in three main approaches. Therefore, in general, therapeutic strategies for 
DMD can be classified into the following four major groups based on their 
approaches:
•  Gene therapy approaches (viral, plasmid and oligonucleotide-based),
•  Cell therapy approaches (myogenic, stem cell transplantation),
•  Pharmacological therapy approaches (anabolic agents and gentamicin),
•  Alternative therapy approaches (upregulation o f some other alternative 
therapeutics, such as utrophin or IGF-I).
1.2.3.1.8.1 Genetic approaches
The main goal o f gene therapy strategies for DMD is either to replace the defective 
dystrophin gene with a functional copy or to “repair” the mutated dystrophin gene. Up 
to now, for vector based supplementary gene therapy (for trying to replace the 
defective gene with a functional copy), both viral and plasmid vectors have been used 
to deliver genetic materials to treat DMD. On the other hand, as non-vector based
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corrective gene therapy, small double stranded fragments (>~100bp) and synthetic 
single stranded oligos (<100 bp) have been used.
For viral vector based gene therapy, a number o f viral vector systems for gene therapy 
o f muscle disorders are currently under development, such as adenoviral (full-length, 
mini- or micro-dystrophin cDNA transfer), adenoassociated viral (mini-, or micro­
dystrophin cDNA transfer), retroviral (mini-dystrophin cDNA transfer), lentiviral 
(mini-dystrophin cDNA transfer) and herpes simplex viral (full-length dystrophin 
cDNA transfer). The advantages o f  their high capacity and o f being able to 
accommodate the full-length dystrophin cDNA and promoter, adenoviral vectors have 
been used widely to treat DMD. Different variants o f adenoviral (Ad) vectors have 
been used in many mdx mice and human clinical trials (Vincent et al, 1993; Acsadi et 
al, 1996; Guibinga et al, 2001; Gilbert et al, 2001; Jiang et al, 2001; Maione et al, 
2001; O ’Hara et al, 2001). Particularly in recent years, the adenoassociated viral 
(AAV) vector based gene therapy have been used to deliver mini- or micro-dystrophin 
cDNA and have yielded comparatively better results (Xiao et al, 1996; Wang et al, 
2000; Stedman et al, 2000; Duan et al, 2001 ; Yuasa et al 2002 ; Harper et al, 2002 ; 
Fabb et al, 2002 ; Watchko et al, 2002 ; Skuk et al, 2002 ; Kapsa et al, 2003 ; van 
Deutekom and van Ommen, 2004 ; Gregorevic et al, 2004). The serotype o f A A Vs 
has been recently improved and most recent variants o f these, such as pseudotyped 
AAV types 5 and 6 are now much more effective (more than 200 folds) for in vivo 
(Duan et al, 2001, Gregorevic et al, 2004). Alongside Adenoviral and AAV vector 
system, retroviral (Dunckley et al, 1993; Fassati et al, 1997; Skuk et al, 2002), 
lentiviral (Kafri et al, 1997) vectors have been also used to treat DMD. Although viral
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gene therapy for DMD mainly focuses on adenoviral, adenoassociated, and retroviral 
vectors, several additional viral systems have also been applied to DMD. These 
include herpes simplex virus (Akkaraju et al, 1999), Epstein-Barr virus (Tsukamoto et 
al, 1999) and chimeric adeno-retrovirus (Tsukamoto et al, 1999).
As non-viral vector based gene therapy for DMD, mainly naked DNA (plasmid 
cDNA) has been used (Liu et al, 2001; Romero et al, 2004). High level and long- 
lasting gene expression has been reached by the development o f improved plasmid 
DNA transfer techniques, such as intravenous injection with high pressure (Budker et 
al, 1998), optimised electroporation conditions (Vicat et al, 2000; Vilquin et al, 2001) 
and use o f ultrasound (Danialou et al, 2002).
As mentioned above, for corrective gene therapy, depending on the nature o f the 
mutations, small fragment homologous replacement (SFHR), chimeraplasty and 
oligonucleotide-mediated exon skipping strategies have been hitherto used. The repair 
o f point mutations in the dystrophin gene has recently been demonstrated in mdx mice 
(in cultured cells and in muscles) (Bertoni and Rando, 2002). This single base pair 
repair is called chimeraplasts, which are single stranded RNA/DNA oligonucleotides. 
The chimeraplasts bind in a first step to the targeted sequence and then in a second 
step, trigger the repair o f  the mutation thraw the endogenous DNA repair machinery 
(Barlett et al, 2000). In theory, chimeraplasty may correct permanently almost all 
kinds o f point mutations and therefore is a very general and promising approach; 
however, in application, it has a very limited effect, such as 1 -  2% o f all fibres per 
muscle were repaired so far (Rando et al, 2000).
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Another possibility o f  DMD gene therapy is to skip a stop codon mutation or to 
restore an open reading frame after shift mutation. To specifically induce exon 
skipping o f  mutations in DMD patients, antisense oligonucleotides (AOs) were used. 
Successful skipping o f the mdx stop codon mutation (in exon 23 o f the mouse 
dystrophin) has already been demonstrated in vitro and in vivo, when AOs specific for 
the junction o f  introns 22 and exon 23 were applied (Duncley et al, 1998; Rando et al, 
2000; Mann et al, 2001; Lu et al, 2003; Goyenvalle et al, 2004). Currently, three large 
clinical trails are being planned to take place in the Netherlands, the UK and Australia 
(Wilton and Fletcher, 2005). Among them, two European consortia (in the 
Netherlands/Belgium and in the UK) are preparing for a clinical trial on antisense 
oligonucleotids (AON) in DMD (Muntoni et al, 2005). According to the report about 
the meeting held in Naarden, the Netherlands on 22-24 October 2004, the UK 
consortium project funded by the Department o f Health is testing novel AON targeted 
against exon-intron boundaries o f exon 51 and 53 in DMD patients. The Dutch / 
Belgian consortium is testing exon 51 in DMD patients (Muntoni et al, 2005).
According to Prof Muntoni, UK consortium participants are Prof Francesco Muntoni, 
Prof Terry Partridge and Prof Dominic Wells o f Imperial College London, Prof Kate 
Bushby o f Newcastle University, Dr Matthew Woods o f Oxford University, and Prof 
George Dickson o f  Royal Halloway College -  London. (Prof M untoni’s talk in GTAC 
- UK Gene Therapy Advisory Committee - public meeting in July 2004; 
http://www.advisorybodies.doh.gov.uk/genetics/gtac/meetings.htm -Delegate Pack 
fo r  Open Meeting 2004).
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1.2.3.1.8.2 Cellular approaches
For cellular approaches, myoblast and stem cell transplantations have been used. For 
myoblast transplantation, Terry Partridge’s group transferred cultured normal 
myoblasts into dystrophin-deficient mdx/nude neonatal mice (Partridge et al, 1989). 
However, the clinical trials o f myoblast transplantations were unsuccessful (Karpati et 
al, 1993; Miller et al, 1997; Neumeyer et al, 1998; Skuk, 2004; Dubowitz, 2004). On 
the other hand, a few systemically injected bone-marrow cells and liver-derived stem 
cells were also introduced to dystrophin-deficient muscle (Bittner et al, 1999; M alouf 
et al, 2001; Zuk et al, 2001). However, the efficiency levels were low (Gussoni et al, 
2002).
1.2.3.1.8.3 Pharmacological approaches
One o f novel strategies for DMD therapy is to introduce gentamicin, an 
aminoglycoside antibiotic, into dystrophin-deficient muscle. Gentamicin-treated mdx 
mice have shown increase o f dystrophin expression and functional improvement 
(Barton-Davis et al, 1999). However, human gentamicin based clinical trials were not 
effective (Wagner et al, 2001). In addition, calcium homeostasis, using calcium 
channel blockers such as diltiazam/nifedipine, was also used to treat DMD (Johnson 
and Bhattacharya,1993).
1.2.3.1.8.4 Alternative approaches
Among other approaches to treat DMD, a few other therapeutic strategies can be 
mentioned. One o f these is utrophin upregulation. Utrophin is an alternative protein to
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repair the mutated dystrophin, because utrophin is dystrophin paralog, and it is 
already moderately upregulated in dystrophin-deficient muscle (Tinsley and Davies, 
1993). The utrophin functionally replaced dystrophin in some transgenic and viral- 
gene transfer studies (Tinsley et al, 1996; Wakefield et al, 2000).
1.2.3.1.8.5 Non -  molecular approaches I specific management implications
Although some promising developments in the preclinical field and various 
therapeutic approaches, there are yet no fundamental treatments aimed at the 
underlying pathology for any kind o f muscular dystrophies. Nevertheless, some 
evidence based specific managements are available for many years. Many o f the life 
threatening complications o f these diseases such as cardiac and respiratory system 
complications can be prevented and / or treated by these managements in order to 
increase life expectancy and to improve quality o f  life (Bushby and Straub, 2005).
According to Bushby and Straub (2005), some o f these specific management 
implications are as follows:
• Drug treatments (the use of corticosteroids [prednisone/prednisolone and deflazacort] 
are useful in maintaining or improving strength);
• Physiotherapy and orthopaedic surgery (MD patients with joint contractures may
benefit);
• Cardiac surveillance and treatment (treatments of arrhythmias and disrhythmias);
• Respiratory management (prevention and treatment of increasing respiratory
insufficiency thraw the prophylaxis; and treatment of chest infections with
immunization, cough augmentation techniques and prompt treatment by antibiotics);
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• Pain management;
• Anaesthesia..
1.2.3.2 Motor Neurone Diseases I Amyotrophic Lateral Sclerosis
Motor neurone diseases (MND) are a group o f disorders, which are characterised by 
progressive degeneration o f the motor neurones o f the brain, brain stem or spinal cord. 
It can affect both upper and lower motor neurones. Upper motor neurons (cortico­
spinal tract cells) originate in the brain. The lesions in upper motor neurones cause 
characteristic signs such as spasticity, muscle stiffness, brisk reflexes, abnormal 
reflexes (e.g. Babinski reflex) and spastic weakness (Shaw, 1999, Strong, 2003).
The lower motor neurones originate in the brain stem or the anterior horn cells o f the 
spinal cord and innervate muscle. The lesions o f lower motor neurones cause 
characteristic signs such as muscle wasting, muscle fasciculation, flaccid weakness, 
and hypertonia and diminished reflexes (Talbot, 2002).
M otor neurone disease is rare, with an overall prevalence o f around 6 in 100,000. 
Incidence rises with age and this is estimated at approximately 1-2 per 100,000 per 
annum overall, increasing to 10 in 100,000 in people aged 65-85. Only 10 % o f cases 
are familial (inherited), and the remaining 90 % sporadic (Shaw, 1999).
The aetiology o f MND is unknown yet. Degeneration o f the motor neurones leads to 
weakness and wasting o f muscles. This generally occurs in arms or legs initially, 
some groups o f muscles being affected more than others. Some individuals may
81
develop weakness and wasting in the muscles supplying the face and throat, causing 
problems with speech and difficulty with chewing and swallowing. Therefore, the 
symptoms o f disease are spasticity, weakness, paralysis and impairment o f speech, 
swallowing and breathing problems. There is no effective treatment for MND that 
substantially halts or slows disease progression. The average survival is only about 
three years after the starting o f symptoms (Shaw, 1999, Strong, 2003).
Some authors term the M otor Neurone Disease as Amyotrophic Lateral Sclerosis 
(ALS). MND is the generic term used more in Europe whilst ALS is sometimes used 
more generically in the USA. These diseases are also known as “Maladie de Charcot”, 
and are often referred to in America as Lou Gehrig’s disease, after the famous 
baseball player who died o f  the disease. The most famous person who has MND is 
Professor Stephen Hawking, the Cambridge University physicist, mathematician and 
cosmologist.
Motor Neurone Diseases can be classified as follows:
1) Idiopathic Motor Neurone Diseases:
• Amyotrophic Lateral Sclerosis (ALS),
• Progressive Bulbar Palsy (PBP),
• Progressive Muscular Atrophy (PMA),
• Hereditary Spastic Hemiplegia (HSH),
• Spinal Muscular Atrophy (SMA),
• Spinobulbar Atrophy (SBMA or Kennedy’s disease),
• Primary Lateral Sclerosis (PLS),
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• Familial ALS,
• Juvenile ALS,
• Madras Motor Neurone Disease,
• Monomelic Motor Neurone Disease.
2) Toxin-related Motor Neurone Diseases:
• Lathyrism,
• Konzo and Guamanian ALS.
On the other hand, Figlewicz and Orrell suggest another classification. They suggest 
that MNDs may be divided into three categories according to their motor neuron 
involvements (Figlewicz and Orrell, 2003):
i) Motor Neurone Diseases with lower motor neuron involvement:
• Spinal Muscular Atrophy (SMA),
• Spinobulbar Muscular Atrophy (SBMA or Kennedy’s disease),
• Progressive Muscular Atrophy (PMA)
ii) Motor Neurone Diseases with upper motor neuron involvement:
• Primary Lateral Sclerosis (PLS)l,
• Primary Lateral Sclerosis (PLS) 2,
• Spastic Paraplegias;
iii) Motor Neurone Diseases with combined upper and lower motor neuron 
involvement:
• Amyotrophic lateral sclerosis (ALS),
• Progressive Bulbar Palsy (PBP).
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Amyotrophic lateral sclerosis (ALS), the commonest form (over 80 percent) o f motor 
neuron disease (MND), is an age dependent fatal neurodegenerative disorder due to 
motor neurons’ degeneration. The overall prevalence is around 5 in 100 000. The 
aetiology o f MND is largely unknown at present. Degeneration o f the motor neurones 
leads to weakness and wasting o f muscles which generally occurs in arms, legs or 
bulbar region (Strong, 2003). There is no effective treatment for ALS that 
substantially halts or slows disease progression (Strong, 2003). The majority o f 
individuals affected with ALS live for less than 5 years, usually about three years 
(Shaw, 1999). Animal model for ALS is transgenic mouse expressing mutant 
superoxide dismutase 1 (SOD1).
1.2.4 Gene Therapy
Although there are many definitions, one o f the simplest and concise definitions o f 
gene therapy can be the introduction o f DNA-based genetic material into humans for 
treating genetic disorders. According to GTAC (UK Gene Therapy Advisory 
Committee), gene therapy is “The deliberate introduction o f genetic material into 
human somatic cells for therapeutic, prophylactic or diagnostic purposes.” (12th 
Annual Report o f  the UK Health M inister’s Gene Therapy Advisory Committee -  
G T A C -, 2005).
More detailed definition o f GTAC about gene therapy is as follow:
“ ... [a] gene therapy medicinal products mean a product obtained thraw a set o f 
manufacturing processes aimed at the transfer, to be performed either in vivo or ex 
vivo, o f a prophylactic, diagnostic or therapeutic gene (i.e. a piece o f nucleic acid), to
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human / animal cells and its subsequent expression in vivo. The gene transfer involves 
an expression system contained in a delivery system known as a vector, which can be 
o f viral, as well as non-viral origin. The vector can also be included in a human or 
animal cell.” (The definition was given in Part IV o f Directive 2003/63/EC [amending 
Directive 2001/83/EC]) (GTAC - 12th Annual Report, 2005). Thus, the main goal o f 
gene therapy is to treat genetic diseases by using genes as a therapeutic drug (Lasic,
1997), and its main effort is to deliver normal copies o f missing or defective genes 
into the individual.
Gene therapy can be classified into two broad categories:
• Germ-line gene therapy
• Somatic gene therapy
In germ-line gene therapy, reproductive germ cells are altered. Therefore, the 
modifications o f germ cells can affect the patient’s offspring because the genetic 
changes will be passed on to next generations. On the other hand, somatic gene 
therapy involves only the alteration o f somatic cells, and therefore, the genetic 
changes only affect the individual, not his / her offspring. Somatic cell gene therapy is 
now the only gene therapy technique in use in humans.
There are also two principal ways in which vectors (gene transporters) can be 
administered to carry new genes into target cells:
• Ex vivo gene therapy
• In vivo gene therapy
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In ex vivo somatic gene therapy, the target cells are removed from the body; vectors 
with new gene are inserted into the cells in the laboratory and cultured, and then the 
cells with vectors are reinserted into the body. In contrast, in vivo somatic gene 
therapy, the vectors with the gene are directly injected into the body, either into the 
target cells o f the tissue o f interest (in situ), or the bloodstream for systemic delivery.
1.2.4.1 The historical background of gene therapy
Although the first approved gene therapy clinical trial started 15 years ago, in 1990 
(Blease et al. 1995), gene therapy discussions and experiments began much earlier. 
The ‘gene therapy’ term was coined to distinguish it from the Orwellian connotations 
o f human genetic engineering, which was derived from the term genetic engineering 
(W olf and Lederberg, 1994). The ‘genetic engineering’ term was first used at the 6th 
International Congress o f Genetics held in New York in 1932 (Crow, 1992; W olf and 
Lederberg, 1994). The experiments o f gene transfer into animals and humans 
increased after the beginning o f gene transfer in bacteria in 1960s (W olf and 
Lederberg, 1994). The earliest discussions o f possibility for gene therapy was made 
by Edward Tatum in a letter dated October 1962. 4 years later, E. Tatum, Jashua 
Lederberg and others discussed the possibility o f gene therapy at a symposium in New 
York, in may 1966 (Tatum, 1966, Lyght, 1967). In 1970, Stanfield Rogers tried to 
treat two girls with a genetic disease, argininemia by argininase gene in a papilloma 
virus; but the attempt was unsuccessful (Rogers, 1976). Discussions o f gene therapy 
maintained their place in scientific agenda, especially in publications (Davis, 1970; 
Freese, 1971; Anderson, 1972; Friedmann and Roblin, 1972; Morrow, 1976). Then, in 
1977, Michael Wigler and Richard Axel transferred a gene into mammalian cells
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(Wigler et al, 1977). In 1979, W. F. Anderson succeeded in the first transfer o f a 
single copy o f a functional Thymidine Kinase gene using microinjection into mouse 
cells and corrected the genetic deficiency o f the cells (Anderson et al, 1980). In Early 
1980s, viral vectors were developed and used for transferring genes into cells. The 
first retroviral, (Joyner et al, 1983; M iller et al, 1983; Watanabe and Temin, 1983, 
Mann et al, 1983 and Willis et al, 1984), then adenoviral (Van Doren et al, 1984) and 
adeno-associated viral vectors (Tratschin et al, 1984 and Hermonat and Muzyczka, 
1984) were developed. The first in vivo gene transfer was obtained in 1985 (Eglitis et 
al, 1985). In 1989, first human gene transfer clinical trial took place in 1989 
(Rosenberg et al, 1990) and next year, the first gene therapy journal, Human Gene 
Therapy, began to be publishing.
On 14th September, 1990, the first approved successful gene therapy clinical trial took 
place and an US team transferred the T cells to 4 years old girl Ashanthi DeSilva with 
ADA -  deficient Severe Combined Immunodefiency (SCID), by retroviral vector 
carrying normal ADA gene (Blease et al. 1995). The attempt was successful. After 
ADA-deficient SCID trial, the first non-viral gene therapy clinical trial began in 1992 
and Gary Nabel et al injected a DNA/liposome complex into HLA-B7 tumours (Nabel 
et al, 1992). Gene therapy clinical trials had increased rapidly and in 1993, the 100th 
gene therapy clinical trial was submitted to US authorities for approval. And then, in 
September 1999, the first gene therapy victim occurred in the Institute o f Human 
Gene Therapy o f the University o f Pennsylvania. Jesse Gelsinger, an 18 year-old male 
from Arizona, died following infusion o f an adenoviral vector. He was the only 
patient to have ever died as a direct result o f a gene therapy application.
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1.2.4.2 Gene delivery vectors
The most important issue in gene therapy is the delivery o f the genetic material into 
the target cells in the body. The vehicles to deliver the gene o f interest to the target 
cell are defined as vectors. Therefore, the choice o f vector is crucial in any gene 
transfer protocol because it can result in either success or failure.
Currently there is no ideal or a “good universal vector” in gene therapy (Fry and 
Wood, 1999). All o f the vectors that are currently available have both advantages and 
disadvantages. Different vectors have different disadvantages as follows: Low 
efficiency (non-viral vectors), high labour and high cost production (viral vectors); 
inability to infect nondividing cells (retroviral vectors); safety concerns including 
unwanted immunological effects (adenoviral vectors) and cytotoxic effects (Herpes 
simplex virus vectors); the capacity o f  carrying limited genetic material (adeno­
associated viral vectors) and so forth. Therefore, some authors suggest that an ideal 
gene delivery vector should fulfil at least the following requirements: (Somia and 
Verma, 2001; Pfeifer and Verma, 2001)
• Safety: The vector should be non-toxic, non-inflammatory, non-immunogenic and 
should be stable for safe storage;
• High transfection efficiency;
• The capacity of easy design and production in high concentration at low cost;
• Sustained and regulated transgenic expression: The gene delivered by the vector 
should be expressed in a desired way. The gene or the product of the gene should be 
biodegradable; its expression should be under the control of a reversible manner;
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• Long-term expression: The gene delivered by the vector should be expressed and be 
stable for a long-term.
• Specific targeting of expression: The vector should be specifically targeting the cells 
or tissues of interest.
• Infection of dividing and nondividing cells: The vector should be able to efficiently 
transduce all kind of cells, both dividing and nondividing alike.
• Site-specific integration: The vector should integrate the delivered gene into the host 
genome at specific site(s) to repair specific genetic defect(s).
Current gene therapy (somatic) vectors can be divided into two categories and thus 
classified as viral and non-viral vectors. The viruses used as viral vectors invade host 
cells, and transport their genetic information into the nucleus either to become part of 
the host’s genome by integrating the transgene into the host’s genome, or to constitute 
an autonomous genetic unit. On the other hand, the non-viral vectors are synthetic or 
are physical gene delivery system and they do not integrate the transgene into the 
host’s genome, they stay as episomal.
1.2.4.2.1 Viral Vectors
Viral vectors can be classified in different ways, usually as follows:
1) Based on their genetic materials:
a) RNA virus vectors (Retroviral and lentiviral vectors),
b) DNA virus vectors (Adenoviral, adeno-associated viral, herpes simplex virus -  
HSV- vectors, and others),
2) Based on their integration into the host’s genome:
a) Integrating vectors (Retroviral, lentiviral and adenoassociated viral vectors),
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b) Unintegrating vectors (Adenoviral vectors and HSV),
3) Based on their envelope: (Table 1.2)
a) Enveloped vectors (Retroviral and lentiviral vectors, HSV),
b) Non-enveloped vectors (Adenoviral and adeno-associated viral vectors)
Retroviruses RNA 8 kb Dividing cells only Low Integrated
Only 
transduces 
dividing cells; 
integration 
might induce
Persistent 
gene transfer 
in dividing cells
oncogenesis
Lentiviruses RNA 8 kb
Broad 
(dividing and 
non-dividing)
Low Integrated
Integration 
might induce 
oncogenesis
Persistent 
gene transfer 
in most cells
HSV dsDNA >30 kb
Broad 
(neurons, 
muscles and 
stem cells)
High Episomal Inflammatory
Large
packeting
capacity
AAV ssDNA 4.7 kb Broad Low
Episomal
(>90%)
Integrated
(<10%)
Small
packaging
capacity
Non­
inflammatory;
non-pathogenic
Adenoviruses dsDNA 7.5 kb Broad High Episomal Inflammatory
Extremely 
efficient 
transduction of 
most tissues
Table 1.2: The main groups o f viral vectors (adaptedfrom Thomas et al, 2003)
1.2.4.2.1.1 Retroviral vectors:
Retroviruses are RNA viruses and thus, their genomes contain two identical single­
stranded RNA molecules in the size range of 3.5-10 kb (Fry and Wood, 1999). They 
also have their own reverse transcriptase enzymes. Therefore, they insert their RNA 
genome into the host cell DNA. Once integrated, these vectors become a part o f the 
host DNA and express the transgene throughout the life of the cell. Therefore,
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retroviruses give good gene expression over a long term. Retroviral vectors were 
subjected to the first clinical trial on human gene therapy for the correction o f ADA 
deficiency (Blease et al. 1995) as mentioned before. The large part o f the retrovirus 
vectors currently used in gene therapy models are derived from the simple Maloney 
murine leukaemia virus (MLV), a C-type oncoretrovirus. Therefore, the retroviruses 
are also called as oncoretroviruses.
The titres o f retroviruses are in low range (up to 1 X 107 colony-forming units per ml) 
(Fry and Wood, 1999). But newly developed pseudotyped retroviruses have higher 
titres and a much broader host range than the wild type retroviruses (Lundstrom, 
2003). For pseudotyping, the MLV envelope glycoprotein is generally pseudotyped 
with the G protein o f vesicular stomatis virus (VSG-G) (Thomas et al, 2003).
Retroviruses can only transduce dividing cells; therefore they cannot infect non­
dividing cells. However, most o f the cells in an adult body do not divide, including 
neurons and muscle cells. The inability o f infecting non-dividing cells is the main 
disadvantage o f  the retroviruses.
1.2.4.2.1.2 Lentiviral vectors
The lentiviruses are also RNA viruses. Lentiviruses are often pseudotyped with VSG- 
G. Although lentiviruses are members o f the retrovirus family, and belong to a 
subclass o f retroviral vectors, their special features necessitate a separate description 
for them. The majority o f  the lentiviral vectors used in gene therapy are derived from 
human immunodeficiency virus (HIV). Therefore, lentiviral vectors can accommodate
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larger gene inserts and then provide long-term transgene expression (Vigna and 
Naldini, 2000; Lundstrom, 2003).
Since lentiviruses are a subclass o f retroviruses, they have the advantage o f possessing 
the ability to integrate into the host genome. Contrary to retroviral vectors, the 
lentiviral vectors can also infect efficiently the non-dividing cells, and can thus be 
applied for non-dividing, terminally differentiated mammalian cells, including 
lymphocytes, macrophages, neuronal and muscle cells. This feature makes lentiviral 
vectors very attractive among gene therapy delivery systems (Trono, 2000; Pfeifer 
and Verma, 2001). Recently, some lentiviral vectors were improved and developed 
for transduction o f  hepatocytes in vivo (Follenzi et al, 2002). Like other retroviruses, 
lentiviruses have also medium size packaging capacity, around 8 kb.
1.2.4.2.1.3 Adenoviral vectors (Ad)
Adenoviruses are non-enveloped, medium sized, double stranded DNA viruses with 
36 kb genome. They do not integrate into the genome o f the target cell. They remain 
as an extra chromosomal entity in the nucleus o f the target host cell. Adenoviral 
vectors were introduced to the field o f gene therapy in the early 1990s. Adenoviral 
vectors were first described in the early 1950’s (Ginsberg, 1999; Warren et al, 2003). 
Since then they have undergone three stages o f  their evolution, namely the first, 
second and third generations o f Adenoviral vectors (Warren et al, 2003).
Adenoviral vectors are very efficient at transducing a large number o f cell types, even 
nondividing cells, and have a high level transgene expression. However, the target
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cells for adenoviral vectors are liver cells, and almost 100% o f liver cells are 
transduced following injection o f an adenoviral vector into a mouse’s tail (Morral et 
al, 1999; Fry and Wood, 1999).
The key features o f adenoviruses, such as the ability o f generating high-titer virus 
stocks and the high level transgene gene expression, have made them very popular 
gene therapy vectors. Early versions (E) o f adenoviruses had very toxic side effects 
and strong immunological reactions. But the many viral genes o f the earlier versions 
o f adenovirus vectors were deleted in their newer, late generation vectors (L), such as 
second and third-generations, and their immunogenicities have been decreased by 
significant improvements. Despite the recent improvements, a major disadvantage o f 
adenoviral vectors in vivo is still immune responses. Because most people have been 
exposed to natural adenovirus’ infections, such as common cold viruses, the 
antibodies o f the host’s body recognise the adenoviral vectors and produce a response 
against them. Consequently, this response can cause the destruction o f vector- 
transduced cells, and leads to local tissue damage and inflammation (Fry and Wood, 
1999).
1.2.4.2.1.4 Adenoassociated viral vectors (AAV):
The adeno-associated viruses (AAV) are nonpathogenic parvoviruses, and contain 
single stranded DNA genome o f 4.7 kb (Pfeifer and Verma, 2001). In spite o f this, 
eight serotypes o f AAV have been identified in humans and primates, the most AAV 
vectors derived from AAV2 (Pfeifer and Verma, 2001; Thomas et al, 2003).
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Currently, AAV vectors are among the most popular gene delivery system, because 
they have long-term and efficient transgene expression in a large number o f cell types 
such as liver, muscle, retina, and CNS (Rabinowtz and Samulski, 1999). Nevertheless, 
they still have some disadvantages, such as small packaging capacity. However, 
unlike the adenoviruses, which can cause a high degree o f cell damage 
(cytopathogenicity), the adeno-associated viral vectors cause only a little damage to 
the host cells (Fry and Wood, 1999) and they do not appear to be associated with 
toxicity.
1.2.4.2.1.5 Other viral vectors
Other than above vectors, there remain several other different viruses used in gene 
therapy delivery systems. Some o f these are herpes simplex viruses (HSV), 
baculoviruses, alpha-viruses, pox viruses, Epstein-Barr viruses and vaccine viruses. 
They all also have several limitations along with their advantages.
1.2.4.2.2 Nonviral Vectors
Along with viral vectors, there are also many nonviral vectors that deliver transgenes 
into the target cells by physical and/or chemical techniques. The use o f nonviral 
vectors involve mainly two ways, which are a direct injection o f naked / plasmid 
DNA (pDNA), or mixing naked plasmid DNA with physical and/or chemical 
compounds that allow it to cross the cell membrane and protect DNA from 
degradation. Therefore, nonviral gene delivery systems can be classified into two 
main categories: synthetic vectors including cationic lipids and polymers, and naked 
plasmid DNA (Huang, et al, 1999). Some synthetic vectors for delivery DNA are as
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follow: cationic carriers such as cationic lipids or liposomes, cationic and also non­
ionic polymers, cationic amphiphiles; electroporation and nucleofection; in vivo DNA 
electro transfer, biolistic gene gun and ballistomagnetic gene transfer, jet injection, 
ultrasound and microbuble-enhanced ultrasound, hydrodynamic pressure, gene- 
activated matrices (GAM) and so forth (Schmidt-Wolf and Schmidt-Wolf, 2003). 
Main groups o f non-viral vectors can be seen from Table 1.3.
There are also some other types of gene delivery vectors, such as hybrid vectors (viral 
and nonviral components), peptide based gene delivery systems, nanoparticules, and 
physical and chemical combinations (magnetofection) (Schmidt-Wolf and Schmidt- 
Wolf, 2003).
Naked plasmid 
DNA
No limit myocytes 10-30%
Until death of 
cell/myocyte
Easy and 
cheap
In vivo
Electroporation 150 kb
Mitosis / 
resting
Stable <0.1-1% Easy In vitro
Microinjection No limit
Mitosis / 
resting
Stable <0.1-1% -
200/400
inject/h
In vitro
Particle
bombardment
10 000 
copies
Mitosis / 
resting
Stable <0.1-1% 
transient <20%
2-12 months Easy
In vitro and 
in vivo
Lipofection No limit
Mitosis / 
resting
Stable <0.1-1% 
transient 80%
Easy
In vitro and 
in vivo
Ligand mediated >48 kb
Mitosis / 
resting
Up to 80% in 
vitro
High,
transient
Labour
intensive
In vitro and 
in vivo
Table 1.3: Main groups o f non-viral vectors. (Adaptedfrom Schmidt-Wolf 2003)
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1.2.4.2.2.1 Naked I Plasmid DNA
Naked DNA is an attractive nonviral vector because o f its simplicity. For a long time 
it has been known that muscle cells are capable o f taking up and expressing plasmid 
DNA. Gene transfer by naked plasmid DNA to the skeletal muscle was first 
demonstrated by intramuscular injection 15 years ago. W olff et al showed that the 
plasmid DNA could be delivered into mouse muscle cells in vivo and result in an 
expression (W olff et al, 1990). Plasmid DNA can stably express in muscle for at least 
2 years (W olff et al, 1992).
Contrary to common belief, long-term transgene gene expression from naked plasmid 
DNA is possible even without chromosome integration if  the target cell is postmitotic 
(as in muscle) or slowly mitotic (as in hepatocytes) (W olff et al, 1992; Miao et al, 
2000; Herweijer et al, 2001; Zhang et al, 2004; W olff and Budker, 2005).
The administration o f naked nucleic acids including naked plasmid DNAs and 
siRNAs into animals has increasingly been used as a valuable research tool 
(Herweijer and Wolff, 2003; Hodges and Scheule, 2003; W olff and Budker, 2005). 
They have also been used in several human clinical trials, such as Duchenne muscular 
dystrophy, peripheral limb ischemia, and cardiac ischemia (Davis et al, 1996;
Tsurumi et al, 1997; Romero et al, 2002; W olff and Budker, 2005).
Nonviral vectors including plasmid DNA have no viral genes and, unlike viral 
vectors, they cannot cause diseases. For instance, plasmid or naked DNA, unlike 
viruses, does not contain a protein coat (hence the term “naked”). Because o f not
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having a protein coat, the naked DNAs cannot move from a cell to another cell freely, 
and integrate into the chromosome. As a result o f not having a protein cat, the naked 
DNA does not cause harmful reactions as viruses. Therefore, it seems today that the 
simplest and safest nonviral gene delivery system among current gene therapy 
systems is the direct injection o f naked / plasmid DNA, although it is too early to say 
which gene transfer method and gene therapy approach is safest and most efficacious 
(Wolff, 1997; Schmidt-Wolf and Schmidt-Wolf, 2003). In spite o f its safety, 
simplicity and reliability, the plasmid DNA has also its limitations such as low 
efficiency. Because the transfection efficiency o f plasmid DNA by intramuscular 
injection is relatively low, it only establishes transgene expression at the injection site 
or the injected muscle (Liu et al, 2001). In contrast, many muscle disorders, such as 
muscular dystrophies, require therapeutic gene expression in most muscles in the 
body. Therefore, plasmid DNA needs to be administered systemically in order to 
achieve effective gene therapy for such disorders (Liu et al, 2001).
1.2.4.2.3 Comparison of Gene Transfer Vectors
As mentioned before, the ideal gene delivery system should be specifically targeting, 
non-toxic, non-immunogenic, non-inflammatory, biodegradable; carrying large 
genetic material, having high efficiency, being produced at low cost and less labour 
(Schmidt-W olf and Schmidt-Wolf, 2003). Nevertheless, none o f the gene therapy 
delivery systems currently in use meets all the above criteria.
Viral vectors have problems with safety, toxicity, immunologic reactions, and the lack 
o f cell specific targeting. Furthermore, viral vectors are rapidly cleared from the blood
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circulation by limiting transfection (Schmidt-W olf and Schmidt-Wolf, 2003). On the 
other hand, nonviral delivery systems, particularly naked plasmid DNA, have several 
advantages over viral vectors:
• Nonviral vectors are generally easy to prepare and scale up. The design and 
production of naked plasmid DNA is cheaper with less labour; whereas virus and 
viral vector production are quiet expensive and labour intensive.
• Nonviral vectors generally have no limitations for the size of delivered gene, whereas 
viral vectors has limitations by the size of their viral capsid; therefore nonviral 
vectors does not have such problems in carrying larger genetic materials;
• Nonviral vectors are generally much safer in vivo. Some viral vectors may still retain 
viral genes and promoters that could express in human cells under certain conditions, 
and they can cause some dreadful diseases or severe immune responses. Such 
dreadful diseases and severe reactions did occur in near past. For instance, in 2000, 
18 years old male patient, Jesse Gelsinger, died during a viral vector based gene 
therapy clinical trial by Institute of Human Gene Therapy of University of 
Pennsylvania of USA (Nature news, 2000). And again, in 2002, two boys of ten 
children who have severe combined immune deficiency (SCID) had developed 
leukaemia -like conditions during a French retroviral based gene therapy clinical trial 
for SCID led by Drs Alan Fisher and Marina Cavazzano-Calvo of the Necker 
Hospital for Sick Children in Paris (Nature news, 2002). On the contrary, the naked 
plasmid DNA does not elicit a specific immune reaction because of not having a 
protein coat unlike viruses, and therefore it does not induce an antibody response 
against itself, such as anti-DNA antibodies. Therefore naked plasmid DNA 
administrations are reasonable safe and can be administered repeatedly (Jiao et al, 
1992).
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The efficiency o f gene transfer o f the currently available nonviral delivery systems in 
delivering transgene into skeletal muscle and other tissues by direct injection is 
relatively low and variable in contrast to viral vectors in vivo, especially in larger 
animals such as nonhuman primates (Jiao et al, 1992). However, in recent years 
efficiency o f naked plasmid DNA transfer has been increased. The recent 
developments demonstrate that naked plasmid DNA can be delivered efficiently to 
cells in vivo, either via electroporation, or by intravascular delivery (Herweijer and 
Wolff, 2003; W olff and Budker, 2005).
Herweijer and W olff suggest that electroporation increases uptake o f injected naked 
plasmid DNA into muscle tissue and skin (Herweijer and Wolff, 2003). The technical 
improvements in electroporation have increased both gene expression efficiency and 
safety (Somiari et al, 2000). M any recent publications have demonstrated that 
electroporation techniques have increased gene expression in different cell types in 
vivo. For instance, they have increased the gene expression levels in muscle 10-fold 
higher than injection o f plasmid DNA without electroporation (Hartikka et al, 2001).
Intravascular injection o f pDNA also results in a very effective gene transfer in liver 
and muscle. Particularly tail vein plasmid DNA delivery has made naked DNA 
transfer a very effective, viable gene therapy method. Plasmid DNA delivery via the 
tail vein in rodents provides a simple and effective in vivo gene transfer technique.
In this method, plasmid DNAs were delivered by rapid injection in large volumes 
(around 10% o f the body weight) via the portal vein, the hepatic vein, and the bile
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duct in mice and rats. The rapid delivery o f large volume into a vessel leads to the 
liver by the vena cava. High levels o f gene expression were first achieved by the rapid 
injection o f naked DNA in large volumes via an artery route with both blood inflow 
and outflow blocked surgically (Budker et al, 1998; Zhang et al, 2001; W olff and 
Budker, 2005). Intravenous delivery has also been shown to be effective (Liu et al, 
2001; Hagstrom et al, 2004; Liang et al, 2004; W olff and Budker, 2005). The tail vein 
delivery results in very high level o f gene transfer. For example, 10-15% o f the 
hepatocytes are transfected in mice following injection o f 10 pg pDNA, whereas the 
expression level in liver rose up to 40% by tail vein injection method (Herweijer et al, 
2001; Maruyama et al, 2002; Zhang 2002; Herweijer and Wolff, 2003). The procedure 
also proved effective in larger animals such as dogs and nonhuman primates (Eastman 
et al, 2002; Zhang et al, 1997).
The W olff group has also demonstrated high level gene expression in vivo in different 
skeletal muscle groups in mice, rats, dogs and monkeys via intravascular plasmid 
DNA delivery (Herweijer and Wolff, 2003). By this method, small interfering RNA 
(siRNA) can also be delivered very efficiently and results in a knock out o f the target 
gene expression (Lewis et al, 2002; McCaffrey et al, 2002; W olff and Budker, 2005). 
On the basis, it seems accurate to suggest that nonviral gene transfer techniques, 
particularly naked plasmid DNA delivery, will become much more important.
1.2.4.3 Skeletal Muscle and Gene Therapy
Skeletal muscle is an attractive target tissues for gene therapy applications o f both 
muscle and non-muscle disorders due to its anatomical, cellular and physiological
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properties. Gene transfer into muscle tissue can produce a variety o f physiologically 
active proteins and may ultimately be applied to the treatment o f many diseases.
Several factors make skeletal muscle an attractive route for gene transfer: i) The tissue 
is abundant, making up about 40% o f the body weight o f an average adult; ii) skeletal 
muscle is accessible to most o f the delivery systems currently used for gene transfer; 
and iii) there is no significant cell replacement in skeletal muscle tissue, so that 
introduced genes are not rapidly lost following mitosis, and transgene expression can 
thus persist for relatively long periods (Liu et al, 2001). Since the first report in 1990, 
using skeletal muscle as a direct target for transgene via naked plasmid DNA delivery 
(Wolff, 1990), many publications have identified that different proteins can be 
synthesized and correctly proceeded by skeletal muscle.
So far, almost all gene delivery systems, both viral and nonviral, have been used for 
delivering transgenes to muscle tissue, particularly skeletal muscle. As well as 
nonviral sytems, many genetically modified viruses, such as retroviruses, lentiviruses, 
herpex simplex viruses, Epstain-Barr virus, adenoviruses and adeno-associated 
viruses have tested for gene delivery vehicles into muscle (Lu et al, 2003). Among 
above, adenoviral and adeno-associated viral vectors have been found to be the most 
efficient vehicles so far for transducing muscle fibers (Lu et al, 2003).
1.2.4.4 Clinical Trials of Gene Therapy (Worldwide)
A clinical trial is a study in human volunteers to answer specific questions about new 
drugs or therapies to treat diseases. Therefore, clinical trials are used to determine
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whether new drugs or treatments are safe and effective in human subjects. Clinical 
trials have the following four phases: Phase I, II, III and IV.
Until January 2007 (between 1989 and July 2006), a total o f 1272 gene therapy 
clinical trials have taken place worldwide. (The majority of these trials (67%) were 
conducted to treat different cancers (The website of the Journal of Gene Medicine, 
Updated Jan 2007 - http://www.wiley.co.uk/genetherapy/clinical). The classification 
o f the trials can be seen in Figure 1.13.
□ Cancer diseases 67 % (842)
■ Vascular diseases 9 % (113)
□  Monogenic diseases 8.4 % (106)
□ Infectious diseases 6.4 % (81)
■ Gene marking 4 % (50)
□ Others 3.7 % (47)
■ Healthy volunteers 1.7 % (21)
Figure 1.13: Indications addressed by gene therapy clinical trails (adapted from 
http://www. wiley. co. uk/gene therapy/clinical/)
On the other hand, as can be seen from Figure 1.14, in the same period (between 1989 
and January 2007), the majority of these gene therapy clinical trails (65 %) had been 
conducted in the USA. Only 28 % of these were in European countries (Asia 2.9 %, 
Australia 1.5 % and Africa 0.1 %) (The website of the Journal of Gene Medicine, 
Updated Jan 2007 - http://www.wiley.co.uk/genetherapy/clinical). 12 % of the trials 
had been conducted in the UK; followed then by Germany (5.9 %) and Switzerland 
(3.3 %). The other European countries such as France, Belgium, Italy and the
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Netherlands were in a 1-2 % in range (1.6%, 1.5%, 1.2%, and 1% respectively) (The 
website o f the Journal o f Gene Medicine, updated Jan 2007).
□ USA 65%  (815)
■ UK 12% (150)
□ Germany 5.9 % (74)
□ Switzerland 3.3 % (42)
■ France 1.6% (20)
□ Belgium 1.5 % (19)
■ Australia 1.3 % (17)
□ Canada 1.3%  (17)
■ Japan 1.3%  (16)
■ Italy 1.2%  (15)
□ Netherlands 1 % (12)
■ Others 5.9%  (75)
Figure 1.14: Geographical distribution o f gene therapy clinical trails by countries (adapted 
from http://www.wiley.co. uk/gene therapy/clinical/)
The complete clinical trials list worldwide (until December 2005) is as follows 
(GTAC 12th Annual Report, 2005):
COUNTRIES % COUNTRIES % COUNTRIES %
Australia 1.5 Germany 6.5 Singapore 0.2
Austria 0.2 Israel 0.5 South Korea 0.3
Belgium 1.6 Italy 1.1 Spain 0.3
Canada 1.1 Japan 1.3 Sweden 0.2
China 0.3 Mexico 0.1 Switzerland 3.5
Czech Republic 0.1 Netherlands 0.6 UK 11.7
Denmark 0.2 New Zealand 0.2 USA 64.8
Egypt 0.1 Norway 0.3 Multi-country 1.0
Finland 0.3 Poland 0.3
France 1.7 Russia 0.1
Table 1.4: Gene therapy clinical trials in worldwide by December 2005. (Source: Journal of  
Gene Medicine -  taken from GTAC 12th Annual Report, 2005)
A various range o f gene delivery systems was used for these clinical trials in the same 
period. More than 70% of the vectors used in the trials were viral vectors, and about
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26 % were non-viral vectors (18 % o f these were naked/plasmid DNA, and 7.9 % of 
them were lipofection). Complete vector distributions worldwide can be seen in 
Figure 1.15.
□ Adenovirus 26 % (322)
■ Retrovirus 23 % (293)
□ Naked / Plasmid DNA 18 % (230)
□ Lipofection 7.9 % (99)
■ Vaccinia virus 7 % (85)
□ Poxvirus 6.8 % (82)
■ Adeno-associated virus 3.7 % (46)
□ Herpes simplex virus 3.4 % (43)
■ RNA transfer 1.3% (16)
■ Others 2.4%  (31)
□ Non-classified 2.9 % (36)
Figure 1.15: Vector used in gene therapy clinical trails (adapted from 
http:/Avww. wiley. co. uk/genetherapy/clinical/)
1.2.4.5 UK Gene Therapy Trials
First gene therapy study was conducted in the UK in 1993. Since then, until 
December 2005, (1993-2005) UK Gene Therapy Advisory Committee (GTAC) 
processed 126 clinical trials applications and approved 113 of them. Five approved 
trials were then withdrawn. Remaining 108 trials were analysed as follows (GTAC 
12th Annual Report [January 2005 to December 2005]):
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Figure 1.16: GTAC approved gene therapy clinical trials by years (n=108). (Taken from 
GTAC 12th Annual Report, 2005)
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Figure 1.17: GTAC approved gene therapy clinical trials by vector system (n=108). (Taken 
from GTAC 12th Annual Report, 2005)
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Figure 1.18: GTAC approved gene therapy clinical trials by diseases (n=108). (Taken from 
GTAC 12th Annual Report, 2005)
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COUNTRIES % COUNTRIES °A
Austria 0.6 Belgium 5.6
Czech Republic 0.3 Finland 0.9
France 5.9 Germany 22.8
Italy 4.0 Netherlands 2.2
Norway 1.2 Poland 0.9
Spain 1.2 Sweden 0.6
Switzerland 12.3 UK 41.4
Table 1.5: Gene therapy clinical trials by countries in Europe by December 2005. (Source: 
Journal o f Gene Medicine -  taken from GTAC 12th Annual Report, 2005).
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Chapter 1 - Part 3:
1.3 The Aim and Hypothesis of the Study
1.3.1 The purpose of the study
As can be seen from the introduction / background and the literature review o f this 
study, neuromuscular / musculoskeletal disorders affect millions worldwide. The 
current expansion o f the aged population in the developed world is predicted, by the 
World Health Organisation, to accelerate some o f these diseases to epidemic 
proportions in the next two decades (Goldspink and Noble, 2006). Nevertheless, there 
is currently no effective treatment o f any form of these disorders. Therefore, the 
treatment for such disorders is vital. Thus, the aim o f this study was to attempt to 
develop a novel gene therapy application for treating muscle degeneration in such 
disorders.
The IGF-I has a very important role in cell and tissue development and growth, 
including proliferation, differentiation, repair and maintenance, and has several 
alternative splicing variants. One o f these variants, MGF, also has a crucial role in 
tissue growth and repair, particularly in muscle; and it is now accepted as a general 
tissue growth/repair factor. There are some therapeutic implications o f IGF-I for 
different pathological conditions including neuromuscular disorders. However, so far,
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the mature peptide o f IGF-I was only used for such therapeutic implications. Neither 
the therapeutic effects o f IGF-I splice variants in such neuromuscular disorders, nor 
the roles o f them were studied in primary cell culture models in human muscle from 
the patients with such disorders has never been investigated yet. Therefore, the main 
purpose o f this study was to investigate such effects o f IGF-I splice variants on 
degenerative muscle conditions in human and animals in vitro and in vivo models in 
comparison with normal conditions.
1.3.2 The purpose of in vitro part of the study
So far, the effects o f IGF-I splice variants on human primary cell culture models have 
not been investigated. Therefore the aim o f in vitro part o f the study was to investigate 
such effects in in vitro cell culture models, comparing with rodent muscle cell lines 
with primary cultured human healthy and degenerative muscle cells such as with 
different muscular dystrophies and ALS.
1.3.3 The purposes of in vivo parts of the study
When cDNAs o f different IGF-I splice variants in plasmid vectors are introduced into 
wild-type mouse skeletal muscle tissue, the MGF increased the muscle fibre size 25 % 
within 3 weeks (Goldspink and Yang, 2001; Goldspink and Yang, 2004). Similar 
experiments were carried out by Lee Sweeney’s group (Barton-Davis et al, 1998) 
using cDNA o f systemic liver-type o f IGF-I in viral vectors. These experiments also 
resulted in a 15% increase in muscle mass (muscle force), but within over 4 months 
instead o f 3 weeks.
108
Nevertheless, the effects o f IGF-I splice variants were never investigated in a murine 
model o f DMD, which is the mdx mouse. Therefore, the purpose o f in vivo part o f the 
study was to investigate in vivo effects o f IGF-I splice variants in mdx mouse 
muscles. Thus, the aim o f the first part o f in vivo model o f the study was to 
investigate the effect o f such variants in muscle tissue growth by measuring maximum 
muscle force after introducing cDNAs o f  the variants to TA muscles o f mdx mice by 
comparing with untreated -  control TA muscles. On the other hand, Hill et al suggest 
that MGF has a significant effect in satellite cell activation after tissue damage in 
wild-type rats (Hill and Goldspink, 2003a, and Hill et al, 2003b). However, so far, no 
study has shown the roles o f IGF-I splice variants in satellite cell activation 
mechanism in degenerative muscle tissue. The second part o f in vivo model o f the 
study concentrated on the effects o f IGF-I splice variants with particular reference to 
MGF in satellite cell activation, which shows tissue growth and regeneration in 
skeletal muscles o f mdx mice.
1.3.4 Hypothesis of the study
Following two hypothesis were established based on above background:
1- E domain o f MGF, in comparison with IGF-I mature peptide, influences cell 
proliferation and prevents myogenic differentiation in primary cultured muscle 
cells from patients with CMD, FSHD and ALS, and rodent muscle cell lines.
2- The coding sequence o f MGF, in comparison to the coding sequence o f IGF-I 
Ea, improves the maximum tetanic contractile force o f muscles and activates 
satellite cells in the mdx mouse.
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Chapter 2:
Materials and Methods
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Chapter 2 - P a r t i :
2.1 Design of Experiments
2.1 The Design of Experiments
Emerging on the hypothesis o f this thesis, the objective o f this study was to 
investigate the roles o f the IGF-I splice variants in muscle cell proliferation and 
differentiation. Therefore, the work focused on the roles o f such variants in muscle 
cell proliferation and differentiation in in vitro and in vivo models. The work was 
designed as (i) in vitro cell culture model, (ii) in vivo animal model o f mdx mouse.
(i) In vitro - cell culture model experimentation was designed for investigating 
the effects o f IGF-I splice variants in myoblast proliferation and 
differentiation in different vertebrates’ species including human primary 
muscle cell culture from the patients with different neuromuscular disorders 
comparing with primary muscle cells from healthy individuals.
(ii-a) In vivo - gene transfer experimentation was designed for investigating 
in vivo effects o f IGF-I splice variants in muscle contractile force after 
introducing cDNAs o f such variants into the skeletal muscles o f the murine 
model o f DMD;
(ii-b) In vivo - satellite cell activation experimentation was designed for
investigating the roles o f such variants in skeletal muscle regeneration and
m
repair by determining gene and mRNA expression of the activated satellite 
cell markers after introducing cDNAs o f such variants into TA skeletal 
muscles o f mdx mouse.
2.1.1 In vitro - cell culture model experimentation
2.1.1.1 Cells
In in vitro part o f the study, it was aimed to investigate the effect o f IGF-I iso forms on 
different types o f myoblasts from different vertebrates’ species. Therefore, animals 
(rat and mouse) and human myoblasts were selected as different type o f the 
myoblasts, which are muscle derived cells that contain a population with myogenic 
potential that can vary enormously.
The skeletal muscles differ according to their anatomy, functions, fibre -  type 
composition, and as well as according to their embryologic origins among individual 
muscles, muscle groups and muscle regions. (Larsen, 1998; Carlson, 1999; Noden et 
al, 1999; Korfega et al, 2000; Buckingham, 2001; Buckingham et al, 2003; Korfega et 
al, 2005a; Korfega et al, 2005b). Therefore, as human primary muscle cells, different 
muscles from different parts o f human body, such as craniofacial masseter muscle as a 
head-neck and cervical region, and quadriceps -  vastus lateralis- muscle as a limb 
muscle were chosen for investigating the effects o f IGF-I isoforms in different muscle 
groups o f the human body. Along with different muscles from healthy individuals, the 
effects o f IGF-I isoforms were also investigated in three different severe degenerative 
muscles from patients with CMD, FSHD and ALS.
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To investigate the effects o f IGF-I isoform on proliferation in different rodent 
myoblast cell lines, rat myoblast cell line (L6 E9) and mouse myoblast cell line 
(C2C12) were used.
For the proliferation assays, for human primary muscle cells, the following muscle 
cells were used:
(i) Healthy craniofacial masseter muscles (obtained from biopsies of three healthy 
individuals). The assays were repeated twice.
(ii) Healthy limb muscles, (obtained from biopsies of the vastus lateralis of two 
healthy individuals). The assays were repeated twice.
(iii) Degenerative craniofacial masseter muscle with CMD (obtained from biopsy of a 
patient with CMD). The assays were repeated three times.
(iv) Degenerative lower limb muscle with FSHD (obtained from biopsies of the 
vastus lateralis of two different patients with FSHD). The assays were repeated 
twice.
(v) Degenerative lower limb muscle with ALS (obtained from biopsies of the vastus 
lateralis of three different patients with ALS). The assays were repeated twice.
For the differentiation assays with human primary muscle cells, healthy craniofacial 
masseter muscle cells were only used, because differentiation assays with muscle cells 
o f masseter muscle, and those o f limb muscles from the patients with different 
neuromuscular disorders failed.
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2.1.1.2 Proliferation Assays
2.1.1.2.1 Proliferation assays for animal cell lines
For both animal cells, rat myoblast cell line (L6 E9) and mouse myoblast cell line 
(C2C12) were treated with E domain o f IGF-I Ec [MGF]. Different concentration 
conditions o f E domain o f MGF peptide were used with both animal cell lines. The 
concentrations for E domain o f MGF peptide were as follows: 0 ,1 , 2, 5, 50 and 100 
ng/ml. The similar concentrations, which Yang and Goldspink were used their 
experiment before, were chosen (Yang and Goldspink, 2002). A set o f 8 wells o f a 96 
well plate was used for each condition.
2.1.1.2.2 Brdll Proliferation Assay
BrdU (5-bromo-2-deoxyuridine) proliferation assay is a non-radioactive method for 
determination o f cellular proliferation in living cells. BrdU works by substituting for 
thymidine during DNA replication and incorporating into the newly synthesised 
DNA. The antibodies, which are specific for BrdU, are used to detect the 
incorporating BrdU into the replicating DNA. Therefore, the indicating cells by a 
monoclonal antibody against BrdU show the proliferating cells. BrdU cell 
proliferation assays based on a 96 well microtiter plate are used as a parameter for 
routine cell proliferation applications. Thus, BrdU assays were used to investigate the 
role o f MGF in myoblast proliferation in rat and mouse myoblast cell lines.
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2.1.1.2.3 Proliferation assays for human primary cultured cells
For human myoblast cell, the cells were not sorted, therefore non-sorted / mixed cells 
were used in order to obtain maximum physiological condition, and also to reduce the 
cost o f experiments. Because the cells were not separated, fibroblasts and myoblasts 
were together in the culture. Then again, because there were not only one type of cell 
in the culture, immunocytochemistry technique was chosen instead o f BrdU 
proliferation assay in order to investigate the effect o f IGF-I isoforms on myoblast 
proliferation in primary cultured human muscle cells, both in healthy and pathologic 
conditions.
Fluorescently labelled antibodies (Desmin and FITC) and a DNA binding fluorescent 
stain (DAPI) were used to determine different cell types in cultures. Thus, the ratios 
o f progenitor myoblasts to other cells were measured after following treatment with 
different IGF-I isoforms. An indirect method o f detection was used with a monoclonal 
primary antibody detected by a FITC conjugated secondary antibody and viewed 
using fluorescent microscopy.
2.1.1.2.3.1 Optimisation of proliferation assays
Initially, three time-points were used as 24, 48 and 72 hours in order to determine 
optimal culture time. The normal (healthy) human craniofacial primary cells were 
treated with MGF (500 ng/ml), long r3 IGF-I (10 ng/ml) and both MGF and r3 IGF-I 
together (500 and 10 ng/ml, respectively) for 24, 48 and 72 hours. For positive 
control, some cells were not treated with any o f such peptides for the same time 
points. As can be seen from Figure 2.1, MGF had not increased myoblast proliferation
115
at either 24 or 72 hours. However, it increased myoblast proliferation at 48 hours 
(Figure 2.1). Therefore, 48 hours had been determined as the time point for the human 
primary cell culture experiments. After determination o f the optimal time point, which 
was 48 hours, all cells in the experiment process were treated for 48 hours.
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Figure 2.1: Investigating time points for myoblast proliferation on healthy human 
craniofacial primary cells. The concentration for MGF was 500 ng/ml; for long r3 IGF-I was 
10 ng/ml and for MGF + long r* IGF-I is 500 ng/ml (for MGF) and 10 ng/ml (for long r3 
IGF-I). Data were presented as mean ± s. d. p  <0.05 was considered significant.
As with the BrdU assays, two different IGF-I peptides were used as different IGF-I 
isoforms. For mature IGF-I receptor domain, recombinant human IGF-I (long r3 IGF- 
I) (Sigma) was used as IGF-I Ea isoform, and for IGF-I Ec, an E peptide o f MGF was 
used that was synthesised with Department o f Biochemistry in UCL. Also the IGF-I 
receptor blocking antibody (Ab-I) (Oncogene) was used in order to investigate 
whether or not MGF had a different signalling pathway from systemic IGF-I. The 
healthy and pathological human primary cells were also treated with Ab-I with and
without MGF. To determine optimal concentrations, different concentrations and 
repeats were used for MGF and long r3 IGF-I. Conditions were as follows:
1 -  Only defined medium, (for positive control);
2 - IGF1R (type 1 IGF receptor) blocking antibody (500 ng/ml);
3 -  MGF (10 and 100 ng/ml);
4 - MGF (10 and 100 ng/ml) with IGF1R blocking antibody (500 ng/ml);
5 -  Long r3 IGF-I (10, and 100 ng/ml);
6 -  MGF (10 and 100 ng/ml) with long r3 IGF-I (10 and 100 ng/ml);
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Figure 2.2: Investigating optimal concentrations for myoblast proliferation on healthy human 
limb muscle primary cells. The concentrations for MGF were 10 and 100 ng/ml; for long r3 
IGF-I was 10 and 100 ng/ml. Data were presented as mean ± s.e.m. p  <0.05 was considered 
significant. NS non-significant. :
As can be seen from Figure 2.2, which shows optimum dose concentration result, 
effects of E domain o f MGF with 10 and 100 ng/ml were very similar. Similar effects 
were seen for long r3 IGF-I doses. Effects o f long r3 IGF-I peptide with 10 and 100
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ng/ml were similar again (Figure 2.1). Therefore, optimum concentrations for both 
MGF and long r3 IGF-I were chosen as 10 ng/ml for all human primary cultured cell 
proliferation assays.
2.1.1.3 Differentiation assays
The role o f IGF-I isoforms in differentiation was also investigated in the part o f in 
vitro cell culture model o f the study. As detailed to a certain extent in section 
1 .2 .1 .1 .5, myoblasts differentiate to form multinucleated myotubes by cellular fusion. 
Therefore, the myotube formation was investigated in order to determine the roles of 
IGF-I isoforms in differentiation process in healthy and pathological human primary 
muscles. The creatine phosphokinease (CPK) activity on myotubes was measured for 
these differentiation assays because myoblasts does not have any CPK activity where 
as the myotubes do. Therefore, the CPK/Protein ratio was used in order to analyse the 
role o f IGF-I isoforms in myoblast differentiation in human muscle cells. Hence, both 
CPK assays and BCA protein assays were used in order to investigate the role o f IGF- 
I isoforms during myoblast differentiation / myotube formation.
2.1.1.3.1 Creatine phosphokinase (CPK) assay
The enzyme creatine phosphokinease (CPK) catalyses the reversible phosphorylation 
o f ADP by phosphocreatine to form ATP and free creatine. The schematic reaction is 
as follows:
ATP + Creatine CPK ^ ADP + Phosphocreatine
Phosphocreatine Hydrolysis ^ Creatine + Inorganic phosphorus
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The reaction may be followed in either direction by measuring the formation o f one or 
the other o f the end products. CPK activity is measured using the colorimetric method 
based on the generation o f phosphorus according to the above reaction. The inorganic 
phosphorus produced is then measured colorimetrically by Fiske and SubbaRow 
procedure and is proportional to CPK activity. The kit used for CPK assay in this 
study is the Sigma Diagnostic CPK kit. It is intended for use in the qualitative, 
colorimetric determination o f creatine phosphokinase in serum at 620-800 nm.
2.1.1.3.2 BCA protein assay
BCA Protein Assay kit (Pierce) is detergent-compatible formulation based on 
bioinchroninic acid (BCA) for the colorimetric detection and quantitation o f total 
protein. The method combines reduction o f CU+2 to CU+1 by protein in an alkaline 
medium with the sensitive and selective colorimetric detection o f cuprous cation 
(Cu+1) using a unique reagent containing BCA. The complex exhibits a strong 
absorbance at 562 nm that is nearly linear with increasing protein concentrations over 
a broad working range ( 2 0  -  2  0 0 0  pg/ml).
2.1.1.3.3 The conditions for differentiation assays
For these assays 96 well -  plates were used for both BCA protein assay and CPK 
assays (One plate was for CPK assay, and another plate was protein assay). For 96 
well plates, 10X104 cells were put into each well. For 96 well plates, 16 conditions 
with 5 repeats (16 X 5) were used. The time point was the same as proliferations 
assays, 48 hours, for both assays.
119
The cells were treated again with and without MGF and long r3 IGF-I separately or 
together. Conditions for differentiation experiments were the same in both CPK and 
BCA protein assays. These are as follows: (1) - Only fusion medium, no growth 
factor, (for positive control); (2) - MGF (10 and 100 ng/ml); (3) - r3 IGF-I (10 ng/ml); 
and (4) - MGF (10 and 100 ng/ml) with long r3 IGF-I (10 ng/ml);
2.1.2 In vivo - gene transfer experimentation
2.1.2.1 Introduction
Up to the present time, various therapeutic strategies to treat DMD have been 
proposed. Many different viral and non-viral plasmid vectors have been used to 
deliver genetic materials to treat DMD. The main goal of gene therapy strategies for 
DMD so far was either to add a functional gene copy or to “repair” the mutated 
dystrophin gene. The main approach o f this study was to regenerate degenerative 
muscles, instead o f replacing or repairing the mutated dystrophin gene. For this aim, 
cDNA o f IGF-I splice variants (IGF-I Ea and MGF) in plasmid/naked DNA vectors 
were transferred into limb skeletal muscles (TA muscles) o f old and young mdx mice, 
and then 3 weeks after injection maximum muscle forces and weights o f TA muscles 
were measured. Because the muscles o f mdx dystrophic mouse are unable to express 
MGF even during mechanical stimuli (Goldspink and Yang, 2001; Goldspink and 
Yang, 2004; Goldspink, 2005), dystrophin deficient mdx mice was chosen as in vivo 
animal models and cDNAs o f IGF-I variants were injected into TA muscles o f mdx 
mice.
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On the other hand, the skeletal muscle provides a good biological example o f a 
structure-function relationship. Since the 1600s, anatomical, physiological as well as 
biomechanical properties o f skeletal muscle have been studied in some detail (Blix, 
1895; Lieber, 1999). Since then, it has been identified that the primary purpose o f 
skeletal muscle is to generate force and movement. The anatomical structure o f 
skeletal muscle, specifically the number and arrangement o f muscle fibers, has a 
profound effect on muscle force and body movement (Lieber, 1999). Muscle mass in 
size and length and also the numbers o f muscle fibre affect the muscle’s contractile 
force. Therefore, the greater numbers o f muscle fibers and the larger muscle fibres in 
size are all contribute for the increase in the contractile force o f muscle (Marieb, 
2001). Therefore, it is possible to investigate the changes o f numbers and size o f 
muscle fibers by measuring the maximum muscle force.
2.1.2.2 Effects of IGF-I splice variants based gene therapy
A considerable body o f research suggest that muscle mass in size, particularly the 
total cross sectional area o f muscle fibres affect muscle’s contractile force. Therefore, 
large number o f  large muscle fibres increase the contractile force o f muscle (Marieb, 
2001). Thus, 21 days after injecting cDNAs o f MGF and IGF-I Ea, and also a 
pcDNA3.1NT/GFP vector not containing any cDNA o f IGF-I splice variants into one 
o f TA muscles, the differences o f maximum muscle force between injected and 
uninjected control muscles presented the effects o f IGF-I variants as gene therapy 
agents in animal model o f Duchenne Muscular Dystrophy (DMD).
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2.1.2.3 Animals
The mdx mouse, an animal model o f human DMD, was chosen for in vivo 
experimentation. Therefore, the mdx mouse, which is a genetic and biochemical 
homologue o f the DMD, has been broadly used for a long time although it has a 
milder phenotype o f human DMD. Because o f this background, mdx mice were used 
for in vivo investigation o f effects o f IGF-I splice variants as gene therapy agents on 
Duchenne Muscular Dystrophy.
Before starting the animal experimentation, a Home Office laboratory animal 
management, welfare and surgery training (module 1 , 2 , 3  and 4) was undertaken. The 
training was successfully completed, and a personal licence was acquired for working 
with mouse, rat, rabbit, guinea pig and hamsters (from administrative responsibilities 
to major surgical procedures). After that, all procedures for animal experimentation 
were performed in accordance with the institutional guidelines for the care and use o f 
laboratory animals, and were approved by the Home Office in the UK.
For animal experimentation, young and old mdx mice (C57Bl/10ScSn mdx) were 
used. The mdx mice were obtained from the cages in Prof Goldspink’s mdx mice 
breeding store in Royal Free CBU unit o f Royal Free and University College Medical 
School (Hampstead Campus) in UCL. For in vivo gene transfer experiments, two sets 
o f animal experiments were carried out, as young and old mdx mice.
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Figure 2.3: Mdx mice
23 young mdx mice (12 females and 11 males) were used for young mdx mice gene 
transfer experiments. Their ages were between 4 and 8 weeks old, and their 
bodyweights ranged from 22.86 g to 30.97 g (26.18 ± 4.78 g).
For old mdx mice experimentation, 23 old mdx mice between 12 and 26 months old 
(11 females and 12 males) were used. The bodyweights o f the old mdx mice used 
ranged from 22.40 g to 36.50 g (32.14 ± 9.74 g). The bodyweights of old animals 
were very broad, because some of the animals were very old (over 2 years old).
Two different cDNAs of IGF-I splice variants, IGF-I Ea and IGF-I Ec (MGF), were 
inserted into a plasmid vector and used for investigating in vivo effects o f these IGF-I 
splice variants on young and old mdx mice. Therefore, before injecting cDNAs o f two 
different IGF-I alternative splice variants to the animal muscles, both young and old 
mdx mice were divided into three groups, as
(i) IGF-I Ea,
(ii) IGF-I Ec (MGF)
(iii) Vector-only (control).
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For young mdx mice experimentations, animals were randomly separated into three 
groups in two sets, such as seven mice for vector-only group, eight mice for MGF 
group, and eight mice for IGF-I Ea group. For the older mdx mice experimentation, 
animals were similarly separated into three different groups as vector: Seven mice for 
vector-only and eight mice for each o f MGF and IGF-I Ea groups. However, in the 
course o f experiments, one older mouse from each group o f vector-only and MGF 
died. The final numbers o f groups were six mice for vector-only, seven mice for 
MGF, and eight mice for IGF-I Ea group. It is known that when the mdx mice, 
particularly female mdx mice, get older, they become weak.
2.1.2.4 Gene delivery system
The naked/plasmid DNA gene delivery system has some advantages such as its 
simplicity and safety in contrast to other types o f gene transfer. The plasmid / naked 
DNA delivery also provides more opportunities for local intramuscular gene injection. 
Emerging on such advantages it has, plasmid cDNA gene delivery system 
(pcDNA3.1NT/GFP o f Invitrogen) was selected as the delivery system of this study.
2.1.2.5 Determining the time course for pcDNA gene transfer
A while ago, some groups introduced different IGF-I variants into skeletal muscle in 
order to regenerate muscle fibers, instead o f replacing or repairing the mutated 
dystrophin gene. These include Lee Sweeney and Nadia Rosenthal’s groups in 
University o f Pennsylvania and Harvard University. They carried out similar strategy 
and technique (Barton-Davis et al, 1998). They transferred cDNA o f liver / systemic 
type o f IGF-I (IGF-I Ea) in adeno-associated virus (AAV) vector into mdx mouse
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muscles. They measured muscle force mechanically 4-9 month after injection. They 
suggested that they found the IGF-I Ea expression promotes an average increase o f 
15% in muscle mass and strength in healthy young adult mice (Barton-Davis et al, 
1998) comparing with uninjected control muscles.
When Goldspink and Yang introduced cDNAs o f IGF-I splice variants including 
MGF into TA muscles o f wild type C57BL/10 mouse by the naked DNA/plasmid 
vector delivery system, they found that MGF increased average o f 25% in muscle 
fibre size in injected muscle by comparing uninjected control muscle, within just 3 
weeks (Goldspink and Yang, 2001; Goldspink and Yang, 2004).
On the other hand, according to W olffs group, CMV promoter-driven plasmid DNA 
expression is very high on day 1 , after injection, but it starts diminishing strongly on 
day 2. It gets relatively stable on day 4 until the end o f week 3. In this period, between 
the 4th and 21st day, expression levels remain relatively stable or decline very slowly. 
After the end o f 3rd week, expression level starts dropping very sharply again 
(Herweijer et al, 2001; Herweijer and Wolff, 2003). However, plasmid DNA can be 
detected for at least 12 weeks after injection. According to above background, the 
time interval was chosen as 3 weeks (21 days) in this study.
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2.1.3 In vivo - satellite cell activation experimentation
2.1.3.1 The selection of the markers for satellite cell activation
In general, the satellite cells are identified and characterized in terms o f molecular 
markers, which are expressed by them. Along with other proteins, the activated 
satellite cells express the following myogenic regulatory factors (MRFs): MyoD,
Myf5, myogenin and MRF4. MyoD (also called Myogenic Factor 3 -MYF-3 / Myf-3-, 
or Myoblast determination protein 1 in human), and myf5 expressions are involved in 
early stage o f satellite cell activation (proliferation stage), whereas myogenin and 
MRF4 expressions are associated with terminal differentiation (Hawke and Garry, 
2001). Upon satellite cell activation, an increase in MyoD transcript and protein occur 
within 12 hours (Dhawan and Rando, 2005). In the late stage o f activation, an 
increase occurs in myogenin (also called myogenic factor-4 -  Myf4- in human) and 
other MRFs expressions. The increase o f myogenin and other MRFs initiates the 
terminal myogenic differentiation program by upregulating the genes such as those 
encoding myosin heavy chain, creatine kinase and sarcomeric actin proteins (Dhawan 
and Rando, 2005). Myogenin appears at the earliest stage in differentiating myoblasts 
or muscle progenitor cell phase and it is not expressed in proliferating myoblasts. 
Similar findings were proposed by Zammit et al (2006). They suggest in most recent 
paper that although there are many satellite cell markers, the most important markers 
are CD34, Pax7, Myf5/p-gal, PCNA, MyoD, Myogenin and MLC3F-tg (Zammit et al, 
2006). CD34 and Pax7 are markers for mainly quiescent stage o f the satellite cells, 
MyoD is for proliferation stage, and Myogenin is for differentiation stage o f those 
cells (Zammit et al, 2006). Therefore, MyoD and Myogenin were selected for
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investigating satellite cell activation. Schematic o f satellite cell myogenesis and some 
typical markers o f each stage can be seen from Figure 2.4.
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Figure 2.4: Schematic o f satellite cell myogenesis and markers typical of each stage.
As a result, MyoD and myogenin was selected as satellite cell activation markers, 
because both markers play an important role in skeletal muscle myogenesis, 
particularly in satellite cell activation. The MyoD was selected as the marker for the 
early stage of satellite cell activation, and myogenin was selected as the marker for the 
late stage of such activation. The mRNA expression levels o f these two satellite cell
1 0 7
activation markers were investigated in TA muscle tissues o f young mdx mice, 21 
days after injecting cDNAs o f IGF-I splice variants (IGF-I Ea and MGF) in 
pcDNA3.1NT/GFP vectors and vector-only for positive control.
On the other hand, mRNA expressions o f MyoD and myogenin were compared with 
mRNA expression o f an internal control/reference (housekeeping) gene. As internal 
control housekeeping gene, P-actin was selected, because P-actin is one o f most 
commonly used internal control/reference gene (Bustin, 2000; Bustin and Nolan, 
2004; Huggett et al, 2005) and its mRNA is expressed at moderately high levels in 
most cell types including muscle cells and it encodes an ubiquitous cytoskeleton 
protein (Bustin, 2000).
2.1.3.2 Gene and mRNA expression methods
To date, many techniques have been developed to measure gene expression in tissues 
and cells. Among them, four methods are in common use for the quantification of 
transcription levels o f specific genes: (a) Northern Blotting, (b) in situ hybridisation, 
(c) RNase protection assays, and (d) reverse transcription polymerase chain reaction 
(RT-PCR) (Bustin, 2000). The most sensitive and the most flexible quantification 
method among above four methods is RT-PCR (Bustin, 2000). Therefore, this method 
can be used to determine the presence or absence o f a transcript, to estimate and 
compare mRNA levels in different samples, and to characterised patterns o f mRNA 
expressions. Therefore, the quantitative real-time reverse-transcription polymerase 
chain reaction (RT-PCR) technique was used to determine gene and mRNA 
expression o f myogenin and MyoD.
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Chapter 2 -  Part 2:
2.2 Materials
Animals
C57BL/10ScSn- mice (mdx mice)
Cells:
- L6 E9 rat myoblasts cell line
The cells were taken from the liquid NO2 store o f the Molecular Tissue Repair Unit of 
Department o f Anatomy and Developmental Biology / Department o f Surgery in 
Royal Free Campus o f UCL, which were bought from European Cell Lines Bank)
- C2C12 mouse myoblasts cell line
The cells were taken from the liquid NO2 store o f the Molecular Tissue Repair Unit of 
Department o f Anatomy and Developmental Biology / Department o f Surgery in 
Royal Free Campus o f UCL, which were bought from European Cell Lines Bank)
- Primary Human Muscle Cells:
- Craniofacial Masseter Muscle non-sorted Cells:
- The Healthy Cells:
The cells were taken from the liquid NO2 store o f Department o f Biomaterials and 
Tissue Engineering in Eastman Dental Institute o f UCL obtained from consented 
healthy children at the Eastman Dental Hospital.
The Cells with Congenital Muscular Dystrophy (CMD):
The cells were taken from the liquid NO2 store o f Department o f Biomaterials and 
Tissue Engineering in Eastman Dental Institute o f UCL obtained from the children 
with CMD disorder, patients undergoing dental surgery and the removal o f third 
molars under general anaesthesia at the Eastman Dental Hospital
129
Limb muscle non-sorted cells of the vastus lateralis:
The Healthy Cells:
The cells from healthy individuals were obtained from Dr Richard W. Orrell o f 
University Department o f Clinical Neuroscience o f Royal Free Hospital.
The Cells with ALS
The cells from patients with ALS were obtained from Dr Richard W. Orrell o f 
University Department o f Clinical Neuroscience o f Royal Free Hospital.
The Cells with FSHD
The cells with FSHD were prapered from the biobsies (percutaneous needle biopsy), 
which were carried out with Richard W. Orrell o f University Department o f Clinical 
Neuroscience o f Royal Free Hospital on patients with Fascioscapulohumeral 
dystrophy (FSHD).
IGF-I peptides
MGF peptide:
The 24 amino acid peptide o f MGF was synthesized by Department o f Biochemistry 
o f UCL according to sequence for C-terminal o f MGF transcript. The sequence o f the 
synthetic peptide was: NH2-Y(Tyr)-Q(Gln)-P(Pro)-P(Pro)-S(Ser)-T(Thr)-N(Asn)- 
K(Lys)-N(Asn)-T(Thr)-K(Lys)-S(Ser)-Q(Gln)-R(Arg)-R(Arg)-K(Lys)-G(Gly)-S(Ser) 
-T(Thr)-F(Phe)-E(Glu)-E(Glu)-H(His)-K(Lys)-COOH. The N terminus was modified 
by a PEG derivative ( 0 ’0-bis(2-aminopropyl)polyethylene glycol 1900) (Jeffamine) 
via a succinic acid bridge. The crude peptide was precipitated, and the product was 
separated by centrifugation. After being washed and vacuum-dried, the peptide was 
purified by HPLC and then analysed.
Human Recombinant IGF-I peptide:
Human Recombinant IGF-I (long r3 IGF-I) (from Sigma-Aldrich)
Antibodies
IGF1R blocking antibody - Ab-I -  (Oncogene)
Monoclonal mouse anti-human Desmin antibody (DAKO)
DAPI
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Anti mouse FITC 
Anti-BrdU
Kits
BrdU labelling and detection kit III (Roche)
Creatine Phosphokinease (CPK) kit (Sigma)
BCA Protein Assay Reagent Kit (Pierce)
QIAGEN EndoFree Plasmid Maxi Kit (Qiagen)
Omniscript Reverse Transcriptase Kit (QIAGEN)
QIAqick Gel Extraction Kit (QIAGEN)
Hoods:
Culture Hoods (All cells were treated in class II biological safety cabinets with double 
fan)
Fume Hoods
CO2 Incubators:
All cells were grown via incubation in a humidified environment at 37 °C and 5% 
C 0 2.
Devices and machines
Light microscopy 
Hemacytometer (Sigma)
Plate reader 
pH meter 
Electronic balance
Different centrifuges (Sarval GS3 rotor, Sarvall SS-34 rotor, and micro centrifuges)
Shaker
Autoclave
Oven
Microwave
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Ultraviolet camera
GeneSpec I device (Naka Instruments)
Force transducer (Harvard Instruments Co. Ltd)
Lightcycler machine (Roche Diagnostics Inc, Germany)
Homogeniser 
Minigel tanks 
Homoeothermic blanket 
Electrical shaver 
Surgical devices (Scalpels etc)
Silk thread 
27 gauge needles 
PC Computer
Softwares
Spike 2 -  Version 4- software (CED- Cambridge Electronic Design - UK). 
GeneSpec I software (Naka Instruments)
Omiga 2.0 software (Oxford Molecular)
Microsoft Office 2003 software package
Tissue Culture Plastics and Glasses
Flasks with vented caps (25 cm2, 75 cm2 and 150 cm2) (Orange)
Multi-well plates (flat bottom and U-shaped bottom) ( 6  and 96 wells) (Orange, 
Nunclon and Coming)
Centrifuges Tubes (20 ml and 50 ml) (Orange)
Petri dishes (glass and plastic, 35 mm, 60 mm, 100 mm and 150 mm) (Orange and 
Nunclon)
Pipettes (1, 2, 5, 10 and 25 ml) (Orange)
Plastic tubes (0.5 ml and 2 ml) (Nunclone)
Cryotubes (2 ml) (Nunclon)
Glass cover slips (13 mm)
Tube racks
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Erlenmeyer Flasks (Orange)
Beakers (250 ml and 1000 ml)
Glass and plastic bottles (different sizes)
Solutions and chemicals
DMEM (Gibco)
PBS (Gibco)
Gelatin (20 %, Sigma)
FBS / FCS (Sigma)
Trypsin / EDTA (Sigma)
Trypan blue 
DMSO
BSA (30% IgG -  free) (Sigma)
EGF
bFGF
Insulin
Dexamethasone
Feutin
Vitamin E (Trolox)
Vitamin H (Biotin)
Vitamin C
Transferrin
Sodium Selenite
Albumax-1
Tripton X-100
Citiflour
Lysine
Sodium Azide - NaN3 (Sigma) 
Parafolmaldehyde 
Methanol (neat)
Acetone (neat)
Absulute Ethanol -  EtOH (neat)
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0.5 mM gly gly buffer 
1 X Reporter Lysis Buffer (RLB)
Fiske and SubbaRow solution 
Agarose
Tryptone (Sigma)
Yeast extract (Sigma)
NaCl (Sigma)
Bacteriologic agar (Sigma)
Urethane
Ethidium bromide
TAE
TBE
PCR dye
DNA size marker ladders (50, 100 and 1000 Kb)
OCT (optimum cutting temperature)
Liquid Nitrogen
RNA Later solution (QIAGEN)
2X Quantitect SYBR Green PCR Master Mix (QIAGEN) 
TRI reagent (Sigma)
RNase-free water (Promega)
DEPC - treated water 
Chloroform (Sigma)
Sodium Acetate 
Isopropanol
RQ1 RNase-free DNase (Promega)
10 X RT Buffer (QIAGEN)
Omniscript Reverse Trinscriptase enzyme (QIAGEN) 
dNTPs (QIAGEN)
RNAse inhibitor (Promega)
Antibiotics
Penicillin (Sigma)
Streptomycin (Sigma)
Ampicillin (Sigma)
Tetracycline (Sigma)
Vectors
pcDNA3.1/NT-GFP vector (Invitrogen)
Restriction enzymes
Apa I restriction enzyme 
Kpa I restriction enzyme 
Reaction Buffer (Buffer 4)
Primers
MyoD (Sigma) (N CBIN M  010866) 123 bp Mw: 38.139 g/mol KD ssDNA 
Upperstream (forward) -TTTCTTCACCACACCTCT- 
Downstream (reverse) -TTAACTTTCTGCCACTCC-
Myogenin (Sigma) (NCBI NM 031189) 102 bp Mw: 31.547 g/mol KD ssDNA 
Upperstream (forward) -AGACGAAACCATGCCCAA- 
Downstream (reverse) -TAAAAGCCCCCTGCTACAGA-
p-actin (Sigma) (GenBank AB117093) 186 bp mw 41.695 g/mol KD ssDNA 
Upperstream (forward) -GACGATGATATTGCCGCACT- 
Downstream (reverse) -GATACCACGCTTGCTCTGAG-
Random hexamers primers (QIAGEN)
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Chapter 2 -  Part 3:
2.3 Methods
2.3.1 In vitro - cell culture experimentation 
2.3.1.11ntroduction
To investigate the role o f IGF-I splice variants in vitro on skeletal muscle cells; 
different cell types from different species, such as mouse, rat and human, were used. 
For animal cells, rat (L6  E9) and mouse myoblasts (C2C12) cell lines; and for human 
cells, primary healthy and degenerative muscle cells, both from craniofacial and lower 
limb muscles were investigated because o f their different embryologic origins,. The 
characteristics o f these cells were determined via light, phase and fluorescent 
microscopy.
2.3.1.2 Cells
The healthy primary craniofacial masseter muscle non-sorted cells and the 
craniofacial masseter muscle primary cells with congenital muscular dystrophy were 
acquired from the liquid nitrogen store o f Department o f Biomaterials and Tissue 
Engineering in Eastman Dental Institute o f UCL. The human craniofacial masseter 
muscle biopsies were previously obtained from healthy children and the children with 
CMD disorder, patients undergoing dental surgery and the removal o f third molars 
under general anaesthesia at the Eastman Dental Hospital. For having primary
136
cultured human craniofacial muscle cells, the biopsies were finely diced and the 
fragments plated into 0.2% gelatin coated T80cm2 culture flasks, incubated in 
standard growth medium (SGM: 20% FCS and 1% P/S in DMEM) and maintained at 
37°C in humidified air/CC>2. The expanded cells were then stored under cryogenic 
conditions.
The human primary limb muscle cells o f the vastus lateralis, from healthy individuals 
and form patients with ALS, were obtained from Dr Richard W. Orrell o f University 
Department o f Clinical Neuroscience o f Royal Free Hospital. A number o f biopsies 
(percutaneous needle biopsy) were also carried out with Dr Orrell on patients with 
Fascioscapulohumeral dystrophy (FSHD). Biopsy procedure was made as follows: 
Following local anaesthesia with 1 % lignocaine (lidocaine; Phoenix Pharma Ltd, 
UK), muscle biopsies were taken from the vastus lateralis muscle using the 
percutaneous needle biopsy technique (Bergstrom, 1962) with applied suction. 0.5-3 
cm of human vastus lateralis muscle tissue samples were then treated via explant 
primary culture technique.
2.3.1.3 Primary Cell Culture
Initially, a 6 -well plate was coated before addition o f cut-tissue samples for 
incubation. For coating, 1 ml o f 0.2 % gelatin in PBS was added to each well. The 
plate was shaken on a plate shaker for 2 hours for coagulation. After coagulation, 
gelatin was removed from wells. 0.2% gelatin coated plate contains 1 ml o f DMEM 
with 1% of P/S/well was carried to an operation room in sterile conditions on ice. 0.5 
cm o f quadriceps (vastur lateralis) muscle tissue sample taken from a patient using the
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percutaneous needle biopsy technique with applied suction was put in a well 
containing DMEM with P/S. The plates were immediately carried into a hood in the 
tissue culture laboratory.
The tissue was washed by DMEM and chopped very finely by microsirurgical scissor 
and scalpels. The pieces in DMEM were transferred to a 50 ml centrifuge tube by 10 
ml wetted pipette. The pieces were washed by resuspending in DMEM and the pieces 
were left to settle for a while, and then the supernatant fluid was removed. The pieces 
were washed again in DMEM, settled; and the supernatant was removed one more 
time; and finally some DMEM was added onto the washed pieces.
The pieces in DMEM were transferred to the wells o f the plate by pipetting. Each 
wells contained 10-15 pieces. DMEM was removed and 200 pi o f growth medium 
with 40% o f FBS and 1% o f P/S was added onto each well to be adhered. The pieces 
were then incubated at 37 0 C and 5% CO2 overnight.
Following day, 200 pi o f growth medium was gently added again and the medium 
volume was increased everyday until each well had 2 ml o f 40% o f growth medium. 
The medium was changed weekly until a substantial outgrowth o f cells was observed. 
When the cells were confluent, which took about 5-8 weeks, the explant was picked 
off from the centre o f the outgrowth with a sterile scalpel and transferred to another 
coated 6  well plate for further culturing. The cells o f the first plate were then passaged 
by routine passage technique and seeded into a 0.2% of gelatin pre-coated 75 cm2 
tissue culture flask. See 2.2.3.
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2.3.1.4 Routine Ceil Culture
The cells were grown in a medium with 10 % FBS and medium changed every 3 - 4  
days. The cells were grown until they formed a monolayer sheet on the plastic (70-80 
% confluent) at 37 0 C and 5% CO2, which took between 3 and 2 1  days.
2.3.1.5 Routine Passage
The growth medium was aspirated o ff and the monolayer cell culture content was 
washed 3 times with Ca2+ / Mg2+ free PBS. The cells were harvested from the plastic 
flask using 1 X Trypsin / EDTA at 5 ml 1 X Trypsin / EDTA per 75 cm2. The trypsin 
digests the ECM links and EDTA Ca2+ on which cell-cell adhesion is dependent. The 
flasks were incubated until all o f the cells had rounded up and detached from the 
plastic, which took approximately 5-10 minutes. Trypsin action was terminated by 
addition o f 5 ml o f growth medium with 10 % FBS. Trypsined cell / medium mixture 
was transferred to a 50 ml centrifuge tube and centrifuged at 1000 rpm for 5 minutes 
to pellet the cells. The supernatant was discarded gently and the cells re-suspended in 
5 ml o f medium by titurating with 10 ml pipette. Re-suspended cells were counted 
using haemocytometer. The cells were seeded again at 2 X 105 cells per 75 cm2 flask 
at 37 0 C and 5% CO2 for continued growth.
2.3.1.6 Cell Density Determination
The cell density was determined using a haemocytometer viewed under a light 
microscope at a magnification o f 10 times. 7pl o f the sample o f the trypsinised and 
resuspended cells were collected and put into a 0.5 ml plastic tube. The cell sample 
was mixed with 7pl o f Trypan blue, and the mixture was allowed to stand for 10
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minutes. 7jj.1 of trypan blue/cell suspension were transferred to both chambers of the 
haemocytometer by carefully touching the edge of the cover slip with the pipette tip 
and allowing each chamber to fill by capillary action (Figure 2.5). At a 10 X 
magnification, the grid was located and the cells were counted within the four primary 
squares, which are circled in Figure 2.6. The value was averaged for the four primary 
squares and by using the calculation formula (c = n x  104). 
c  = cell concentration (cells / ml), n = average number of cell counted.
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Figure 2.5: Mounting a cover glass onto a haemocytometer slide.
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Figure 2.6: The grids and squares in a haemocytometer slide.
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2.3.1.7 Freezing down Cell Stocks
After trypsinisation and centrifugation, cells were counted and 1 X 106 o f cells were 
re-suspended in 10 % DMSO in FBS. The 1 ml o f cell solution was transferred to a 
cryotube, labelled and placed in a plastic container with isopropanol, overnight at -  
80° C. Next day, the cryotubes were transferred to a liquid nitrogen tank for long term 
storage.
2.3.1.8 Thawing Out Cell Stocks
Frozen vial o f cells were taken from the liquid nitrogen store and thawed in room 
temperature or in a 37 °C water bath. The content (1 ml) was transferred to a 50 ml 
centrifuge tube containing 9 ml o f growth medium and then centrifuged at 1000 rpm 
for 5 minutes. The supernatant was discarded and the cells resuspended in 15 ml o f 
growth medium with 10 % FBS and then transferred to 75cm2 flask. The flask(s) were 
left for incubation at 37 0 C and 5% CO2.
2.3.1.9 Coating Flasks
For primary non-sorted human muscle cells, the flasks were coated before addition of 
cells for incubation. For coating, 5 ml o f 0.2 % gelatin in PBS was added into the 
flask(s). They were shaken on a shaker for 1 -2 hours to allow gelatin to adhere to the 
tissue culture plastic. After this time, all liquid was removed from flask(s) and then 
the cells were transferred in.
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2.3.1.10 Proliferation Assays
To investigate the effects o f IGF-I splice variants cell proliferation in muscle cells of 
different species, different proliferation assay methods were used for different cell 
types as explained before. For rat L6E9 and mouse C2C12 cell lines, BrdU (5-Bromo- 
2 -deoxy-uridine) labelling and detection kit III (Roche -  Cat. no. 1 444 611), and for 
non-sorted human primary cells immunocytochemistry assays were used.
2.3.1.10.1 BrdU Proliferation Assay
2.3.1.10.1.1 Plating Cells
Frozen vials o f  rat L6E9 and mouse C2C12 cells were taken out from the liquid 
nitrogen store and thawed in room temperature. The cells were transferred into T75 
flasks with growth medium and grown until becoming 70-80 % confluent and then 
harvested and counted by using a haemocytometer. Both rat L6E9 and mouse C2C12 
cell lines were plated into 96 well cell culture plates at a density o f 5 x 103 per well in 
200 pi of growth medium (for L6E9, in 20 % FBS with 0.5 % Ampicillin and 0.5 % 
Gentamicin in DMEM, and for C2C12 cells, 10 % FBS with 0.5 % Ampicillin and 0.5 
% Gentamicin in DMEM) and incubated at 37 0 C and 5% CO2 for 3 days. Growth 
mediums was removed from wells and the cells then washed 3 times with 100 pi of 
serum free medium with antibiotics in above concentrations. The washed cells were 
added 200 pi o f serum free medium with antibiotics and incubated 37 0 C and 5% CO2 
for 24 hours. Next day, serum free medium was removed and different dozes o f MGF 
and systemic type o f IGF-I (R3IGF-I) in 200 pi o f DMEM with 100 pg/ml o f BSA 
were added into wells. Then, the cells treated with growth factors were incubated at 
37 0 C and 5% CO2 for 24 hours again.
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2.3.1.10.1.2 Labelling Cells with BrdU
10 p.1 of 10 pM BrdU labelling solution were added into each well for all 4 plates for 3 
hours. The wells were washed 3 times with 250 pi o f washing medium containing 10 
% FBS in PBS. After the last wash, the cells were fixed with 200 pi of pre-cooled 
fixative per well for 30 minutes at room temperature. The fixative was removed and 
the cells were washed 3 times again with 250 pi o f washing medium again. The 
washing solution was removed. The plates were left without buffer at 4 °C overnight.
2.3.1.10.1.3 Detecting Cells with BrdU
Next day, wells were washed once with 250 pi o f washing medium containing 10 % 
FBS in PBS and then the solution was removed. Then 100 pi o f nuclease working 
solution was added into per well and the plate was incubated at 37 0 C and 5% CO2 
for 30 minutes. The nuclease working solution was removed and the cells were 
washed again 3 times with the washing medium. The washing solution was removed 
and the cells were incubated with 100 pi of anti BrdU -  POD at 37 0 C and 5% CO2 
for 45 minutes and then washed again 3 times with 250 pi o f the washing solution. 
The solution was removed and 100 pi o f peroxidase substrate was added and then 
incubated at room temperature for about 30 minutes until positive samples show a 
green colour. After occurring green, the colour the plates were mixed with shaker and 
measured in microtiter plate reader at 405 nm with a reference wavelength at 490 nm.
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2.3.1.10.2 Immunocytochemistry Proliferation Assay 
2.3.1.10.2.1 Preparing Coverslips
A small jar with an airtight lid was filled to 2/3 o f its volume with 70 % absolute 
ethanol (EtOH) in tissue grade water. A moderate number o f 13 mm glass coverslips 
(from BDH) were put in the ja r containing 70% EtOH. The ja r was closed tightly and 
sealed with parafilm and then left overnight. The coverslips were removed from the 
jar and placed into a clean Pyrex Petrie dish, using a forceps and a needle. Excess 
EtOH was pipetted off and a small volume o f tissue grade water was added to prevent 
coverslips from aggregation. The glass Petrie dish was wrapped in aluminium foil and 
labelled with autoclave tape and then baked at 200 °C for 2 hours. The baked Petrie 
dish was cooled. The cooled coverslips were transferred to a new plastic sterile Petrie 
in a hood. The plastic Petrie was then sealed with parafilm and stored in a sealed 
sandwich box to store.
2.3.1.10.2.2 Preparing the Cells for Proliferation Assay
Three pre-prepared 13 mm coverslips were placed into each well o f a 6  well cell 
culture plate. 1 ml o f 0.2 % gelatin in PBS was added into each well o f the plate(s). 
The plates were shaken on a shaker for 1-2 hours. And then the gelatin was removed.
Human primary non-sorted cells were plated out onto the coverslips in wells o f 6  well 
plate(s) at a density o f 4.5 x 104 in 2 ml o f the defined medium (Muscle Cell Growth 
Medium -  MCGM) per well and left to grow at 37 0 C and 5% CO2 overnight. For 
details o f MCGM, see appendix. After incubating the cells on the coated coverslips 
overnight, next day, MGF, long r3 IGF-I, and IGFIR blocking antibody (Ab-I) were
144
added in different concentrations for different conditions (Figure 2.7). The coverslips 
on which the cells were placed were incubated at 37 0 C and 5% CO2 for 24, 48 and 72 
hours for different time points, and then fixed.
Figure 2.7: The plated out human primary muscle cells onto the coverslips in 6 well plate, 
and the main conditions for each well. A, B, C, D, E, and F are the wells o f a 6 well plate 
which are in a shape of big circles. The small circles are coverslips. All wells had non-sorted 
human primary muscle cells at a density o f 4.5 x 10* in 2 ml o f Muscle Cell Growth Medium -  
MCGM. A had only the cells in MCGMfor control; B had the cells in MCGM + Ab-I; C had 
the cells in MCGM + MGF; D had the cells in MCGM + MGF + Ab-I; E had the cells in 
MCGM + long r3 IGF-I; and F had the cells in MCGM + MGF +  long r3 IGF-I.
2.3.1.10.2.3 Fixing and Storing the Treated Cells on Coverslips
50 % of the culture volume (1 ml) was removed from the wells. An equal volume 
(lml) o f ice cold methanol was added onto cells to ensure cells were exposed to a 
minimum volume of 1:1 culture medium / methanol. The cells were fixed on ice for 5 
minutes, and then 50 % the methanol / culture medium mixture were removed gently. 
The coverslips in wells were washed with addition o f 2 ml o f PBS for each well. 2 ml 
o f ice-cold methanol was added to each well and the cells were fixed again on ice for
a further 10 minutes. The methanol was then removed and coverslips washed again 
with 2 ml o f PBS again. PBS was removed and 2 ml o f 0.1 % sodium azide (Na N3) in 
PBS was added onto each well to store fixed coverslips. 6  well plates containing fixed 
coverslips were sealed with parafilm and stored at 4 °C prior to use.
2.3.1.10.2.4 Immunostaining
The fixed coverslips were removed from the wells with a microsurgical crossover 
forceps and were curved tip needle. The coverslips were drained by their edges being 
placed in contact with absorbent paper tissue so that the fluid was removed by 
“wicking” or capillary action. The coverslips were then washed x 6  with PBS in a 60 
ml container and placed on pedestals by scooping PBS in order not to allow the 
coverslips to dry-out. The coverslips with PBS on pedestals were drained again with 
absorbent paper tissue and then 100 pi o f 0.25 % Triton X-100 / PBS were added onto 
each coverslips to permeabilise cell membrane for 15 minutes at room temperature. 
The coverslips were drained and washed 6  times with PBS, and were drained again. 
For myoblast staining, the coverslips incubated with 50 pi o f monoclonal mouse anti­
human desmin antibody (DAKO clone D33) diluted (1: 200) in special Antibody 
Diluting Solution -A D S (ADS: 10% dentured FBS, 0.1M lysine and 0.1% Sodium 
Azide in PBS) for 1 hour at room temperature. For positive control, 50 pi o f PBS was 
added onto one randomly chosen coverslip, instead o f monoclonal mouse anti-human 
desmin antibody.
After one hours treated with monoclonal mouse anti-human desmin antibody, the 
treated coverslips were drained, washed and drained again as above. For nuclear
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staining, all coverslips incubated with 50 pi o f donkey anti-mouse FITC / DAPI 
antibody in ADS for 30 minutes at room temp. The dilutions were 1 in 200 for FITC 
(Jackson Lab ltd -  USA), and 1 in 1000 for DAPI. The coverslips were drained, 
washed 6  X PBS, drained and mounted onto labelled glass slide with Citifluor 
antifade media and then sealed edges with clear nail varnish. 3 coverslips were 
mounted for each slide. The mounted slides were stored at 4-6 °C for counting.
2.3.1.10.2.5 Epi-fluorescence and light contrast microscopy:
Cell - associated fluorescence and morphology were visualised with epi-fluorescence 
and Leica Modulation Contrast microscopy, using an inverted Leica DMIRB 
microscope equipped with a COHU CCD camera and FW4000TZ imaging software 
in order to capture and save images. The cells were counted under a fluorescent 
microscope at a magnification o f 63 X. Fluorescents were blue (for DAPI nuclear 
stained -  for all cells), and green (for Desmin stained -  for myoblast). All cells were 
counted in a field, in blue and green fluorescent.
2.3.1.11 Differentiation Assays
BCA protein assay reagent kit (Pierce), and creatine phosphokinase (CPK) kit 
(Sigma), and immunocytochemistry techniques were used to investigate cell 
differentiation (fusing mononuclear cells to multinuclear myotubes).
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2.3.1.11.1 Differentiation Experiments by CPK Assays
2.3.1.11.1.1 Preparing the Cells
Cells were grown in normal muscle growth medium -  NGM- (20% FBS and 1% 
penicillin /streptomycin in DMEM) in T75 flasks until having enough number of 
cells. 96 well -  plates were used for both the BCA protein assay and CPK assays. For 
96 well plates, 200 pi o f NGM containing 10X104 cells were put into each well. For 
96 well plates 16 conditions (16 X 5) were used. The time point was 48 hours for 
both assays. For each experiment, two pre-gelatinised plates were prepared (1 for 
protein assay, 1 for CPK assay).
After plating, cells in NGM were incubated at 37 °C for 3-5 days until 70 -  80 % 
confluent. The cells were washed with DMEM 3 times and then growth factors in 200 
pi o f muscle cells defined medium were added. 2  different defined mediums were 
used. They were either 2 % FBS and 1 % P/S in DMEM, or 0.5 % BSA, with low 
insulin (5 ng/ml) with 1 in 100 P/S in DMEM. As presented in chapter 2, the 
conditions containing different concentrations o f growth factors were different such as 
positive control, different conc. o f MGF, different conc. IGF-I, different conc. MGF 
and r3 IGF-I combinations, control with IGF-I receptor blocking antibody, MGF with 
IGFIR blocking antibody. The cells with and without growth factors (for positive 
control) were incubated at 37 °C and 5% CO2 for 48 hours.
After 48 hours, the cells were washed with 3 X PBS and then added 150 pi o f 0.5 mM 
gly gly buffer for 96 well plates experiments to fix the cells, and then filmed, foiled
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and stored at -  70 °C without adding any buffer. For immediate using, the cells were 
not put into -  70 °C. Experiment was carried on adding 1 X Reporter Lysis Buffer 
(RLB).
2.3.1.11.1.2 Lysition cells with Reporter Lysis Buffer
A sufficient amount o f 1 X RLB was prepared with d t^O  from 5 X RLB stock. The 
defined medium containing growth factors was removed from wells and then was 
washed with 3 X PBS. 150 pi o f 1 X RLB was added into each well. For frozen cells, 
they were thawed and 150 pi o f 1 X RLB was added. The cells were shaken on a 
shaker at room temperature for 5-7 minutes. After that, the cells were incubated for 15 
minutes at room temp. The cells in 1 X RLB solutions were crashed carefully using a 
tip. The crashed cells were taken into pre-labelled tubes and centrifuged at 10 000 rpm 
for 2 mins. Then, the supernatant was carefully transferred into another labelled tube. 
(Only the supernatants were transferred, not pallets). The tubes were foiled and stored 
at -  70 °C for later protein and CPK assays.
2.3.1.11.1.3 Preparation of standards and working reagent
First o f all, the standards and working reagent (WR) were prepared. For WR, 50 parts 
o f BCA reagent A were mixed with 1 part o f BCA reagent B (50:1). For preparation 
o f standards, different amount o f albumin (BSA) were mixed with either 0.5 mM gly 
gly buffer (for 96 well plates) or 1 X RLB (for 24 well plates). Final BSA 
concentrations were 0, 0.05, 0.125, 0.250, 0.5, 1, 1.5 and 2 mg/ml.
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2.3.1.11.1.4 Procedure of Protein Assay
3 X 25 pi o f each standard and samples were pipetted into a labelled 96 well plate. 
200 pi o f WR was added into each well (to both, to standards and samples). The plate 
content was mixed on a plate shaker for 30 seconds. It was incubated at 37 °C for 30 
minutes and then cooled at room temperature for 10-15 minutes. Finally, the 
absorbance was measured at 562 nm on a plate reader.
2.3.1.11.1.5 Procedure of CPK Assay
A set o f labelled 1.5 ml centrifuge tubes were prepared (3 tubes for each standard and 
sample).
TEST BLANK 1 BLANK 2
Trizma buffer sol. - 100 pi -
Creatine sol. 100 pi - 100 pi
Sam ple 30 pi - -
0.5 mM gly gly buffer - 30 pi 30 pi
W ater 100 pi 100 pi 100 pi
Above reagents were added into centrifuge tubes as shown above in the table and 
were then mixed. The tubes were placed in 37 °C water bath to warm up for 1-2 
minutes. 10 pi o f ATP -  Glutathione solution was added to each tube and mixed and 
then incubated at 37 °C water bath for 30 minutes to initiate the reaction.
160 pi o f ice cold 20 % Trichloracetic acid (TCA) was added to stop the reaction and 
were mixed and was left at room temperature for 5 minutes. The tubes were 
centrifuged at 2000 rpm for 5 minutes.
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100 pi o f supernatants o f tubes were transferred to a new set o f 1.5 ml centrifuge 
labelled tubes, which were prepared earlier. 400 pi o f water, 100 pi o f Acid 
Molybdate solution and 25 pi o f Fiske and SubbaRow solutions were added to each 
tube including blanks. The tubes were mixed well and left for 30 minutes at room 
temperature for colour development. Finally, 150 pi o f the solution o f each tube was 
transferred to 96 well plate and immediately measured at 620 nm on a plate reader.
2.3.1.11.1.6 Standard Calibration for CPK Assay
The phosphorus standard solution was mixed with distilled water in different 
concentrations to prepare 0, 0.5, 1, 1.5, 2 and 2.5 g/tube for final standard. The 
standard solutions were transferred to 1.5 ml centrifuge tubes. 100 pi o f Acid 
Molybdate solution was added to each standard tube and mixed well. Then, 25 pi o f 
Fiske and SubbaRow solutions was added to tubes and were mixed again. The 
standard tubes were incubated at room temperature for 1 0  minutes and then 150 pi of 
the tube content was transferred to the same sample 96 well plate. The plates 
measured at 620 nm on a plate reader in 10 minutes. After measuring, a standard 
calibration curve was prepared.
2.3.1.11.2 Differentiation Experiments by Immunocytochemistry
The cells were grown in normal muscle growth medium -  NGM- (20% FBS and 1% 
penicillin /streptomycin in DMEM) in T75 flasks until having sufficient number of 
cells. After preparing the baked coverslips (see 2.2.10.2.1), 3 prepared 13 mm 
coverslips were placed into each well o f a 6  well cell culture plate and were coated by
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0.2% gelatin as mentioned in 2.2.10.2.1.2. Different primary human degenerative 
muscle cells were plated out onto the coverslips in wells o f 6  well plate(s) at a density 
o f 2 x 105 in 2 ml o f the Normal Growth Medium - NGM (20% FBS and 1% P/S in 
DMEM), and were left to grow at 37 0 C and 5% C 0 2 until approximately 80% 
confluent. When the cells on coverslips were more than 80% confluent, the NGM was 
changed with the MCDM (Muscle Cells Differentiation Medium). The MCDMs were 
either 0.5 % BSA, with low insulin (5 ng/ml) with 1 in 100 P/S in DMEM or 2 % FBS 
and 1 % P/S in DMEM. Before adding the MCDM, the NGM was removed and the 
cells on coverslips were washed with DMEM three times.
The cells were daily checked under light microscopy for observation o f fusing 
myoblasts to myotubes. As soon as fusing starts different growth factors were added 
onto the wells for different conditions. The conditions containing different 
concentrations o f growth factors were as follows: no growth factors for positive 
control, MGF (10 and 100 ng/ml), long r3 IGF-I (10 and 100 ng/ml) for IGF-I Ea, and 
MGF plus long r3 IGF-I (10+10, 10+100, 100+10 and 100+100 ng/ml). The cells with 
and without growth factors (for positive control) were incubated at 37 °C and 5% C 0 2 
for 48 hours, and then fixed and stored as mentioned in 2.2.10.2.1.3. The 
immunostaining and counting protocols were the same as mentioned in 2.2.10.2.1.4 
and 2.2.10.2.1.5. Differentiation status would be determined by counting both Desmin 
positive myoblast and Desmin positive myotubes. The percentages o f the cells would 
be then calculated. After that, the percentages o f myotubes would be compared to 
those of myotubes. As can be seen from 3.2.3.3.2, the differentiation by
152
immunocytochemistry assay was not successful. Therefore differentiation states for 
degenerative muscle cells were not determined.
2.3.2 In vivo -  gene transfer experimentation
2.3.2.1 Plasmid design and gene construction
The pcDNA3.1/NT-GFP vector (Invitrogen), which is driven by CMV 
(cytomegalovirus) promoter, was used in this part o f the study to produce IGF-I 
isoforms in muscle fibres o f mdx mice. The CMV (cytomegalovirus) was used as a 
promoter. The pcDNA3.1/NT-GFP contains 6160 nucleotides (Figure 2.8). The 
cDNAs of rabbit MGF and IGF-I Ea were previously cloned in Prof. Goldspink’s 
group. These were subcloned into Kpn I (on 1650th bp, GGTAC/C) / Apa I (on 1730th 
bp, GGGCC/C) sites o f the pcDNA3.1/NT-GFP. The multiple cloning site o f 
pcDNA3.1/NT-GFP was between 1645-1738 bases. The constructs were checked by 
sequencing from T7 promoter upstream of GFP (Green Fluorescent Protein) to ensure 
that MGF and IGF-I Ea cDNA insertions had been cloned into the multiple cloning 
site o f the vector. As well as MGF and IGF-I Ea constructed plasmids, a non 
constructed plasmid (for positive control) were stored in -80 °C.
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Figure 2.8: pcDNA3.1/NT-GFP vector map and its multiple cloning site.
2X22 Preparation of LB Agar Plates for Plasmid Purification
Firstly, 1 litre o f Luria Bertani (LB) Agar was prepared. For preparation o f LB Agar, 
10 g tryptone, 5 g yeast extract, 10 g NaCl, and 15 g bacteriologic agar were put in a 1 
litre clean bottle, and dissolved in 1 litre o f distilled water by mixing well. The 
suspension was autoclaved at 121 °C for 15 minutes. LB Agar was then allowed to 
cool about 60 °C, and was then added an appropriate amount of ampicillin (the final 
concentration o f ampicillin was 1 0 0  pg/ml).
The LB Agar was poured into 60 mm of Petri plates at room temperature. It was 
waited for until the gel in the plates to set. After setting, the plates were put in 37 °C 
o f oven to dry off for about 2 hours. The LB Agar plates were separated into three 
groups and they were labelled as “MGF”, “IGF-I Ea”, and “Vector only” . The pcDNA 
3.1 GFP/NT plasmid vectors containing cDNAs of IGF-I Ea and MGF, and only
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vector (not containing any cDNA) were taken from -  70 °C store and were then 
placed on dry ice. The pcDNA 3.1 GFP/NT plasmid vectors were cultured onto 
labelled LB Agar plates. The plates were placed in a 37 °C oven for overnight to 
enable the growth o f colonies. The next day, the plates were checked for whether or 
not they had colonies. The colonised plates were filmed and stored at 4 °C for future 
experimentations.
2.3.2.3 Preparation of LB medium:
Three 100 ml o f LB medium was prepared. For preparation o f the medium, three 500 
ml o f clean flasks were labelled as “MGF”, “IGF-I Ea” and “Vector only”. 1 g 
tryptone, 0.5 g yeast extract and 1 g NaCl were put into each flask. Then 100 ml of 
distilled water was added into each flask and they were mixed well for dissolving. The 
pH was adjusted to 7.0. The medium in flasks was autoclaved at 121 °C for 15 
minutes and were then cooled to about 60 °C and then added ampicillin (100 pg/ml).
2.3.2.4 Plasmid DNA purification (Maxi prep)
A QIAGEN EndoFree Plasmid Maxi Kit (Qiagen) was used for plasmid DNA 
purification. MGF, IGF-I Ea, and vector only plates were picked out from cold store. 
A single colony was picked out from each plate and inoculated into labelled 
autoclaved LB mediums. LB mediums were put in a shaking incubator. The colonies 
in LB mediums were grown at 37 °C for 16 hours with vigorous shaking at 300 rpm.
Next day, the bacterial cells were poured into 250 ml o f previously autoclaved and 
labelled centrifuge bottles and were harvested by centrifugation at 6000 x g (6500 rpm
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in Sarval GS3 rotor) for 15 mins at 4 °C. All traces of supernatant were removed from 
the bottles by not disturbing the pallets. 1 0  ml o f chilled resuspension buffer (buffer 
P I) containing 50 mM Tris-Cl, pH 8.0; 10 mM EDTA; 100 pg/ml RNase A was 
added onto the bacterial pallet in bottle. The bacteria were resuspended completely by 
vortexing until no cell clumps remained. 10 ml o f Buffer 2 (Lysis buffer) containing 
200 mM NaOH, 1% SDS (w/v), was added to lysate and mixed gently by inverting 6  
times and was incubated at room temperature for 5 minutes. The QIAfilter Maxi 
Cartridge was prepared during the incubation period. The cap was screwed onto the 
outlet nozzle o f the QIAfilter Maxi Cartridge and it was placed into a labelled 50 ml 
o f sterile centrifuge tube.
10 ml o f chilled Buffer P3 (Neutralisation buffer) containing 3.0 M potassium acetate, 
pH 5.5 was added onto the lysate and mixed gently immediately by inverting 6  times. 
The lysate was poured into the barrel o f the QIAfilter Maxi Cartridge, and it was then 
incubated at room temperature for 10 minutes. The cap was removed from the 
cartridge’s outlet nozzle. The plunger was inserted gently into the cartridge and the 
cell lysate was filtered into a sterile 50 ml tube. 2.5 ml o f Buffer ER was added to the 
filtered lysate and mixed well gently by inverting the tube 1 0  times and then 
incubated on ice for 30 minutes.
During the incubation period, QIAGEN -  tip -500  was prepared for equilibration. The 
tip was placed into another sterile 50 ml tube and was applied 10 ml o f Buffer QBT 
(Equilibration buffer) containing 750 mM NaCl; 50 mM MOPS, pH 7.0 and 15 % 
isopropanol (v/v), 0.15 % Triton X -  100 (v/v) and was waited for until the column to
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be emptied by gravity flow and to be drained completely. After incubation, the filtered 
lysate was poured into the tip and was allowed to enter the resin by gravity flow.
The tip was washed twice by 30 ml o f the washing buffer [1.0 M NaCl; 50 mM 
MOPS, pH 7.0 and 15 % isopropanol (v/v)]. The washed tip was placed into an 
autoclaved 30 ml endotoxin-free glass tube and was applied 15 ml o f the elution 
buffer containing 1.6 M NaCl; 50 mM MOPS, pH 7.0 and 15 % isopropanol (v/v) to 
collect the elute. The DNA was precipitated by 10.5 ml (0.7 volume) o f room- 
temperature isopropanol in order to elute the DNA. It was mixed well and 
immediately centrifuged at 15,000 x g (11,000 rpm in Sarvall SS-34 rotor) for 30 
minutes at 4 °C. The supernatant was decanted very carefully.
The DNA pellet was washed by 5 ml o f room-temperature endotoxin-free 70 % 
ethanol ( 1 0 0 % ethanol was diluted in the endotoxin-free water); and then centrifuged 
at 15,000 x g for 10 mins. The supernatant was again decanted carefully without 
disturbing the pellet. Finally, the pellet was air-dried for 10 minutes, and then the 
DNA was redissolved in 100 pi o f sterile PBS. 10 pi o f purified plasmid DNA was 
separated for DNA cutting to asses the quality o f the purified DNAs, and then 
remaining purified DNAs was stored in -20 °C.
2.3.2.5 The cutting and checking of DNAs using restriction enzymes
In order to asses the quality o f the purified DNAs, purified DNAs were cut by 
restriction enzymes Apa I an Kpa I in a master mix and then visually inspected after 
staining by ethidium bromide under ultraviolet light.
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R eagents For each  tube (ml) For m aster mix tube (4X) (ml)
Apa 1 1 4
Kpn 1 1 4
Reaction buffer (Buffer 4) 2 8
BSA 0.2 0.8
dd H20 5.8 23.2
Total volume 10 40
Table 2.1: A master mix for DNA cutting to investigate DNA quality
All reagents were aliquoated into a labelled sterile tube on an ice, and were then 
mixed by vortexing. Then, 10 pi o f master mix solution was put into new labelled 
sterile tubes. 10 pi o f purified plasmid DNA were added into the tubes containing 10 
pi of master mix solution. The solutions were mixed again by vortexing and were then 
placed into a water bath at 37 °C for 2 hours in order to cut the DNAs.
While the DNAs were being cut, a 1.5 % o f agarose minigel was prepared. For gel, 
0.75 g o f agarose was put in a 200 ml o f flask and 50 ml o f 1 X TAE was added into 
it. The suspension was microwaved for 80 seconds. The flask containing gel was 
cooled under cold tab water. Then, 2.5 pi o f Ethidium Bromide was added into 50 ml 
o f cooled (warmed) gel for inspecting visually under ultraviolet light. A minigel tank 
was set and then the gel was poured into the minigel tank and was kept until being set. 
After the gel was set, a sufficient volume o f 1 X TAE was added into the tank. As 
soon as the purified plasmid DNAs were cut, 3 labelled 1.5 ml sterile tubes were 
prepared. 20 pi o f cut DNAs were put into each labelled tube. 4 pi o f dye (1 in 6  
volumes) were added into the tubes and mixed. 24 pi o f the DNA and dye mixture (20 
pi o f DNA and 4 pi of dye) were loaded into wells o f the gel, and also 10 pi of 50 Kb
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ladder marker. The gel was electrophoresed at 90 V for 40 minutes. Finally the 
electrophoresed gel was imaged by ultraviolet camera. The image was then printed 
out. The image o f cut DNAs can be seen from Figure 2.7 below.
IGF-I Ea MGF Vector-only
' . i
.. - *
x *
Figure 2.9: 1.5 % agarose gel picture showing cut purified DNAs in pcDNA3.1/NT-GFP 
vectors. There is only one product shown for each group as IGF-I Ea, MGF and Vector-only. 
Lane 1: 50 kb DNA size markers; lane 2: IGF-I Ea; lane 4: MGF; and lane 6: vector-only.
As can be seen from Figure 2.7, while IGF-I Ea and MGF were clearly visualised as 
having good quality DNAs, on the other hand, no DNA product was seen in vector- 
only group because it does not contain any cDNA insert.
2.3.2.6 Measuring of DNA concentration
DNA concentrations were determined by spectroscopy at 260 nm using the GeneSpec 
I device and software (Naka Instruments, Japan). Firstly, the GeneSpec I parameters 
were set as follows: the calculation mode was dsDNA, the calculation item was pure 
calculation and the dilution fact was 1 .
A cuvette was washed with 5 pi o f DEPC-treated water and the water was then 
removed. The cuvette was re-washed with 5 pi o f absolute ethanol which was then
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removed. Then the possible remaining ethanol was vaporised by waiting for 1 -2 mins.
1.5 pi o f sterile PBS was put into the ‘room’ o f the washed cuvette and then the 
cuvette was placed into the device. Then the “baseline” item on the screen was 
clicked. The PBS was removed from the ‘room’ and then the room o f the cuvette was 
washed again with 5 pi o f DEPC water and absolute ethanol as explained above.
1.5 pi of the sample DNA was put into the room and the ‘measure’ item on the screen 
was clicked. The value was recorded and also written on the label o f the sample tube. 
The DNA sample in the room was then removed and washed again with 5 pi o f DEPC 
water and ethanol. The second sample was measured as mentioned before. All 
samples were measured in the same way, and the values were recorded and written on 
the sample tubes. Finally, the values were printed out and recorded in the lab book. 
The concentrations were adjusted to 1 pg/pl thraw ethanol precipitation, vaporising or 
diluting with PBS.
2.3.2.7 Direct Intramuscular Injection of Plasmid DNAs into Animal Muscles
1 pg/g (of the bodyweight o f mice) o f plasmid DNA in PBS (1 pg /pi) was injected 
thraw a 27 gauge needle into the middle o f the right Tibialis Anterior (TA) muscle of 
the mice. The injections were applied directly into TA muscles by not making any 
skin incision. (Figure 2.10) No injection was made to the left TA muscles o f animals 
for control. The same injections were applied into right TA muscles o f all animals.
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Figure 2.10: Direct injection ofplasmid DNAs into TA muscle of a mouse
2.3.2.8 The Surgery Procedure
After injections, all animals were carefully monitored on a daily basis until the 21st 
day. In this period (on the 15th and 17th day after the injection), as was mentioned 
above, it was observed that two animals were in acute distress. After discussing with 
the vets in the CBU, these two animals were killed by cervical dislocation.
On the 21st day, animals were taken to the operation room. Surgery procedure was 
undertaken under terminal anaesthesia by 25% urethane diluted in double distilled 
H2O (2.5 g urethane diluted in 10 ml o f dd H2O). Initially, a mouse was taken out o f 
the cage with care and was then anaesthetised intraperitoneally using 0.3 ml of 25% 
urethane.
The anaesthetised animal was placed on a platform maintained at 37 °C with a 
temperature-controlled homoeothermic blanket. Both right and left legs were carefully 
shaved using an electrical shaver. A superficial longitudinal incision was made 
carefully onto right leg of animal on Tibialis Anterior (TA) muscle area and skin, and 
the facia of the muscle was opened. The muscle and its tendon were carefully
dissected from their distal insertions, taking care to avoid damage to neurovascular 
pedide (Figure 2.11). The TA muscle was separated from the other leg muscles.
Figure 2.11: Dissecting of TA muscle
The distal tendon of the right TA muscle was cut and then fixed by a silk thread to an 
isometric transducer that was linked to a computer. Additionally, a deep horizontal 
incision was made to the right side o f gluteal area of the animal, and the sciatic nerve 
was found. A silk thread was passed underneath the nerve, and then both electrodes of 
a bipolar silver electrode were attached to the nerve by being passed underneath the 
nerve. A cotton bud was placed in between the electrodes to not touch each other.
The muscles were then activated indirectly by delivering maximal electric stimuli 
(square pulses, 0.2 sc pulse duration, 8 V and 50 Hz) to the sciatic nerve proximal to 
nerve graft. The stimuli were generated by dual impedance research stimuli (Harvard 
Instruments Co. Ltd) and were delivered with a shielded bipolar silver electrode 
(Figure 2.12).
Figure 2.12: Measuring muscle force o f mouse TA muscle
2.3.2.9 The Maximum Muscle Force Measurement
Before maximum muscle force measurement, a linear calibration o f force transducer 
were figured out using different weight. Details of linear calibration o f force 
transducer and the figure o f it can be found from section 4.1.2.1.
After a linear calibration o f force transducer were figured out, optimal muscle length 
(Lo) was determined by measuring the length o f the TA muscle. The strongest 
contractions were generated following supramaximal stimuli by a device (Cambridge 
Electronic Device Ltd). The maximum muscle force was measured and recorded into 
a computer using a Spike 2 software program. The same surgical procedure was 
applied to the TA muscle of the untreated left control leg, and the maximum muscle 
force was measured and recorded by the same way. The same surgery and 
measurements were repeated for all animals.
Both the right and left TA muscles were removed from the animal (Figure 2.13) after 
physiological maximum muscle force were measured and then both TA muscles were 
weighed separately. Then TA muscles were cut into 3 pieces horizontally. The middle 
piece o f the muscle was mounted in embedding medium (optimum cutting 
temperature compound -  OCT) on a cork, and then was immediately frozen in 
isopentane cooled to the temperature o f liquid nitrogen in order to prepare the future 
frozen sections for immunohistochemical analysis. The samples were then stored in - 
80 °C. However, immunohistochemical analysis were not used for this study.
The distal and proximal parts o f samples were put into labelled tubes containing 300 
pi of RNA Later solution (QIAGEN) and then the tubes were stored in -80 °C for 
future quantitative real-time RT-PCR analysis.
Figure 2.13: Mouse TA muscle
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2.3.3 In vivo - satellite cell activation experimentation
2.3.3.1 The Quantitative Real-Time Reverse Transcription Polymerase Chain 
Reaction (RT-PCR)
RT-PCR has been developed by quantitative real-time RT-PCR technique in 1993 
(Higuchi et al, 1993). Since then this technique has been increasingly used for the 
quantification o f specific mRNA expression. Because quantitative real-time RT-PCR 
technique is highly sensitive and allows quantification o f transcripts even in very low 
abundance, this technique was selected to determine satellite cell activation markers 
transcripts.
2.3.3.1.1 SYBR Green
SYBR Green I is a fluorescent dye which binds to the minor groove o f dsDNA. 
Therefore, fluorescent signals o f different amounts can be detected during various 
stages o f PCR by the lightcycler machine and its software. As SYBR Green I 
fluorescent dye, 2X Quantitect SYBR Green PCR Master Mix (QIAGEN) was used.
2.3.3.1.2 Lightcycler
The cDNA amplifications and data collection was carried out using the Lightcycler 
machine (Roche Diagnostics Inc, Germany) with incorporation o f fluorescent dye 
SYBR Green I. The lightcycler performs the real-time RT-PCR in small volume glass 
capillary tubes, contain within a rotor-like carousel. The rotor-like carousel are heated 
and cooled in an air stream (Bustin, 2000).
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2.3.3.1.3 The Internal Control Reference Gene and Control Reactions
To facilitate optimisation, comparison and troubleshooting of the RT-reactions, 
different controls procedures including using internal control gene expression, an 
internal control / reference / housekeeping gene (p-actin) was used. All transcripts of 
mRNA levels for specific primers, including MyoD and myogenin, in different 
samples were compared with transcription levels o f p-actin expression. Along with p- 
actin, other controls were used (two positive and three negative controls). For positive 
controls, (1) transcription levels o f mRNA expressions from the TA tissues o f injected 
and uninjected muscle samples from vector-only group, and (2 ) uninjected TA muscle 
samples from all three groups, and for negative controls, (i) No RNA, (ii) No RT, and 
(iii) only RNase-free water were used.
2.3.3.1.4 RNA Isolation
RNAs were isolated by TRI reagent (Sigma) according to manufacturer’s instructions. 
First o f all, the tissue samples which are in the tubes containing RNA Later were 
taken out from -  70 °C store and dissolved at room temperature, and then placed on 
ice. A couple o f samples were randomly selected and their weights were measured. 
Having found the average weight, the volume o f appropriate TRI reagent was then 
determined. The average tissue weight was about 30g, so the volume o f TRI reagent 
was selected as 500 pi (500 pi TRI reagent per up to 50 mg of tissue).
In a fume hood, RNA Later was removed, and tissue samples were placed onto a 
clean tissue paper. The samples were dried and cut finely, and were then put into a 
sterile labelled 2 ml cryotube. 500 pi o f TRI reagent was added into the cryotube. The
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samples in the cryotube, containing TRI reagent, were homogenised well by sterile 
homogeniser until no pulp remained. After complete homogenisation, the probe o f the 
homogeniser was washed in 5 ml o f DEPC-treated water and 5 ml o f absolute ethanol. 
The homogeniser was shaken well in order to dry. Another sample was taken and then 
dried and cut and homogenised in TRI reagent as explained above.
The homogenised samples in the cryotubes were transferred into a new labelled 1.5 
ml sterile centrifuge tubes and then centrifuged at 12,000 x g for 10 min at 4 °C. The 
supernatants were again transferred into other new labelled 1.5 ml tubes, and the tubes 
were allowed to stand for 5 minutes at room temperature. 100 pi o f chloroform was 
added into each tube. The tubes were covered tightly and vortexed for 15 seconds and 
then waited for 15 mins at room temperature. The mixture was centrifuged at 12,000 x 
g for 15 minutes at 4 °C. The centrifugation separated the mixture into three phases: a 
colourless upper aqueous phase for RNA, a white inter phase for DNA, and a red 
lower organic phase for protein. The colourless upper aqueous phase was carefully 
transferred into a fresh labelled tube without disturbing the white inter phase. 250 ml 
o f isopropanol was added into the tube and mixed very well and then waited for 1 0  
minutes at room temperature. The mixture was spanned down at 12,000 x g for 10 
minutes at 4 °C and all supernatant was removed carefully without disturbing the 
pellet. The pellet was washed by adding 500 pi o f 75% ethanol in RNAse-free water 
and vortexed. The sample was centrifuged at 7500 x g for 5 minutes at 4 °C. All 
supernatant was decanted again. The RNA pellet was dried fir 10 minutes for air -  
drying. Finally, 50 pi o f diethylpyrocarbonate (DEPC)-treated water was applied onto
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dried pellet and was mixed well in order to dissolve the pellet. It was waited for 20 
minutes at room temperature and then the dissolved RNA was stored at -  20 °C.
2.3.3.1.5 Ethanol Precipitation
The concentrations o f RNAs (or DNAs) were increased or decreased thraw ethanol 
precipitation. Therefore low concentrations o f RNAs were treated by ethanol 
precipitation and the concentrations were increased. The following protocol was 
carried out for RNA ethanol precipitation. 50 pi o f RNA was put into a sterile 1.5 ml 
centrifuge tube. 10% o f total volume of RNA (5 pi) of Sodium Acetate (3M Sodium 
Acetate, pH 5.2) was added onto the RNA (5 pi o f Sodium Acetate onto 50 pi of 
RNA, total mixture was 5+50=55 pi) and the mixture was mixed well. 2.5 volumes of 
total mixture o f -20 °C 100% absolute EtOH was added onto the mixture (EtOH 
volume was 55X2.5=140 pi). RNA, Sodium Acetate and ice-cold EtOH mixture was 
incubated at -80 °C for 30 minutes, and then was centrifuged at 13,000 rpm for 10 
minutes at 4 °C. The supernatant was carefully removed, taking care for the pallet. 
500 pi o f 75% EtOH was added into the tube, which contains a pallet. After vortexing 
the tube to dissolve the pallet, the tube was centrifuged at 13,000 rpm for 5 minutes at 
4 °C. The supernatant was completely removed, taking extra care for the pallet again. 
The lid o f the tube was left open and the pallet was air-dried by waiting at room 
temperature for about 10 minutes. Finally, 30 pi o f DEPC-treated water was applied 
onto dried pellet and mixed well to dissolve it. The dissolved RNA was placed on ice 
and the concentration o f the RNA was determined by spectroscopy at 260 nm, and 
then stored at - 2 0  °C.
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2.3.3.1.6 The Determination of RNA concentrations
The concentrations o f RNAs were also determined by measuring the absorbance at 
260 nm (A260) in the Gene Spec I spectrophotometer (Naka Instruments, Japan), with 
the same protocol, as explained in chapter 3 (3.2.3.4). However, the calculation mode 
of the parameters o f the GeneSpecI software was set as RNA, instead o f dsDNA. 
Other parameters and protocols were the same as those detailed 3.2.3.4 (measuring 
DNA concentrations).
2.3.3.1.7 The DNase Treatment of RNA Samples (DNase Digesting)
Successful reverse transcription is dependent on the purity o f the mRNA used as the 
template. To remove any DNA contamination from RNA samples during RT-PCR is 
therefore crucial for having optimal results. The RNA templates should be DNA-free. 
Extra care should be taken to avoid the potential nucleic acids contamination. Thus, 
along with taking extra care in laboratory bench to minimize the potential cross­
contamination, all RNA samples were also treated with 10 units of RQ1 RNase-free 
DNase (Promega) at 37 °C for 30 min followed by inactivation at 65 °C for 10 
minutes in order to remove the possible amplification o f contaminating genomic 
DNA. The samples were treated with DNase as explained in the following protocol:
Firstly, the RNA samples were thawed on ice. Then 1000 units o f RQ1 RNase-free 
DNase (Promega), lOx Buffer (Promega) and RNase-free water were thawed at room 
temperature and then were stored on ice immediately after being thawed. Each 
solution was mixed by short-vortexing, and was then centrifuged briefly to collect
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residual liquid from the sides o f the tube. 1000 units o f RQ1 RNase-free DNase was 
diluted as 50 units/pl. Then, a master mix was prepared for DNase digesting.
The master mix was prepared for 53 samples (46 for young mdx mice RNA samples, 
2 for negative controls and 5 for the extras for unexpected pipetting losses). All 
samples were treated with DNase at the same time in order to have optimal results. 
The master mix for DNase digesting was prepared on ice according to the following 
table (Table 2.2):
R eagents
Stock
solution
Final
concentration
Volume for 
per reaction
Volume for 
m aster mix
RQ1 DNase 50 units 10 units 5 pi 5 X 53 = 265 pi
Buffer 10X 1 X 2.5 pi 2 .5 X 5 3 =  132.5 pi
Total 7.5 pi 397.5 pi
Table 2.2: A master mix for DNase digesting for RNA samples from young mdx mice TA 
muscles.
As shown in Table 2.2, to prepare a mister mix, 265 pi o f DNAse (50 units/pl) were 
put into the master mix tube for 53 samples (46 RNA samples, plus 2 negative 
controls and 5 extras). 132.5 pi o f 10 X Buffer were added into the tube. Total volume 
o f the master mix was 397.5 pi. The tube was mixed by being vortexed shortly.
After preparing the master mix, 48 fresh autoclaved tubes were labelled (46 for RNA 
samples and 2 for negative controls). 7.5 pi o f master mix solution was distributed 
into individual labelled tubes. The tubes were kept on ice. The variable volumes of 
RNA samples were individually aliquoated to each labelled tube according to their 
concentrations to make up their concentrations as 5 pg per reaction. No RNA sample 
was put into one o f the negative control tubes (into the “no RNA” labelled negative
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control tube). Appropriate RNA was added into second negative control tube (into the 
“no RT” labelled negative control tube). The variable volumes o f nuclease-free water 
were also individually aliquoated into the tubes according to RNA aliquoatetions to 
make up a total volume o f 25 pi per reaction.
Following short-vortexing and centrifuging briefly to collect residual liquids from the 
walls o f the tubes, the tubes were incubated at 37 °C for 30 minutes. 2.5 pi o f stop 
solution (Promega) were added into each tube, and the tubes were then short-vortexed 
and short-centrifuged again. Finally, the tubes were incubated at 65 °C for 10 minutes 
for inactivation the DNase. After the final incubations, the tubes, which contained 
DNase treated samples, were placed on ice and their concentrations were determined 
again by spectroscopy at 260 nm. All samples were then stored at -20 °C.
2.3.3.1.8 Reverse Transcriptase Reaction (cDNA synthesis)
Reverse transcriptase (RT) reactions were made for cDNA synthesis. Omniscript 
reverse transcriptase (QIAGEN) were used for the RT reactions. RT reactions for all 
RNase-free DNase treated-RNA samples from young mdx mice TA muscles were 
also carried out at the same time in order to yield optimal results.
Firstly, all DNase treated RNA samples including negative controls were thawed on 
ice. Then, random hexamers primers, lOx Buffer, dNTP mix, RNase inhibitor and 
RNase-free water were thawed at room temperature and were then stored on ice 
immediately after being thawed. Each solution was mixed by short-vortexing, and was 
then centrifuged briefly to collect residual liquid from the sides of the tube. The RT
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reaction was carried out using the following concentrations o f the following reagents
which are shown in the table below (Tab 2.3):
Reagents Stock solution Final concentration Wolume/reaction
Buffer RT 10X 1 X 3
dNTPs 5 mM 0.5 mM 3
Random primers 50 pmol/ml 2.5 pmol/ml 1.5
RNAse inhibutor 10 u/pl 0.5 u/pl 1.5
RT enzyme 4 u/ pi 0.2 u/pl 1.5
Template RNA - 0.75 pg/per reaction variable
RNAse-free water - - variable
Total volume 30 pi
Table 2.3: RT Reaction reagents and their concentrations
For the RT reaction, firstly, the master mix was prepared for 53 samples (46 DNase 
treated-RNA samples from young mdx mice TA muscles and plus 2 negative controls 
and plus 5 extras for unexpected pipetting losses). The mixture o f the master mix was
prepared according to the following table (Table 2.4).
Reagents
Stock
solution
Final
concentration
Volume for 
per reaction
Volume for 
master mix
Buffer RT 10X 1 X 3 pi 3 X 5 3  = 159 pi
dNTPs 5 mM 0.5 mM 3 pi 3X 5 3  = 159 pi
Random primers 50 pmol/ml 2.5 pmol/ml 1.5 pi 1.5X 53 = 79.5 pi
RNase inhibutor 10 u/pl 0.5 u/pl 1.5 pi 1.5X 53 = 79.5 pi
RT enzyme 4 u/ pi 0.2 u/pl 1.5 pi 1 .5X 53 = 79.5 pi
Total 10.5 pi 556.5 pi
Table 2.4: A master mix for the RT reaction for RNase-free DNase treated-RNA samples from 
young mdx mice TA muscles.
As can be seen from Table 2.4, to prepare a master mix for 46 DNase treated-RNA 
samples from young mdx mice TA muscles and 2 negative controls, all aliquotations 
were prepared for 53 samples (46 for RNA samples, 2 for negative controls, and 5 for 
the extras). All the following reagents were put into a 1.5 ml o f fresh autoclaved 
centrifuge tube to prepare a fresh master mix: 159 pi of 10 X Buffer RT (QIAGEN) (3 
pi for each reaction), 159 pi of 5mM deoxynucleotide triphosphates (dNTPs)
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(QIAGEN) (3 pi for each reaction), 79.5 pi of random hexamers primers (QIAGEN) 
(50 pmol/ml) (1.5 pi for each reaction), 79.5 pi of RNAse inhibitor (Promega) (10 
u/pl) (1.5 pi for each reaction) and 79.5 pi o f Omniscript Reverse Trinscriptase 
enzyme (QIAGEN) (4 u/ pi) (1.5 pi for each reaction). The total volume o f the master 
mix was 556.5 pi, and that o f per reaction was 10.5 pi. After putting all above 
reagents into the same tube (the master mix tube), the tube was short-vortexed and 
then centrifuged briefly.
48 freshly autoclaved tubes were labelled (46 for the RNA templates and 2 for 
negative controls -  one for noRT enzyme with RNA, and one for no RNA with RT).
10.5 pi of master mix solution was distributed into individual labelled tubes except 
the “no RT” labelled negative control tube. For the “no RT” labelled negative control 
tube, a separate master mix was prepared with no RT enzyme. Instead o f RT enzyme,
1.5 pi of RNase-ffee water was added into the master mix o f the “no RT negative 
control”. All tubes were kept on ice. The variable volumes o f RNA templates were 
individually aliquoated to each labelled tube to make up their concentrations 0.75 pg 
per reaction, except to the “no RNA” labelled negative control tube. An appropriate 
volume o f RNAse-free water was put into the “no RNA” labelled negative control 
tube instead o f RNA template. Then, variable volumes o f nuclease-free water were 
individually aliquoated into the tubes according to RNA aliquotations to make up a 
total volume o f 30 pi per reaction (Table 2.5). Individual tubes were then short- 
vortexed and centrifuged briefly to collect residual liquids from the walls of the tubes. 
Finally, all samples were incubated in a water bath tank at 37 °C for one hour, and
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were heated to 93 °C for 5 minutes to inactivate the reverse transcriptase enzyme. The
samples were then stored at -20 °C.
Reagents Volume for each reaction
Master mix 10.5 pi
Template RNA variable volume
RNAse-free water variable volume
Total 30 pi
Table 2.5: RT reaction components for quantitative real-time RT-PCR.
2.3.3.1.9 Primer Design
The primer sequences were designed by Omiga 2.0 software (Oxford Molecular). 
After finding the gene sequence o f mouse MyoD, Myogenin and P -actin  genes from 
NCBI web page, the sequences were transferred to Omiga 2.0 designing software, and 
specific primers were designed for mouse MyoD, Myogenin and P -actin. The 
parameters o f Omega 2.0 software were set as follows: The primer length: 18-24, G/C 
content, 40-60 percent; PCR product size: 100-300 bp; and annealing temperature: 50- 
65 °C. The Table 2.6 below shows the specific mouse primers for Myod, Myogenin 
and P -actin.
Myogenin
Forward (5’ 
Reverse (3’
AGACGAAACCATGCCCAA 
T AAAAGCCCCCTGCT ACAGA 20 mer
18 mer
MyoD
Forward (5’ 
Reverse (3’
TTT CTT C ACC AC ACCT CT 
TTAACTTTCTGCCACTCC
18 mer
18 mer
p-actin
Forward (5’ 
Reverse (3’
G ACG AT GAT ATTGCCGCACT 
GAT ACCACGCTTGCTCTGAG 20 mer
20 mer
Table 2.6: Specific primers used to quantify MyoD and Myogenin expression by Real-time 
RT-PCR.
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2.3.3.1.10 Optimising the annealing temperature of primers
Appropriate annealing temperature (Tm) o f primers during PCR might be higher or 
lower than annealing temperature calculated from the sequence o f the primers. 
Therefore, for optimising annealing temperatures, Tm was first calculated from 
nucleotide sequence o f primers, according to the following formula.
Tm ( °C) = 2 (A+T) + 4 (G+C)
The annealing temperatures o f each primer were then separately determined by real­
time RT-PCR using SYBR Green I detection dye and lightcycler. For initial 
experiment, the target annealing temperature was started 5-6 °C below the calculated 
temperature. The target temperature in the annealing segment o f the amplification 
programme was then increased 2 °C in each trial. Melting curves and points were 
analysed for each trail, and then, the annealing temperature for each primer was 
determined according to their melting peaks (whether or not having non-specific 
melting peaks). Annealing temperatures were determined for each primer as follows: 
MyoD: 54 °C, myogenin 57 °C and P-actin: 62 °C.
2.3.3.1.11 The Preparation of the standards
For the quantification o f different mRNA transcript levels for target genes and the 
control gene (p-actin), the appropriate homologues of the gene standards were used to 
confirm that the cDNA and the standard were amplified with the similar efficiency.
For preparing the standards, a sample, which has a high concentration, was selected 
and treated by RNase-free DNase according to the previously described protocol. The 
same sample was treated by RT-reaction and its cDNAs were synthesised. Then, a
175
real-time RT-PCR experiment was carried out by SYBR Green I master mix and 
lightcycler for 40 cycles and at 57 °C annealing temperatures. The 2% o f agorose gel 
was then autoclaved at 121 °C for 15 minutes to remove possible RNase 
contamination, the PCR product was loaded into the gel and then electrophoresed at 
100 mAmp for one hour by 2% agarose mini gel. The gel product was then visualised 
by ethium bromide-stained 18S and 28S rRNA under ultraviolet light.
In order to make the standards, the electrophoresed DNA products in the gel were 
extracted by Gel Extraction method, QIAqick Gel Extraction Kit (QIAGEN). The 
extraction protocol was as follows: The electrophoresed DNA fragments were excised 
from 2% of agarose gel with a clean and sharp scalpel under UV light in a dark room. 
Extra agarose was removed by cutting the slices as small as possible to minimize the 
size o f the gel slices. The cut gel slices were weighed in a 15 ml colourless tube. 6 
volumes o f Buffer QG (guanidine thiocyanate) were added to 1 volume o f the gel, 
because the gel concentration was 2%. The gel size was -300 mg, therefore, 1800 pi 
(6X300) o f Buffer QG was added onto the tube contains sample gel.
The tube containing gel-Buffer QG mixture was incubated in a hot bath at 50 °C until 
the gel slices had completely dissolved (it took about 15 minutes). During the 
incubation period, the tube was vortexed every 2-3 minutes for helping the gel to 
dissolve. The coloured o f the dissolved gel Buffer QG mixture was yellow. 1 gel 
volume (300 pi) isopropanol was added to the sample mixture and mixed well. A spin 
column was placed in a 2 ml collection tube. 800 pi of sample was applied to the 
column and was centrifuged at 13,000 rpm (-17,900 x g) for 1 minute to bind the
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DNA. The flow-thraw collected in the collection tube was discarded and the same 
spin column was placed in the same collection tube again. Another 800 pi o f sample 
was applied to the column and centrifuged and the flow-thraw was discarded again 
until all sample solution was applied to the column. 750 pi of Buffer PE containing 
ethanol was added to the column and was centrifuged for 1 minute at 13,000 rpm to 
wash the DNA. The flow-thraw was discarded again, and the column was centrifuged 
for an additional 1 minute at 13,000 rpm. The column containing washed DNA was 
then placed into a sterile 1.5 ml microcentrifuge tube. Then, 50 pi o f DEPC-treated 
water was carefully added onto the centre o f  the column membrane and the column 
was centrifuged for another 1 min. at 13,000 rpm to elute the DNA. After the column 
was removed, the concentration o f the eluted DNA, which was collected in the tube, 
was measured.
The concentrations were arranged as 1X10*1 (0.1) pg/pl and IX 10'2 (0.02) pg/pl by 
diluting with DEPC-treated water. The samples were then stored at -  20 °C to be used 
as standards in future PCR experiments. During PCR experiments, the stored 
standards were diluted several times again with DEPC-treated water to have 10'1 pg/pl 
to 10'8 pg/pl o f standards.
2.3.3.1.12 The Quantitative Real-Time RT-PCR
Firstly, great care was taken to minimise any contamination in this stage o f the 
experiment. For instance, the laboratory bench was wiped thrawout by DEPC-treated 
water twice and then was cleaned again by 70% ethanol. Furthermore, the bench was 
wiped thrawout by nuclease-free aerosol. All materials, which were used in this stage
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of the RT-PCR, including tubes, pipettes, were freshly autoclaved. The gloves used 
were frequently changed.
All template cDNA samples, including negative controls, 2X Quantitect SYBR Green 
PCR Master Mix, DNA primers and RNAse-ffee water were thawed on ice. Each 
individual solution was mixed carefully. Then, a master mix was prepared according 
to 35 samples (24 DNA samples, plus 6 standards, plus 2 negative controls [1 for “no 
RT” sample, 1 for “no RNA” sample or 1 for “no RNA” sample, 1 for RNase-free 
water], and plus 3 extras for unexpected pipetting losses). The master mix volumes 
were aliquoated according to Table 2.7 below.
R eagents Volume for each sam ple
Volume for m aster mix 
(for 35 sam ples)
2X SYBR Green PCR master mix 10 pi 10X 35 = 350 pi
RNase-free water 6 pi 6 X 3 5  = 210 pi
Forward (5’) primer (5mM) 1 pi 1 X 35 = 35
Reverse (3’) primer (5mM) 1 pi 1 X 35 = 35
Total 18 pi 630 pi
Table 2.7: A master mix components for Real-time RT-PCR using LightCycler system.
The master mix tube was mixed thorawly. The lightcycler capillaries were prepared. 
As shown in Table 2.8, 18 pi o f master mix solution was distributed into each 
lightcycler PCR capillaries. Then, 2 pi of DNA templates, including standards and 
negative controls were individually added to PCR capillaries, paying attention to their 
numbers.
Master mix 18 pi
cDNA template 2 pi
Total 20 pi
Table 2.8: Reaction components for Real-time RT-PCR using LightCycler system.
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The covers o f the capillaries were closed. The capillaries were then gently centrifuged 
very briefly and then put in the lightcycler machine and the program was set. The 
Lightcycler machine was programmed according to the program outlined in Table 2.9 
below. After setting the programme, the PCR was run. 3 repeats were carried out for
each condition.
STEP TARGET TEMP.(°C)
HOLDING TIME
(sec)
TEMP TRANSITION
(°C/sec)
Initial activation s tep
Initial activation step 95 900 (15 min) 20
Amplification s tep
Denaturation 94 15 20
Annealing 57 25 20
Extension 72 25 20
81 5 20
Melting s tep
95 0 20
65 30 20
95 0 0.1
Cooling s tep
40 30 20
Cycle n u m b e r : 40
Table 2.9: Real-time cycler conditions for the Lightcycler system.
2.3.3.1.13 Analysing quantitative real-time RT-PCR products
After the completion o f PCR amplification, the data was analysed with the lightcycler 
software (Roche Diagnostic).
2.3.3.1.13.1 Melting Curve and Melting Peaks
All samples were compared by analysing melting curves and melting peaks for 
checking whether or not it had any unspecific PCR amplification. As can be seen from 
Figure 2.15, all PCR amplifications were melted at the same temperature (around 82 
°C) and there was no unspecific amplification which melts in different temperature. 
Figure 2.15 also shows that, negative control samples did not have any melting peak,
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which meant that there were no amplifications of the negative control sample. The 
straight linear at the bottom of both melting curves (Figure 2.14) and melting peaks 
(Figure 2.15) represent the negative control sample.
Figure 2.14: Melting curves. The straight linear at the bottom represents the negative control.
02 -
Figure 2.15: Melting peaks. The straight linear at the bottom represents the negative control.
2.3.3.1.13.2 Standard logs
For every single run, a serial standard dilution (6 standards for each assay) was 
prepared. The standard dilutions were as 1 X 10'1, 10'3, 10'5, 10*6, 10‘7, and 10*8. After 
the completion of the PCR amplification, a standard curve was made by the 
lightcycler program (Roche) according to their log concentrations. The standard curve 
was analysed according to their linear curve, and its slope, intercept, mean squared
error and r. Figure 2.16 shows a linear standard curve in six magnitudes o f copies o f 
MyoD. The slope of the standard curve was -3.938, and intercept was 3.222, mean 
squared error was 0.156 and the r  was 1.00.
  Lnear Regression
■ C/osang PociU
Slope --3.938 
Intercept -1222 
Error -  0156 
r -  -1.00
Figure 2.16: Standard curve. The panel shows a linear standard curve in six magnitudes o f  
copies of MyoD. The standard curve generated by the Lightcycler software ranging from 1 X  
lCf1 to I X  10s ng ofMyoD.
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Figure 2.17: An amplification profile of standards and samples. The standards and samples 
show similar amplification efficiency.
AQ<\
AS
Myogenin MyoD
Figure 2.17: 2 % agarose gel pictures showing PCR products myogenin and MyoD. There 
are 4 products shown for each target. Picture A shows myogenin PCR product, and the 
picture B shows MyoD. Lanes 1 in A, and 5 in B are 100 bp DNA size markers; and lanes 2-5 
in A are myogenin PCR product and, lanes 1-4 in B are MyoD PCR products.
18 2
Chapter 2 -  Part 4:
2.4 Statistical analysis
Microsoft Excel software program o f Microsoft Office 2003 software package were 
used for statistical analysis o f this study. For in vitro cell culture experimentation data, 
1-way ANOVA test was applied. The data were pooled for all runs for all 
observations on each condition, and the data were presented as mean ± s.e.m. or ± s.d. 
On the other hand, for in vivo -  animal experimentations data of the study, paired t- 
test was applied to data. For the PCR part o f the animal experimentation, the data 
were not pooled for all runs. Instead o f pooling, paired t-test were applied using the 
mean values data (the mean values of all runs o f the same samples were separately 
determined for every single sample); and then the data for injected muscle samples 
were compared with the data for uninjected muscle samples by paired t-test of 
Microsoft Excel statistics program. The data were presented as mean ± s.e.m.
For significance test, p <0.05 was considered significant (*). On the other hand, (**) 
was p < 0.005, and (***) was p < 0.0005.
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Chapter 3
In Vitro Effects of IGF-I Isoforms 
on Myoblast Proliferation and Differentiation 
in Rodent Muscle Cell Lines and in 
Degenerative and Healthy Human Primary
Muscle Cells
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Chapter 3 - P a r t i :
3.1 The Effects of MGF on Myoblast 
Proliferation in Rodent Cell Lines
3.1.1 INTRODUCTION
For a very long time, it has been known that, cells can grow in cell culture conditions. 
Although the history o f cell culture dates back to early twentieth century, even to 
nineteenth century, animal cell culture did not become a routine technique until the 
1950s. Since then, it is a very common method to investigate normal physiological 
and biochemical functions o f cells as well as pathological ones.
One of the main hypothesis o f this study was that E domain o f MGF influences 
muscle cell proliferation in in vitro cell culture models with muscle cells from 
different species, including human beings and rodents. Therefore, in this part o f the 
study, in vitro - cell culture model experimentation with different rodent muscle cell 
lines (rat L6 and mouse C2C12) was designed for investigating the effects o f IGF-I 
isoforms in animal myoblast proliferation.
3.1.2 METHODS
To study the effects o f IGF-I isoform on muscle cells proliferation in different rodent 
myoblast cell lines, rat myoblast cell line (L6 E9) and mouse myoblast cell line
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(C2C12), and BrdU proliferation assay technique were used. For both animal cells, rat 
myoblast cell line (L6 E9) and mouse myoblast cell line (C2C12), were treated with 
two different IGF-I isoforms (E domain o f IGF-I Ec [MGF], and recombinant peptide 
of IGF-I [long r3 IGF-I]).
BrdU proliferation assays are used as a parameter for routine cell proliferation 
applications in living cells. BrdU works by incorporating into the newly synthesised 
DNA. The antibodies, which are specific for BrdU, are used to detect the incorporated 
BrdU into the replicating DNA. Therefore, the cells detected by a monoclonal 
antibody against BrdU indicates the proliferating cells. Thus, BrdU proliferation 
assays were used to investigate the roles o f IGF-I isoforms in myoblast proliferation 
in rat and mouse myoblast cell lines.
3.1.3 RESULTS
3.1.3.1 The Effect of MGF in Myoblast Proliferation on Rat L6 Cells.
MGF did not show any effect on rat L6 cell lines. As can be seen from figure 3.1, any 
effect o f MGF were not observed in the cell proliferation on rat L6 cell line even in 
different doses. The levels o f cell numbers were similar between control cells and the 
cells which were treated with the different concentrations o f MGF. In spite o f three 
repeats, no significant changes on the cell proliferation on rat L6 cell line were 
observed. Because L6 cells were not responsive to MGF, no further work was done 
with these cells.
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Figure 3.1: The effect of MGF on myoblast proliferation on rat L6 cells. MGF concentrations 
were various (0, 1, 2, 5, 50 and 100 ng/ml). p  >0.05 (non significant). Data were presented as 
mean ±s.d.
3.1.3.2 The Effect of MGF in Myoblast Proliferation on Mouse C2C12 Cells
The same proliferation experiment was repeated three times on mouse C2C12 cell line 
by BrdU assay in the same conditions. Significant changes were observed in these 
experiments. The numbers o f the dividing cells, which had been treated with MGF in 
different concentrations, were increased substantially. As can be seen from Figure 3.2, 
particularly in the numbers of the cells which were treated with 5, 50 and 100 ng/ml 
of MGF induced proliferation more than 2 fold. Figure 3.2 shows that, the effect of 
MGF was dose dependent. MGF had no effect in 1 ng/ml dose. The effect started in 2 
ng/ml dose, and the doses between 5 and 100 ng/ml showed similar maximal results.
187
MGF effect on m o u se  C2C12 cell 
proliferation
1.4
1.2
1
0.8
0.6
0.4
0.2
0
f
**
I
1 2 5 50
MGF concen tration  (ng/ml)
100
Figure 3.2: The effect of MGF on mouse C2C12 cells. MGF concentrations were various (0, 
1, 2, 5, 50 and 100 ng/ml). p<0.005 (** very significant). Data were presented as mean ± s.d.
3.1.4 DISCUSSION
The study showed that MGF has a significant effect on mouse myoblast (C2C12) 
proliferation. The proliferation effect o f MGF on C2C12 was dose dependent, and the 
effect was therefore not high in lower doses. In recent years, the physiological effects 
o f two main splice variants of the IGF-I gene in muscle cells were studied and found 
that one of these variants (MGF) significantly increased myoblast proliferation in 
some vertebrates, including rabbits and mice (Yang et al, 1997; Yang and Goldspink, 
2002). Yang and Goldspink showed that MGF increased mouse C2C12 myoblast 
proliferation, and its effect was higher than IGF-I Ea (Yang and Goldspink, 2002). 
This study demonstrated that the MGF had a significant effect on mouse myoblast 
proliferation; therefore, the study confirmed Yang and Goldspink’s findings.
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The study also showed that the MGF had no effect on myoblast proliferation in rat 
myoblast cell lines (L6 E9). Rosen et al suggests that IGF-I expression very low or 
nonexistent in the neonatal rat L6 cell line (Rosen et al, 1993). On the other hand, 
Braun et al suggests that L6 cells are restricted in their expression of myogenic factors 
(Braun et al, 1989), and MyoD is not expressed in L6 cells (Braun et al, 1989; Rhodes 
and Konieczny, 1989). MyoD is vital for myogenesis, and myoblast proliferation 
cannot start without MyoD expression. Therefore, MGF might be stimulating in L6 
E9 cells, but the proliferation could not occur due to lack o f MyoD expression. Thus, 
it seems that MGF could not affect myoblast proliferation in the lack o f MyoD 
expression conditions.
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Chapter 3 -  Part 2:
3.2 The Effects of IGF-I Isoforms 
on Human Primary Muscle Cells
3.2.1 INTRODUCTION
In recent years, the physiological effects o f two main splice variants of the IGF-I gene 
in muscle cells were studied and observed that one o f these variants, which is the 
MGF, dramatically increased myoblast proliferation in some vertebrates, including 
rabbits and mice (Yang et al, 1997; Yang and Goldspink, 2002). As can be seen from 
first part o f this chapter (3.1), similar effects was also observed in this study in mouse 
myoblasts -  C2C12 cell lines . However, the physiological functions o f the splice 
variants o f the gene on human muscle in in vitro culture models have not been 
previously investigated. Therefore, this study, for the first time ever, investigated such 
peptides in humans muscles in in vitro primary cultured cell model.
3.2.2 METHODS
The effects of IGF-I isoforms on human primary myoblast proliferation (from healthy 
and degenerative muscles) were investigated by using immunocytochemistry assay; 
and on myotube formation by using CPK/BCA protein assay. As mentioned in section 
1.1.1, because head and neck, and limb muscle tissues have a different embryologic 
origin, two different human muscle cells, namely the craniofacial masseter (head and
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neck) and vastus lateralis (lower limb) muscle cells, were used in this study. 
Proliferation experiments have been completed with healthy craniofacial and limb 
muscle cells from healthy individuals; craniofacial muscle cell with congenital 
muscular dystrophy from a dystrophic (CMD) patient, limb muscles with motor 
neurone disease/ALS from different ALS patients and limb muscles with 
fascioscapulohumeral dystrophy from different FSHD patients. All five types o f cells 
have been treated with IGF-I peptides with different doses, and fixed, stained with 
monoclonal primary and secondary antibodies, mounted on to slides and then stored at 
4°C.
3.2.2.1 Counting of the Immunostained Cells
30 fields were blindly counted in each coverslip by epi-fluorescence and phase 
contrast microscopy.
Figure 3.3: Methodology of counting of immunostained muscle cells on coverslips. Diamond 
shape (^ )  shows starting point, and arrows show moving way.
For blind counting, the labels of the slides were closed, mixed and then relabelled as 
1, 2, 3, 4, and so on. For counting, first o f all, a field at left bottom comer o f the 
coverslip was chosen and DAPI positive and Desmin positive cells in the field were
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counted. Then another field next to first field was chosen by moving up vertically, and 
cells were counted. When reaching the top, it was moved to right horizontally. Then 
moved down vertically again. All fields were systematically counted by this way, 
which can be shown from Figure 3.3, until 30 fields were counted. Extra care was 
taken for not counting the same cells (or fields) twice.
The explant culture methodology generates cells o f  mixed lineage. These are daughter 
cells o f satellite cells (muscle precursor cells) most o f which are committed to 
myogenesis (desmin positive cells); and, the daughter cells of connective tissue cells 
(desmin negative cells). Therefore, some cells in this experiment were observed as 
desmin positive and some as desmin negative. On the other hand, the staining levels 
o f desmin positive cells were differently stained, such very weak, weak, moderate or 
strong. Therefore, the staining levels were marked as + (very weak), ++ (weak), +++ 
(moderate), or ++++ (strong). Thus, very weak cells, which were marked as (+), did 
not consider as desmin positive and hence they were marked as desmin negative cells. 
Only the cells marked as (++), (+++), or (++++) were considered as desmin positive 
ones.
As can be seen from Figure 3.4, the nuclei o f all living cells (DAPI positive cells) 
were seen in blue (A l, A2 and A3). On the other hand, in the same field, some cells 
were seen in green (desmin positive cells -  myoblasts) (B l, B2 and B3), and some 
were not seen (desmin negative cells -  fibroblasts) (B2 and B3). All living cells in the 
same field were also seen in the phase contrast microscope (C l, C2 or C3).
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Figure 3.4: The non -  sorted (mixed) cells under fluorescent and phase contrast microscopy. 
1 for DAP1 nuclear stained cells which indicates all living cells in a field, (nuclei are blue); 
2s for desmin positive cells, which indicates myoblasts in the same field (myoblasts are green) 
and desmin negative cells; and 3s indicates all living cells in the same field under phase 
contrast microscopy. A, B and C show different fields. My: myoblast, Fb: Fibroblast.
After counting all coverslips on all slides and recording data in a lab book, the labels 
were re-opened, and recorded according to their original labels. Finally, the 
calculations o f percentage were done. The ratios o f the desmin positive myoblasts 
(green) to the DAPI positive living cells (blue) were used for interpretation.
3.2.3 RESULTS
3.2.3.1 Results for proliferation assays
3.2.3.1.1 Healthy Human Muscle
3.2.3.1.1.1 Healthy Human Craniofacial Muscle Cells
Figure 3.5 show that, MGF had increased myoblast proliferation significantly. The 
increase o f MGF was 38 percent. On the other hand, long r3 IGF-I, and MGF and long 
r3 IGF-I together had not increased myoblast proliferation significantly. As can been 
seen from figure 3.5 and table 3.1, the long r3 IGF-I had increased myoblast ratio only 
17 percent. When both IGF-I peptides were added together, the ratio had increased 
only 19 percent.
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Figure 3.5: The effects o f IGF-I isoforms on healthy craniofacial muscle cells. The 
concentration for MGF was 10 ng/ml; for recombinant IGF-I was 10 ng/ml and for MGF + 
long r3IGF-I was 10 ng/ml (for MGF) and 10 ng/ml (for long r3IGF-I). (***): p Value: 
<0.0005. Data were pooledfor all runs and presented as mean ± s.e.m.
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Treatments (growth factors) Desmin + ve  mean  
<%>
Increase (%) 
(compare to control
Control 49.8 -
MGF 6 8 . 8 38.2
Long t* IGF-I 58.4 17.3
MGF + long F IGF-I 59.5 19.4
Table 3.1: Data for myoblast proliferation experiments on healthy craniofacial masseter 
muscle cells
3.2.3.1.1.2 Healthy Human Limb Muscle (Vastus Lateralis) Cells
The same effects o f IGF-I isoforms were also observed on normal human limb 
muscles. Figure 3.6 and table 3.2 show that both, MGF and r3 IGF-I had increased 
myoblast proliferation significantly. The MGF raised it significantly (51 %). In 
contrast, systemic IGF-I increased the proliferation only to 23 percent.
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Figure 3.6 The effects of IGF-I isoforms on healthy human limb muscle cells. The 
concentrations for both MGF and long r3IGF-I were 10 ng/ml. (***)■’ P- <0.0005 Data were 
pooledfor all runs and presented as mean ± s.e.m.
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On the other hand, as can be seen from the figure 3.6 and table 3.2, when MGF and 
long r3IGF-I are used together, the effects decreased dramatically. When MGF and 
long r3IGF-I were used together, almost no change was observed (only 1% increase).
Treatments (growth factors) Desmin + ve  Mean 
(%)
Increase (%) 
(compare to control
Control 38.4 -
MGF 57.9 50.6
Long r3 IGF-I 47.1 2 2 . 6
MGF + long r3 IGF-I 38.8 1
Table 3.2: Data for myoblast proliferation experiments on healthy limb muscle cells
3.2.3.1.2 Degenerative Human Muscle
3.2.3.1.2.1 Proliferation Experiments on the Muscle Cells with CMD
Figure 3.7 and Table 3.3 show again that IGF-I isoforms had similar effects on the 
muscle cells from the muscle o f a patient with CMD. In this experiment, craniofacial 
muscle cells from a patient with CMD had been treated with MGF, long r3 IGF-I and 
Ab-I, together and separately.
Myoblast proliferation was increased significantly when CMD cells had been treated 
with MGF both with and without IGFIR blocking antibody. The MGF had increased 
myoblast proliferation as 68 percent. The long r3 IGF-I with and without MGF had 
also increased myoblast ratio, but only slightly (26%), not as dramatically as MGF. 
(Figure 3.7 and table 3.3). On the other hand, another significant fact was observed. 
Myoblast ratio was very low, around just 10 percent (10.4 percent). (Figure 3.7 and 
table 3.3) In contrast, in normal human primary muscle non-sorted cells, the rate o f 
myoblasts in mixed cells was between 38 and 49 percent. In normal (healthy) limb
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muscle cells, the ratio was 38 percent (Figure 3.7 and Table 3.2), while in normal 
craniofacial cells, the ratio was 49 percent (Figure 3.5 and table 3.1).
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Figure 3.7: The effects o f IGF-I isoforms on the muscle cells from the muscle of patients with 
CMD. The concentrations for both MGF and long r3IGF-I were 10 ng/ml (***): p: <0.0005. 
Data were pooled for all runs and were presented as mean ± s.d.
Treatments (growth factors) Desmin + ve Mean 
(%)
Increase (%) 
(compare to control
Control 10.4 -
MGF 17.5 68.1
Long rJ IGF-I 13.2 26.6
MGF + r3 IGF-I 13.1 26.2
Table 3.3: Data for proliferation experiment on craniofacial muscle cells with CMD.
3.2.3.1.2.2 Proliferation Experiment on the Muscle Cells with ALS
As can be seen from Figure 3.8, quite similar effects have been observed on 
myoblasts from muscle o f patients with ALS. MGF increases myoblast proliferation 
dramatically again (49%). The long r IGF-I did not increase the proliferation with and 
without MGF.
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A low ratio of myoblast was observed again in ALS, like in congenital muscular 
dystrophy. In ALS, the ratio was much lower (just 4.8 percent). Data can be seen from 
Table 3.4.
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Figure 3.8: The effects of IGF-I isoforms on the muscle cells from the muscle ofpatients with 
ALS. The concentrations for both MGF and long r3IGF-I were 10 ng/ml; (***): p: <0.0005. 
Data were pooled for all runs and were presented as mean ± s.d.
Treatments (growth factors) Desmin + ve Mean 
<%)
Increase (%) 
(com pare to control
Control 4.8 -
MGF 7.2 49.8
Long r* IGF-I 4.9 1
MGF + long F IGF-I 5.2 8
Table 3.4: Data for proliferation experiment on limb muscle cells with ALS.
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3.2.3.1.2.3 Proliferation Experiment on the Muscle Cells with FSHD
Almost the same effects have been observed on myoblast proliferation derived from 
patients with FSHD. Figure 3.9 shows that MGF increases on myoblast proliferation 
in higher ratio (74%). The long r3IGF-I increased the proliferation in lower ratios with 
and without MGF (both 24%). Low ratios of myoblast were observed again in 
myoblasts from patients with FSHD, like in CMD and ALS. In FSHD, the ratio was 
low again (just 11 percent). Data can be seen from Table 3.5.
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Figure 3.9: The effects of IGF-I isoforms on the muscle cells from the muscle of patients with 
FSHD. The concentrations for MGF and long r3IGF-I were 10 ng/ml; (***): P Value: <0.05 
(8. IE-07). Data were pooled for all runs and were presented as mean ± s.d.
Treatments (growth factors) Desmin + ve  
<%)
Increase (%) 
(com pare to control)
Control 11.7 -
MGF 20.4 74.4
Long rJ IGF-I 14.5 23.8
MGF + long rJ IGF-I 14.5 23.8
Table 3.5: Data for proliferation experiment on limb muscle cells with FSHD.
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3.2.3.1.3 Proliferation Experiments with IGF1R blocking antibody
Healthy and degenerative cells were also treated with type 1 IGF receptor (IGF1R) 
blocking antibody (Ab-I) in order to investigate whether or not MGF affects 
proliferation thraw IGF1R activity. For this aim, the cells from the craniofacial 
masseter muscle of healthy individual, and the cells from the vastus lateralis muscle 
of patients with CMD and ALS. When the cells had been treated with anti IGFIR 
blocking antibody (Ab-I), significant changes were not observed. For instance, as can 
be seen Figure 3.10, in healthy craniofacial muscle cells, when the myoblast 
percentages of untreated control cells compared to the same cells treated with Ab-I, 
the ratio decreased only 2 percent. Similar observation was seen in MGF treated cells. 
Comparing to increasing ratio of MGF treated cells, with the same cells treated with 
Ab-I, the increasing ratio was decreased only 3 percent.
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Figure 3.10: The effects of MGF and Ab-I on healthy human craniofacial muscle cells. The 
concentrations for MGF were 10 ng/ml; for Ab-I is 500 ng/ml (***): p: <0.0005, ns: non 
significant (>0.05). Data were pooledfor all runs and presented as mean ± s.e.m.
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Similar effects were also observed on the cells from the muscles of patients with 
CMD and ALS. It was observed again that Ab-I did not change the effects o f MGF. 
(Figures 3.11 and 3.12). Figures 3.10, 3.11 and 3.12 show that MGF does not act 
thraw IGFIR Therefore, These experiments confirmed that MGF does not appear to 
affect proliferation thraw activity of IGFIR (Figures 3.10, 3.11 and 3.12).
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Figure 3.11: The effects o f MGF with and without anti IGFIR blocking antibody (Ab-I) on the 
muscle cells from the muscle of patients with CMD. The concentration for MGF was 10 ng/ml 
and for Ab-I was 500 ng/ml. (***): p: <0.0005, ns: non significant (>0.05). Data were pooled 
for all runs and were presented as mean ± s.d.
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Figure 3.12: The effects o f MGF with and without anti IGF-IR antibody (Ab-I) on the muscle 
cells with from the muscle o f patients ALS. The concentrations were that MGF was 10 ng/ml 
and Ab-I was 500 ng/ml. (***); p: <0.0005. Data were pooled and presented as mean ± s.d.
Figure 3.13 shows all three experiments together in the same figure.
□ C  aC +A b-1 1MGF flMGF+Ab-1
CMD ALS
Figure 3.13’. The effects of MGF and IGF-IR blocking antibody (Ab-I) on the muscle cells 
from muscle o f healthy individuals and the cells from the muscle ofpatients with CMD and 
ALS. The figure also shows myoblast ratios in healthy and degenerative (CMD and ALS) 
muscle. N (normal) shows the cells from healthy individuals. The concentrations were that 
MGF was 10 ng/ml and Ab-I was 500 ng/ml. (***): p: <0.0005. Data were pooled for all 
runs and were presented as mean ± s.d.
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3.2.3.2 Results for differentiation assays
3.2.3.2.1 Differentiation experiments for healthy human muscle cells
Differentiation experiments using CPK/BCA protein assays were carried out on the 
cells from the craniofacial masseter muscle of a healthy individual. Creatine kinase 
(CK) or creatine phosphokinease (CPK) is a marker of differentiated muscle fibres. 
Therefore, CPK/BCA protein assay were carried out to investigate differentiation state 
o f myoblasts.
Figure 3.14 shows that MGF has no overall effect on myoblast differentiation 
(myotubes formation). The long r3 IGF-1 stimulates myotube formation effectively at 
10 ng/ml. The MGF does not affect at doses between 10 and 100 ng/ml, but it 
antagonises the effect o f IGF-I in a dose-dependent manner. This can be seen from 
Figure 3.14.
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Figure 3.14: The effect o f MGF with and without long r3IGF-I on differentiation for normal 
(healthy) human craniofacial muscle cells. MGF doses were 0 (for control), 10 and 100 
ng/ml. long r3 IGF-I dose was 10 ng/ml. (***): p: <0.0005, ns: non significant (>0.05). Data 
were presented as mean ± s.d.
3.2.3.2.2 Differentiation experiments for human degenerative muscle ceils
After completing differentiation experiments for healthy human muscle cells by CPK/ 
BCA protein assays, Sigma company had stopped the production of CPK assays kit, 
therefore CPK assay kit could not provided any longer. Thus, the remaining 
differentiation experiments for degenerative muscle cells were not able to carried out 
by the same assay. Instead of such assay, immunocytochemistry technique was 
designed. As can be seen from Figure 3.15, it is possible to determine myotube 
formation by this technique. Differentiation would be observed by the calculation of 
the percentages of desmin positive multi nucleated myotubes to the percentages of 
single nucleated myoblasts. The study had sufficient data to suggest that
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immunocytochemistry assay was a good technique for determining cellular 
differentiation in muscle tissue. As can be seen from Figure 3.15, some 
multinucleated myotubes were visualised in normal (healthy) human primary muscle 
cells after being immunostained with primary and secondary antibodies.
Figure 3.15 shows both mononucleated myoblasts (marked as My) and multinucleated 
myotubes (marked as Mt) in the same field. Both myoblasts and myotubes were seen 
as DAPI positive (blue stained cells -Ai and Bi) and desmin positive (green stained -  
Bi and B2). The cells were also seen in phase contrast microscope (A 3 and B 3 ). 
Multinucleated myotubes (marked as Mt) can be seen in Figure 3.15.
A 1  A 2  A 3
Figure 3.15: The multinuclear myotubes under epi-fluorescent and phase contrast 
microscopy. At and Bj show DAPI positive myoblasts, fibroblasts, (nuclei are blue); A2 and 
B2 show desmin positive myoblasts, myotubes and desmin negative fibroblast in green 
fluorescent; and A3 and B3 show phase contrast microscopy in the same fields. My: 
mononucleated myoblasts, Mt: multinucleated myotubes, Fb: Fibroblasts. A and B show 
different fields.
one
Although myotube formation were clearly observed and multinucleated myotubes 
were growth in healthy human muscle cells, they could not be seen in degenerative 
muscle cells. Despite all efforts, those differentiation experiments with the 
degenerative muscle cells by immunocytochemistry assays were unsuccessful to 
identify any multinucleate myotube. After adding Muscle Cell Differentiation 
Medium, the cells were daily checked under light microscopy until being seen the 
development o f myotube formation in order to add different growth factors in 
different doses for different conditions. Even though the experiments were repeated 
several times with different types o f degenerative muscle cells (those from CMD, 
FSHD and ALS patients), it was observed that myoblasts were not fused to myotubes. 
Cells were cultured for up to 10 weeks with no evidence of myotube formation. 
Although the differentiation medium was changed every 3-4 days, before adding 
growth factors, myotube formation was not observed. The composition of 
differentiation medium was also changed (from 0.5 % BSA, with low insulin [5 
ng/ml] with 1 % P/S in DMEM to 2 % FBS with 1 % P/S in DMEM); the result was 
the same again: myotube formation did not occur. Nevertheless, some cells were fixed 
and immunostained without seeing myotube formation. All DAPI positive and 
Desmin positive cells were single nucleated myoblasts. No desmin positive 
multinucleated myotubes was observed. Therefore, differentiation states for 
degenerative muscle cells could not be determined.
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3.2.4 DISCUSSION
This part of the study has showed that MGF has an effect on muscle cell proliferation. 
The MGF dramatically increased muscle cell proliferation in vitro in human primary 
cultured myoblasts. In humans, the MGF dramatically increased myoblast 
proliferation in every kind of cells, which are studied, in the cells with different 
embryological origins (from a head and neck muscle, and from a limb muscle), and 
also, the cells healthy and with degeneration from both head and neck muscle, and 
from limb muscle). The study showed that the E peptide o f MGF induces progenitor 
cell proliferation significantly in primary cultured muscle cells from patients with 
CMD, FSHD and ALS as well as healthy individuals. In this study, E peptide o f MGF 
increased myoblast proliferation 38.2 % in healthy craniofacial muscle cells (Figure 
3.6 and Table 3.1), in healthy limb muscle cells 50.6%, (Figure 3.7 and Table 3.2), in 
the cells from the muscle of patients with CMD 68.1% (Figure 3.8 and Table 3.3), in 
the cells from the muscle of patients with ALS 49.8% (Figure 3.9 and Table 3.4) and 
in the cells from patients with FSHD 74.4% (Figure 3.10 and Table 3.5). All data 
were very significant.
On the other hand, long r3 IGF-I (systemic IGF-I) peptide increased myoblast 
proliferation in lower levels. The long r3 IGF-I peptide increased the proliferation in 
healthy craniofacial muscle cells 17.3 % (Figure 3.6 and Table 3.1), in healthy limb 
muscle cells 22.6%, (Figure 3.7 and Table 3.2), in the cells from patients with CMD 
22.6% (Figure 3.8 and Table 3.3), in the cells from patients with ALS only 1%
(Figure 3.9 and Table 3.4) and in the cells from patients with FSHD 23.8% (Figure 
3.10 and Table 3.5). The increase effects o f the MGF were always higher (more than
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one fold) than those of systemic IGF-I one. When the cells treated with MGF and long 
r3 IGF-I peptide together, the effects were similar to those o f long r3 IGF-I peptide 
alone. According to these data, it can undoubtedly say that, MGF increases in all kind 
of human muscle cells, head and neck or limb, healthy or degenerative. On the other 
hand, it was observed that the increase effects of MGF was clearly higher than those 
of systemic IGF-I.
In contrary, MGF had not any effect on muscle differentiation (myotube formation).
As can be seen from Figure 3.14, two IGF-I isoforms, IGF-I Ea (systemic IGF-I) and 
MGF, have antagonist effect in differentiation. The data in this study clearly showed 
that MGF had not any effect on myoblast differentiation although it remarkably 
stimulated myoblast proliferation. Whereas, the systemic form of IGF-I had a huge 
effect on myotube formation while having limited stimulation on myoblast 
proliferation. The study also demonstrated that MGF had reduced the effect o f IGF-I 
Ea on myoblast differentiation. When E peptide o f MGF was added to long r3 IGF-I, 
which were used as an IGF-I Ea peptide in this study, the effect of long r3 IGF-I on 
myotube formation decreased (Figure 3.15). The preventative effect of E domain o f 
MGF on myoblast differentiation was dose dependent, and the effect of IGF-I Ea 
decreased more when MGF was added to IGF-I Ea in higher doses. The present work 
therefore demonstrated that the MGF E domain had a distinct biological activity 
compared to long r3 IGF-I. It caused the mononucleated progenitor (satellite) cells to 
replicate but it has no effect on myotube formation. In contrast, long r3 IGF-I had a 
marked effect on such formation. Gillian Butler-Brown and Vincent Mouly suggest 
that systemic IGF-I starts signalling by Akt pathway after fusion competent myoblasts
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fuse to myotubes, not before (Unpublished data by Butler-Brown and Mouly) (this 
information was obtained by Prof Goldspink from Drs Gillian Butler - Brown and 
Vincent Mouly during a private communication in Myores meeting, held in Rome, in 
November, 16th -19th, 2005). Thus, the data in this study confirmed that, MGF and 
long r3 IGF-I had different cellular actions: MGF increased myoblast proliferation 
whilst systemic IGF-I Ea induced myotube differentiation. This finding confirms 
Yang and Goldspink’s, and Mouly and Butler-Browne’s data (Yang and Goldspink, 
2002; Mouly and Butler-Browne, unpublished data).
Previous studies have used BrdU or Alamar Blue, particularly those that claim IGF-I 
causes satellite cell replication. However, these studies have often not used markers to 
distinguish cells at different stages of the lineage pathway. This study found that a 
satellite cell activation marker, desmin, to be suitable to distinguish the muscle 
progenitor cell for other myoblasts. This part o f the study also found that 
immunocytochemistry using desmin and DAPI markers is a good technique for 
determination o f cellular proliferation and differentiation in skeletal muscle tissue. As 
can be seen from Figure 3.4 and 3.16, mononucleated myoblasts and fused 
multinucleated myotubes can be clearly seen in the culture conditions, and their 
proliferation and differentiation stages can be easily determined by the technique 
under fluorescent microscopy.
It has been known that the ratios o f satellite cells drop in elderly people. This study 
also demonstrated that the ratios o f myoblasts (progenitor or activated satellite cells) 
of degenerative muscles cells were also low. As can be seen from the result section of
209
this chapter, the ratios o f myoblasts from the patients with FSHD, CMD and ALS 
were very low (5, 10 and 12 percent) compared to the ratios of myoblasts from 
healthy individuals (between 38 and 50 percent). According to data in this study, 
satellite cell pools are quite low in degenerative muscles compare to the cells in 
healthy individuals. The lack o f satellite cells in degenerative muscles might be cause 
the decline o f regeneration capacity in the patients with degenerative muscles.
The E peptide o f MGF increased myoblast proliferation in the cells from a healthy 
limb muscle more than the cells from a healthy craniofacial masseter muscles. The 
ratios of increase were respectively 50 and 38 percents. Pavlath et al suggest that head 
and neck muscles, for instance the craniofacial masseter muscle, which used in this 
study, regenerate poorly compared to limb muscles (Pavlath et al. 1998). This finding 
might explain the differences between increase levels o f two different healthy 
muscles.
In this study, despite extensive efforts, to obtain any muscle differentiation (myotube 
formation) in culture of human degenerative muscle cells was unsuccessful. 
Degenerative myoblasts did not fuse and myotube formation was not observed despite 
all efforts. Thus, differentiation state was only determined in healthy human muscles. 
In this study, it was observed that the ratios o f degenerative myoblasts were low, 
compare to those o f healthy cells were high. As it will discuss in details later in the 
general discussions, inhibition of calcineurin may play an important role in 
degenerative muscle pathophysiology (Stupka et al, 2004). It has been known that 
calcineurin is a mediator of IGF-I signalling pathway (Musaro et al, 1999). Thus,
2 1 0
Shavlakadze et al propose that muscle degeneration can be due to the lack of IGF-I 
signalling (Shavlakadze et al, 2004). As a result, myotube formation might not be 
occurred because o f decreasing activated satellite cells ratios / myoblasts number; 
that of lack o f IGF-I, particularly MGF, signalling; that o f insufficiency of 
mechanotransduction, etc.
This study also demonstrated that IGFIR blocking antibody (Ab-I) did not prevent the 
action of MGF in myoblast proliferation. The effects o f MGF alone were similar to 
those of MGF with Ab-I in healthy craniofacial muscle cells and also the cells from 
the muscles of patients with CMD and ALS. In all cells, when the data o f control cells 
compared to those o f MGF treated cells, the data always were very significant 
(Figures, 3.11., 3.12., 3.13 and 3.14). Whereas, the data o f the cells compared to those 
of the cells also treated with Ab-I (control to control + Ab-I, and MGF alone to MGF 
+ Ab-I), the data were non-significant (Figures, 3.11., 3.12., 3.13 and 3.14). 
According to these data, different actions of different IGF-I isoforms are probably 
mediated via different receptors. The data concerning the blocking o f the type 1 IGF 
receptor in this study provided some evidence that MGF increases myoblast 
proliferation via a different signalling pathway, and it does not bind to IGF-I receptor. 
Therefore, MGF might bind to different cell surface receptor or receptors other than 
IGFIR; and it seems that MGF peptide is an independent growth factor to systemic 
form of IGF-I, although both are splice variants o f the same IGF-I gene.
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Chapter 4
An In Vivo Gene Therapy Application 
for mdx Mouse Model of DMD Using cDNAs 
of IGF-I Splice Variants, and the Role of 
MGF in Tissue Repair Mechanism I  
Satellite Cell Activation
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Chapter 4 - P a r t i :
4.1 Roles of IGF-I Splice Variants in Muscle 
Growth in mdx Mouse Model of DMD
4.1.1 INTRODUCTION
Currently, there are millions o f patients with neuromuscular disorders, and some other 
conditions associated with muscle weakness and wasting worldwide. Among them, 
DMD is the most common muscular dystrophy. Therefore, treatment for such diseases 
and conditions is crucial. Thus, the aim o f this study was to attempt a novel gene 
therapy application for treating muscle degeneration in such disorders. Previous IGF-I 
delivery research have shown some anatomical and biochemical improvements in 
skeletal muscles (Lynch et al, 2001; Barton et al, 2002). Therefore, cDNAs o f IGF-I 
splice variants were delivered into mdx mice skeletal muscles to drive functional 
improvements and restoration o f muscle strength.
4.1.2 METHOD
The previous chapter o f the study focused on investigating in vitro effects o f IGF-I 
isoforms on skeletal muscle cells (myoblasts) proliferation and differentiation by cell 
culture model. It has been known that in vivo experimentation provides more 
knowledge holistically. Thus, the roles of cDNAs of IGF-I splice variants in skeletal
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muscle tissue were also investigated in an animal subject with muscle degeneration, 
which was mdx mouse model. On the other hand, it was previously shown that mdx 
skeletal muscle did not produce MGF even during exercise (Goldspink and Yang,
2001; Goldspink and Yang, 2004; Goldspink, 2005; Goldspink, 2006). In addition, 
Prof Goldspink suggests that the production of MGF is deficient in certain diseases 
such as in the muscular dystrophies in which the mechanotransduction mechanism is 
defective. According to Prof Goldspink, deficiency of MGF production in dystrophin 
deficient degenerative muscles, because o f insufficiency of mechanotransduction 
mechanism in such conditions (Goldspink, 2006). This was another reason why mdx 
mouse model was chosen as in vivo experimentation subject. For the same reasons, it 
was logical to study the transfer o f MGF cDNA as an alternative gene treatment to 
replacing or repairing the dystrophin. Goldspink, 2005).
After three weeks (21 days) introducing cDNAs of IGF-I splice variants into one o f 
TA muscles o f young and old mdx mice, the maximum muscle forces and the weights 
of both TA muscles (untreated control, and treated ones) were measured in order to 
investigate the effects o f such variants in muscle growth by strength and size. The 
detailed methods o f in vivo experimentation section.
4.1.2.1 Calibration of the force transducer
Before maximum muscle force measurement for each TA muscle o f each animal, a 
linear calibration of the force transducer was figured out using different weight in 
grams as force. Weights were as 10, 15, 25, 37.5, 50, 62.5, 75 and 100 gr. 
Measurements were done with above weight by a force transducer device (Harvard
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Instruments Co. Ltd) and the voltage output in V for each weight in grams were 
recorded into a computer using Spike 2 - Version 4 (from CED- Cambridge Electronic 
Design - UK) software program. After founding reading values (voltage output) for 
each weight, a linear standard curve were figured out (Figure 4.1). Then a formula to 
convert voltage output of the force in grams into maximum muscle force value in 
milli Newtons (y = 0.0784 X -  0.0758) was calculated by the computer from the data 
of the linear calibration plot. The force measurements were in grams, then these 
measurements were converted into milli Newtons (mN) by using above formula.
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Figure 4.1. A linear calibration of the force transducer, y =0.0784 X -  0.0758; R2: 0.9994.
As the measurements were isometric this is just multiplying contractile tension (force) 
by a constant. In 1938, A. V. Hill hypothesized specific relationships between the 
force generated by a muscle and the speed at which a stimulated muscle contracts 
under a given load. A stimulated muscle may contract to 1/3 its size at a particular 
speed. (Hill, 1938). Then Hill expressed this hypothesis in following equitation:
(P + a)(V+b) = c.
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P describes the force generated by a muscle, V is the speed at which a muscle 
contracts, and a, b, c are constants. The constant (a) describes the force expended to 
make the muscle contract, and (b) describes the smallest contraction rate of the 
muscle. Then, the equitation for maximum muscle contraction can be changed as 
follow: (Beals et al, 1999) 
c
P = -------------------a
V + b
4.1.2.2 The calculation of maximum muscle force:
After completing all measurements, and removing and then storing the TA muscles, 
the calculations for maximum muscle force values were carried out using the 
computer by Spike 2 software -  Version 4 (CED- Cambridge Electronic Design - 
UK). The raw data in mV were then calculated by using above formula to determine 
the maximum muscle force in mN.
As an example, as can be seen Figure 4.2-A, two force measurements were made for 
each TA muscle, and therefore, there were two peaks (Al and A2). The reading value 
of the peak o f the first force (A l) for the mouse (a young mouse which MGF was 
injected into its right TA muscle) was 4.79887. The starting level of A l force was 
below of 0 level (- 0.106026). Thus, this value was added to the peak value to 
calculate maximum muscle force. In this sample, the reading value of the maximum 
force measurement of A l was 4.79887 + 0.106026 = 4.904896. (Figure 4.2-A)
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Figure 4.2: Individual maximum force of an MGF injected TA muscle from a young mdx 
mouse. Axes are (V) and time (sec).
In the second measurement (4.2- A2), the reading value o f the peak was 4.11046, and 
the stimulation started from -0.932113. Then, after adding the starting reading value (- 
0.932113) to the reading value o f the peak (4.11046), the reading value o f the 
maximum muscle force o f the second measurement was calculated as 4.11046 + 
0.932113 = 5.042573. The reading value of the A l was 4.904896, and that o f the A2 
was 5.042573. Because the reading value of the second measurement (A2) was bigger 
than first one (A l), the reading value o f A2 was selected as the reading value o f the 
maximum force o f that MGF treated animal. For this example, 5.042573 was selected 
instead of 4.904896.
The same calculations were also carried out for the untreated left control TA muscle. 
As shown from Figure 4.3, the reading value of the maximum force of untreated TA 
muscle of the same animal was just 4.1. In contrast, the reading value o f the
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maximum force of MGF injected TA muscle (right TA muscle) was 5.042573 (nearly 
20% increase) (Figure 4.2 -  A2). The reading values of the maximum muscle force 
were repeated by the same calculating method for all animals both old and young, and 
for both injected (control) and uninjected (experimented) TA muscles.
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Figure 4.3: Individual maximum force of untreated TA muscle from the same MGF treated 
young mdx mouse. Axes are (V) and time (sec).
Figure 4.4 shows the reading value of the maximum force o f an old mdx mouse. 
Figure 4.4-A shows MGF injected TA muscle, and 4.4-B shows uninjected TA 
muscle o f the same animal. Differences between two maximum force measurements 
showed the effect of the MGF. As can be seen from the Figures 4.4-A and B, the 
maximum force o f an MGF uninjected old mdx mouse was about 6.5 (Figure 4.4 B), 
the uninjected control was just about 8.5 (Figure 4.4 A).
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Figure 4.4: Individual maximum forces o f an MGF injected and uninjected - control TA 
muscle of the same old mdx mouse. A: Maximum force o f MGF injected TA muscle and B: 
Maximum force o f uninjected control TA muscle. Axes are (V) and time (sec).
However, the reading values do not show the exact maximum force values. In order to 
find the exact maximum muscle force, a formula (the formula was calculated by a 
linear standard calibration) was applied to all reading values. The formula was as 
follows: Y (reading value) = 0.0784 X -  0.0758;
If, Y (reading value) = 0.0784 X -  0.0758;
X = Y + 0.0758/0.0784.
X (the exact maximum muscle force -  in mN) = y (reading value) + 0.0758 / 0.0784. 
For instance, the reading value (y) o f above example was 5.042573 mV.
Then, the exact maximum muscle force was:
X = 5.042573 + 0.0758 / 0.0784 = 65.28537 mN.
All calculations for both legs o f TA muscles o f all animals were completed using the 
same formula (Y = 0.0784 X -  0.0758 or X = Y + 0.0758 / 0.0784).
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When all measurements were calculated, and the means and graphs were extracted 
from these calculations, it was observed that the means of maximum muscle forces for 
each group were quite different from each other, because the bodyweights and the 
ages of old animals varied. Therefore, in order to demonstrate the changes more 
clearly, the muscle force values o f both treated and untreated TA muscles were re­
calculated again and the data were normalised to 100 for untreated control muscles. 
Following this, all calculations and graphs for all animals (old and young) were drawn 
again according to these new data.
4.1.3 RESULTS
This study showed that IGF-I splice variants, particularly MGF, increased muscle 
forces in mdx mice in both old and young ages. MGF increased muscle strength more 
than IGF-I Ea in both age groups. Comparing the old and young animals, the effect of 
MGF was considerably high in young animals in just 3 weeks time and by only one 
injection. MGF also increased muscle strength in older ages, though not with same 
rate as with the younger animals, and the rate was in a lower rate (data was also 
significant statistically).
4.1.3.1 Effects of IGF-I splice variants in old mdx mice
After calculations of maximum muscle force measurements and weights o f all TA 
muscles o f old mdx mice, and comparison between the uninjected controls and the 
injected ones, it was observed that the MGF increased muscle strength more than the 
IGF-I Ea although the effects o f both splice variants (MGF and IGF-I Ea) were
2 2 0
similar to each other in old mdx mice (Figures 4.6 and 4.7). Figures 4.5 shows some 
individual maximum forces of single injected and uninjected control TA muscles o f 
old mdx mice in order to show some examples.
Old MGF Group 
A B
Old IGF-I Ea Group 
A B
221
Old Vector-only Group 
A B
Figure 4.5: Individual maximum forces o f injected and uninjected control TA muscles from 
MGF, IGF-I Ea and Vector-only groups o f old mdx mice. A: uninjected control, B: injected 
TA muscle o f the same animals. Axes are (V) and time (sec).
As it is evident from Figures 4.6, and 4.7, the increase caused by MGF was around 
10.6 percent while the figure for IGF-I Ea was 9.5 %. On the other hand, the same 
figures demonstrate that a slight increase also recorded in the muscles o f control 
group (vector-only group). The increase by vector-only control group was just 2.4 
percent. Although increase rates caused by both MGF and IGF-I Ea were very similar 
each other (10.6 and 9.5 % respectively), the data for increase level caused by MGF 
was significant statistically (p value was 0.015), though the data was not significant 
for IGF-I Ea group (p: 0.211).
Empty Vector MGF IGF-! Ea
Treatm ents
□  Untreated ■  Treated
Empty Vector MGF
Treatments
^□Untreated ■  Treated j
Figure 4.6: IGF-I splice variants based gene therapy application for old mdx mice. A: 
According to absolute data, B: According to normalised data to 100 for controls. N: Vector- 
only (N:6), MGF (N:7) and IGF-I Ea (N:8). P value for MGF was <0.05 (0.015), and for 
empty vector and IGF-I Ea were >0.05 (0.862 and 0.211 respectively). Data were presented 
as mean ± s. e.m .
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Figure 4.7: The percentage o f the changes in muscle force in old mdx mice. N: Vector-only 
(N:6), MGF (N:7) and IGF-I Ea (N:8).
On the other hand, MGF also increased muscle mass. The changes in muscle masses 
were determined by weighing the treated (injected with MGF, IGF-I Ea or empty 
vector) and untreated (uninjected, resting) TA muscles for all groups in old and young 
mdx mice. Figure 4.8 shows the percentages o f the changes in treated / injected (gene 
transferred in vector) TA muscle weights in old mdx mice comparing to those of 
untreated / uninjected TA muscles. As can be seen in figure 4.8, MGF increased 
muscle masses by 7 percent and the data was significant statistically (p value was 
0.009), while IGF-I Ea increased it by only 2 percent and the data was not significant 
statistically (p value was 0.087). In contrast, 5 percent o f decrease were observed in 
vector-only control group and this data was also not significant statistically (p value 
was 0.309).
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F i g u r e  4 . 8 :  T h e  c h a n g e s  i n  m u s c l e  w e i g h t  i n  o l d  m d x  m i c e  a f t e r  g e n e  t r a n s f e r .  D a t a  w e r e  
o p t i m i s e d  t o  1 0 0  f o r  u n i n j e c t e d  c o n t r o l s .  N :  E m p t y  v e c t o r  ( N : 6 ) ,  M G F  ( N : 7 )  a n d  I G F - I  E a  
( N : 8 ) .  P  v a l u e  f o r  M G F  w a s  < 0 . 0 5  ( 0 . 0 0 9 ) ,  a n d  f o r  e m p t y  v e c t o r  a n d  I G F - I  E a  w e r e  > 0 . 0 5  
( 0 . 3 0 9  a n d  0 . 0 8 7  r e s p e c t i v e l y )  . T h e  d a t a  p r e s e n t e d  a s  m e a n  ±  s . e . m .
4.1.3.2 Effects of IGF-I splice variants in young mdx mice
After all calculations, it was observed that the MGF dramatically increased muscle 
fibre mass by strength and size in young mdx mice. Figure 4.9, 4.10 and 4.11 show 
some individual tetanic forces o f single injected and uninjected control TA muscles of 
young mdx mice in order to show some examples.
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Figure 4.9: Individual tetanic forces o f injected and uninjected control TA muscles from MGF 
group of young mdx mice. A: uninjected control, B: injected TA muscle of the same animals. 1 
and 2 are the TA muscles of different animals. Axes are (V) and time (sec).
\
Figure 4.10: Individual tetanic forces of injected and uninjected control TA muscles from 
IGF-I Ea group of young mdx mice. A: uninjected control, B: injected TA muscle o f the same 
animals. 1 and 2 are the TA muscles of different animals. Axes are (V) and time (sec).
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Figure 4.11: Individual tetanic forces o f injected and uninjected control TA muscles from 
vector-only control group of young mdx mice. A: uninjected control, B: injected TA muscle of 
the same animals. 1 and 2 are the TA muscles of different animals. Axes are (V) and time 
(sec).
Figures 4.12, and 4.13 show that MGF has a marked effect on young mdx mice. The 
MGF increased muscle force of young animals by more than 37 percent in 3 weeks 
and the data was significant statistically (p value was 0.014). In contrast, IGF-I Ea 
increased the muscle force only by 14 percent (but not significant). The effect o f MGF 
in muscle force was 2.5 fold higher than that of IGF-I Ea. Again, there was not a 
significant change in vector-only control group. In the young muscles o f the vector- 
only control group, the maximum muscle force decreased 3.6 percent after 3 weeks 
from the injection. Although the maximum muscle force changes between injected 
and uninjected TA muscles o f vector-only control and IGF-I Ea groups were not 
significant statistically (p: 0.783 and 0.292 respectively), the changes o f MGF group 
were clearly significant statistically with a p value less than 0.05 (0.014).
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The MGF also increased muscle mass in higher rate in TA muscles of young mdx 
mice. Figure 4.14 shows the percentages of the changes in treated TA muscle weights 
in young mdx mice comparing to those of untreated TA muscles. As can be seen the 
figure 4.14, MGF increased muscle masses by 13 percent while IGF-I Ea increased it
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by only 6 percent. The increase in empty vector control group was just 2 percent. The 
data were statistically significant for MGF but not significant (0.04) for empty vector 
control and IGF-I Ea groups (0.598 and 0.079 respectively). The same data for old 
mdx mice were just 7 percent increase for MGF, 2 percent increase for IGF-I Ea, and 
5 percent decrease for vector-only control group (Figure 4.8). Data for MGF was 
significant again although they were not significant for both vector-only control and 
IGF-I Ea groups.
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Figure 4.14: The percentage of the changes in muscle weight in young mdx mice. Values were 
normalised to 100 for uninjected controls. N: Empty vector (N:7), IGF-I Ea (N:8) and MGF 
(N:8). P value for MGF was <0.05 and significant (0.04), and for empty vector and IGF-I Ea 
were >0.05 and non significant (0.598 and 0.079 respectively). The data presented as mean ± 
s. e. m.
4.1.4 DISCUSSION
This study found that cDNAs of MGF, which were transferred into TA muscles of 
mdx mice in a plasmid vector, increased muscle growth of dystrophic mdx mice in 
strength, and that this was much more effective in younger animals. MGF
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dramatically increased muscle strength in young mdx mice by average of 37.4%, only 
3 weeks after injection. Whereas the increase effect o f IGF-I Ea in maximum tetanic 
muscle force in young animals was lower than that o f MGF. cDNA of IGF-I Ea 
slightly increased maximum muscle force (14.1 %). On the other hand, while the 
increase effect o f MGF was significant, the effect o f IGF-I Ea was not significant. 
Therefore, the study clearly showed that MGF splice variant of IGF-I was 
considerable more effective than systemic variant of the gene (IGF-I Ea) in restoring 
muscle strength.
MGF also increased muscle force in old mdx mice although the increase level was 
lower than that in young animals. The ratios o f the increase o f MGF and IGF-I Ea 
were very close in old mdx mice; they were for MGF 10.6 %, and for IGF-I, increase 
ratio was 9.5 % (they were 37.4% and 14.1% in young animals). Similar to the data of 
young animal experimentation, the data o f old animals also were statistically 
significant for MGF group. The data o f IGF-I ea and vector only groups were not 
significant statistically again.
Similar effects were also observed in TA muscle weights in both young and old 
animals. The MGF also increased muscle mass in higher rate (13%) in TA muscles of 
young mdx mice when comparing treated muscles to untreated ones. The increase 
ratio of IGF-I Ea was only 6% in young animals (Figure 4.14). Whereas MGF 
increased muscle mass in old animals only 7 percent, and IGF-I Ea increased the mass 
2% (Figure 4.8). MGF data for both young and old animals were statistically 
significant (0.04 and 0.009 respectively). Whereas, as can be seen from Figures 4.14
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and 4.8, vector-only control and IGF-I Ea groups for both young and old animals, data 
were not significant statistically.
Comparing this observation in old mdx mice to the effect o f MGF in young animals, it 
can be said that the effects of cDNAs of MGF in muscle growth of old mice is not 
high. This is in accord with the findings of Wells and Goldspink (1992) who reported 
that the age significantly influenced the level of expression of the injected plasmid 
DNA (Wells and Goldspink, 1992). They found that the highest levels of plasmid 
DNA expression were obtained from the 4-6 weeks age young mice, and they were 
significantly higher than those o f from the mice older than 10 weeks (Wells and 
Goldspink, 1992). In this study, young mdx group was age of 4-8 weeks, whereas, the 
age of the old mdx mice were between 15-26 months old.
It is known that, in degenerative skeletal muscle states, including DMD, motor nerve 
innervation reduces in advanced age; satellite cell numbers and proliferative potential 
significantly decrease; skeletal muscle's regenerative capacity and contractility 
diminishes; particularly in DMD, regenerative capacity is exhausted (Jejurikar and 
Kuzon, 2003; Shi and Garry, 2006). In addition to above observations, plasmid 
distribution drops in advanced ages. The animals in old mdx groups of in vivo part of 
this study had two disadvantages: They were old and also had degenerative muscles 
(mouse model o f DMD). The lower effect of cDNAs o f MGF in muscle growth in old 
mdx mice can be explain under all above conditions (degenerative muscles and age 
concern).
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Chapter 4 Part 2:
4.2 Roles of IGF-I Splice Variants 
in Satellite Cell Activation
4.2.1 INTRODUCTION
A number of studies suggest that satellite cells are involved in repair and regeneration 
following local injury and/or damage o f muscle fibers. When satellite cells are 
activated by a variety of external stimuli (e.g. loading, injury, disease, age), daughter 
cells (muscle precursor cells) are generated that go on to repair muscle fibers by 
supplying extra nuclei.
In healthy adult undamaged muscle, the satellite cells are quiescent. The quiescent 
satellite cells are activated and begin proliferating in response to stimuli. Hill and 
Goldspink suggest that MGF activates quiescent satellite cells in vivo in rats (Hill and 
Goldspink, 2003, Hill et al, 2003). Therefore, it is crucial to investigate the role of 
IGF-I splice variants, particularly MGF, in satellite cell activation mechanism in 
degenerative muscles.
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4.2.2 METHODS
mRNA transcripts levels of the activated satellite cell markers, which are MyoD and 
Myogenin (comparing with that o f internal control p-actin), were investigated by 
quantitative real-time RT-PCR after three weeks introducing cDNAs o f IGF-I splice 
variants. The detail o f the quantitative real time RT-PCR method can be found from 
chapter 2.2 o f this study.
4.2.2.1 Analysing of data
Although real-time RT-PCR is the most sensitive technique for detection mRNA 
targets, and its application is broadly used to quantitate biologically changes in 
mRNA levels, there remain some problems associated with its use. RT-PCR specific 
errors in the quantification o f mRNA transcripts are easily compounded by any 
variation in the amount o f starting material between samples. These errors become 
particularly important when the samples have been obtained different individuals (or 
animals), and they can result in the misinterpretation of the expression levels o f the 
target gene/genes (Bustin, 2000; Bustin and Nolan, 2004; Huggett et al, 2005). 
Therefore, it is important to choose an accurate normalisation method to control for 
the possibility o f misinterpretation of the data (Huggett et al, 2005). One o f most 
commonly used normalisation method is to use an internal control / reference / 
housekeeping gene by dividing absolute copy numbers o f target genes against 
corresponding absolute copy numbers of internal reference / housekeeping gene 
(Huggett et al, 2005). In this study, as an internal reference or housekeeping gene, (3- 
actin was selected, because p-actin is one of most commonly used internal control / 
housekeeping / reference gene (Bustin, 2000; Bustin and Nolan, 2004; Huggett et al,
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2005; Bustin and Mueller, 2006; Nolan et al, 2006) and its mRNA is expressed at 
moderately high levels in most cell types including muscle cells and it encodes an 
ubiquitous cytoskeleton protein (Bustin, 2000). Therefore, the P-actin mRNA was 
amplified to ensure equal quantities o f starting RNA before performing RT-PCR.
Then after RT-PCR were performed with target mRNAs (MyoD and myogenin), 
mRNA expressions o f MyoD and myogenin were compared with that of P-actin by 
calculating their absolute gene copy numbers. For this aim, copy numbers o f MyoD, 
myogenin and p-actin for each sample, both injected and uninjected ones, were 
calculated separately. Each of the calculated copy numbers for either MyoD or 
myogenin was normalized against the corresponding p-actin copy numbers by 
dividing absolute gene copy numbers for either MyoD or myogenin to the absolute 
gene copy number of P-actin o f the same sample.
As can be seen from the materials chapter (chapter 2.2), the primers, which were used 
this study, were MyoD myogenin and p-actin. Their primer sequences, the sequences 
o f their amplified fragment and molecular weights are as follow:
MyoD (NCBINM  010866) 123 bp Mw: 38.139 g/mol KD ssDNA 
Primer:
Upperstream (forward) -  TTT CTT C ACC AC ACCT CT - 
Downstream (reverse) -  TTAACTTTCTGCCACTCC -
Amplified fragment (123 bp):
5’TTTCTTCACCACACCTCTGACAGGACAGGACAGGGAGGAGGGGTAGAG 
GACAGCCGGTGTGCATTCCAACCCACAGAACCTTTGTCATTGTACTGTTGG 
GGTTCCGGAGTGGCAGAAAGTTAA - 3’
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Myogenin (NCBI NM 031189) 102 bp Mw: 31.547 g/mol KD ssDNA 
Primer:
Upperstream (forward) -  AGACGAAACCATGCCCAA - 
Downstream (reverse) -  TAAAAGCCCCCTGCTACAGA -
Amplified fragment (102 bp):
5 ’ AG ACG AA ACC AT GCCC AACT GAG ATT GT CT GTC AGGCT GGGT GT GC AT G 
TG AGCCCCC AAGTTGGT GT C AAAAGCC AT C ACTTCT GT AGC AGGGGGCTT 
TTA -3’
P-actin (GenBank AB117093) 186 bp mw 41.695 g/mol KD ssDNA 
Primer:
Upperstream (forward) -  GACGATGATATTGCCGCACT - 
Downstream (reverse) -  GAT ACC ACGCTT GCT CTG AG -
Amplified fragment (186 bp):
5 ’ G ACG AT GAT ATT GCCGC ACT CGTT GTTGAC AATGG ATCCGGT AT GT GC A 
AGGCCGGCTTCGCGGATGATGCTCCACGTGCTGTCTTCCCATCCATCGTGG 
GGCGC CC AAG AC ATC AGGGT GT GAT GGTT GGC AT GGGCC AG AA AG AC AG 
CTACGTTGGTGATGAAGCTCAGAGCAAGCGTGGTATC -  3’
4.2.2.2 Calculation of Copy Numbers
Copy number of each PCR product (MyoD, myogenin and p-actin) was calculated 
separately. Calculations of copy numbers were made as follow: As an example, the 
reading value (the value for fluorescent absorbance) of myogenin mRNA expression 
in young MGF treated sample was 5.94 x 10 ~6 ng/pg. The reading value was then 
multiplied by 10 " 9 to establish the number in grams. 5.94 x 10- 6 x 10_9 = 5.94 x 10
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15 g. Therefore, the final weight was divided by molecular weight of myogenin: 102 
bp (size of product for myogenin) x 31.547 g/mol (weight o f ssDNA in g/mol) = 
3217.794 g/mol. (5.94 x 10 " 15 g) / 3217.794 g/mol = 1.84 x 10 “ 18 mols. This was 
then multiplied by the Avogadro constant which is 6.0221415 x 1023. (1.84 x 10 18) x 
(6.022 x 10 23) = 1111678.39. Thus, 1111678.39 molecules were presented in 2 pi of 
30 pi solution containing 0.75 pg of RNA [2 x (30x0.75)]. To calculate the copy 
number per pg of RNA, the value (111 1678.39) was multiplied by 2 and then by 22.5 
(30x0.75). An finally, absolute copy number for above sample was: 111 1678.39 x 2 x 
22.5 = 50025526 (5 x 10 7) copies / pg RNA.
An example for copy number calculation:
Reading value o f myogenin mRNA expression: 5.94 x 10 ~6 ng/pg
5.94 x 10 ~6 x 10 ~9 = 5.94 x 10 - 15 g
(5.94 x 1 0 " 15 g ) / 3217.794 g/mol = 1.84 x 1 0 " 18 mols
(1.84 x 10 “ 18) x (6.022 x 1023) = 1111678.39
(1111678.39) x 2 x 22.5 = 50025526 (5 x 10 7) copies / pg RNA
An example for the calculation of ratios of copy numbers of myogenin and p- 
actin (myogenin copy number / p-actin copy number):
Myogenin copy number for an MGF treated sample in young mdx mice group was 
= 3815546.304
p-actin copy number for the same sample was = 17104850
Myogenin copy number / P-actin copy number = 3815546.304 / 17104850
= 0.223068 (2.23E-01).
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Copy numbers and the ratio o f copy numbers o f target gene mRNA and internal 
reference gene mRNA of all samples (uninjected and injected of both, young and old 
mdx mice groups) were separately calculated by this way, and the results were 
interpreted.
4.2.3 RESULTS
4.2.3.1 Satellite cell activations in the young mdx mice.
4.2.3.1.1 MyoD expression
As can be seen from Figures 4.15A, 4.15B and 4.16, the MyoD expressions in the 
samples o f the treated TA muscles in the young MGF group were higher than 
untreated ones. Although the data were statistically not significant, Figure 4.15A, 
4.15B and 4.16 show that MyoD expression was clearly increased in the young MGF 
group comparing with untreated controls. As can bee seen from such Figures and 
from the raw data in appendix 5, the normalised absolute MyoD gene copy numbers 
in MGF injected samples was increased by more than 13 folds (increased from 1.02 to 
13.07) than uninjected samples in the same animals. Whereas, normalised MyoD copy 
numbers o f IGF-I Ea and empty vector injected samples were almost similar when 
comparing them to uninjected samples of the same animals. A slight increase occurred 
in empty vector injected samples, and a small decrease occurred in IGF-I Ea injected 
samples.
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Figure 4.16. MyoD expression with raw data for young mdx mice after gene transfer: N: 
empty vector (N:7), MGF (N:8) and for IGF-I Ea (N:8). P values for all three group were 
P>0.05 and then non significant.
Although the data were not statistically significant for MGF group, As it can be 
clearly seen from Figure 4.16, MyoD expressions were increased in almost all MGF 
injected samples while MyoD expressions were both increased and decreased in 
Empty vector and IGF-I Ea group. Therefore, although the data were not statistically 
significant, the data and three figures show that MGF activates MyoD expression 
while IGF-I Ea had no role in this activation.
4.2.3.1.2 Myogenin expression
Figures 4.17A, 4.17B, and 4. IS show the myogenin expressions in the samples of 
young mdx mice. Similar effect was also observed in myogenin expression in young 
MGF group. Figures 4.17A, 4.17B, and 4.18 show that MGF clearly increased 
myogenin expression in young mdx mice. Normalised Myogenin copy numbers from 
MGF treated samples were quite higher than untreated ones. As can bee seen from 
such Figures and from the raw data in appendix 5, normalised absolute Myogenin
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copy numbers from MGF treated samples were almost 25 folds higher (increased 
from 0.39 to 9.83) than those of uninjected samples o f the same animals. The data 
were also significant statistically (p; 0.009). Again, similar to MyoD, normalised 
MyoD copy numbers of IGF-I Ea and empty vector injected samples were almost 
similar when comparing them to uninjected samples of the same animals. In addition, 
while the data for MGF group was significant statistically (0.009), The data for both 
empty vector and IGF-I Ea groups were also not significant. Thus, above three figures 
clearly show that MGF also activates Myogenin expression in young mdx mice 
whereas IGF-I Ea had no role in this activation. Figure 4.18 also show that myogenin 
expression were increased in all samples of MGF group, while MyoD expressions 
were both increased and decreased in Empty vector and IGF-I Ea group
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Figure 4.17. Myogenin expression for young mdx mice after gene transfer: A shows the data 
in column chart, and B shows the same data in line chart. N: for empty vector N: for empty 
vector (N:7), MGF (N:8) and for IGF-I Ea (N:8). Data were statistically analysed by paired 
t-test and presented as mean ± s.e.m..*: P values. P values for MGF group was P<0.05 
(0.009) and significant, and for both empty vector and IGF-I Ea groups were P>0.0 and then 
non significant.
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Figure 4.18. Myogenin expression with raw data for young mdx mice after gene transfer: N: 
empty vector (N: 7), MGF (N:8) and for IGF-I Ea (N:8). P values for MGF group was P<0.05 
(0.009) and significant, and for both empty vector and IGF-I Ea groups were P>0.0 and then 
non significant
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4.2.3.2 Satellite cell activations in the old mdx mice.
Similar effects were also observed in old mdx mice myofibre samples. As it can be 
seen from Figures 4.19 to 4.22, MGF increased both MyoD and myogenin 
expressions in TA muscles o f old mdx mice after 3 weeks introducing cDNAs of 
MGF. Similar to young mdx experimentation, while the data o f MGF were 
statistically significant for myogenin expression, they were not significant for MyoD 
expression again.
4.2.3.2.1 MyoD expression
Figure 4.19A and B, and 4.20 shows that MGF also increased MyoD expression by 
4.5 folds in old mdx mice, despite the data were not significant statistically. On the 
other hand, MyoD expressions were slightly decreased in both groups, in empty 
vector, and IGF-I Ea injected animals. The data for them were also not significant.
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Figure 4.19. MyoD expression for old mdx mice after gene transfer: A shows the data in 
column chart, and B shows the same data in line chart. N: for empty vector (N:5), MGF (N:7) 
and for IGF-I Ea (N:7). Data were statistically analysed by paired t-test and presented as 
mean ± s.e.m.. *: P values. P values for all three group were P>0.05 and then non significant.
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Figure 4.20. MyoD expression with raw data for old mdx mice after gene transfer: N: empty 
vector (N:5), MGF (N:7) and for IGF-I Ea (N:7). P values for all three group were P>0.05 
and then non significant.
243
4.2.3.2.2 Myogenin expression
Similar effects were also observed in myogenin expression in old animals.
Figures 4.21 A, 4 .2IB, and 4.22 show that MGF clearly increased myogenin 
expression in old animals as well. The Figures show that MGF increased myogenin 
expression 2.5 folds while IGF-I Ea sharply decreased. Myogenin expression was also 
decreased in empty vector injected samples when compared to injected samples. The 
data for MGF were also significant statistically (p: 0.04). On contrary, the data for 
both empty vector and IGF-I Ea groups were also not significant. Figure 4.22 also 
show that myogenin expression were increased in all samples of MGF group, while 
Myogenin expressions were both increased and decreased in Empty vector and IGF-I 
Ea group
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Figure 4.21. Myogenin expression for old mdx mice after gene transfer: A shows the data in 
column chart, and B shows the same data in line chart. N: for empty vector (N:5), MGF (N:7) 
and for IGF-I Ea (N:7). Data were statistically analysed by paired t-test and presented as 
mean ± s.e.m.. *: P values. P values for MGF group was P<0.05 (0.044) and significant, and 
for both empty vector and IGF-I Ea groups were P>0.0 and then non significant.
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Figure 4.22. Myogenin expression with raw data for old mdx mice after gene transfer: N: 
empty vector (N:5), MGF (N:7) and for IGF-I Ea (N: 7). P  values for MGF group was P<0.05 
(0.044) and significant, and for both empty vector and IGF-I Ea groups were P>0.0 and then 
non significant.
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4.2.4 DISCUSSION
The data in this study showed that the effect o f transfer o f the MGF on satellite cell 
activation by investigating satellite cell markers expression in young mdx mice was 
higher and than those o f old animals. Similar effects with muscle growth were also 
observed in the same experiments. In all analysis, the effects o f MGF in muscle 
growth and satellite cell activation in young mdx mice was higher than in old ones.
When uninjected control muscle samples were compared with injected muscle 
samples, the study demonstrated that transfer o f MGF activated satellite cells, 
however IGF-I Ea did not. The study showed that both MyoD and myogenin 
transcript levels were significantly higher in TA muscle tissues from MGF treated 
young mdx mice when compared to uninjected control muscles o f the same animals. 
In this way, the study indicated that MGF activated muscle satellite cells o f mdx mice, 
particularly in young animals, although the data were not significant statistically for 
MyoD expression, they were significant for myogenin expression in young animals. 
On the other hand, IGF-I Ea were ineffective in both activated satellite cell markers 
expressions, MyoD and myogenin.
As they can be seen from figures of all young and old animals (figures, 4.16, 4.18, 
4.20 and 4.22), both MyoD and myogenin expressions in all samples o f MGF injected 
muscles were always increased when compared to those o f uninjected ones. Whereas, 
in samples o f IGF-I Ea and in those o f empty vector, both MyoD and myogenin 
expression were increased or decreased or did not change.
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On the other hand, in old mdx mice, while MGF slightly increased both MyoD and 
myogenin expressions, IGF-I Ea and empty vector decreased the expression levels of 
MyoD and myogenin. MyoD is expressed in the early stage o f satellite cell activation 
process and then indicates myoblasts proliferation. Whereas, myogenin is expressed 
in the late stage o f the satellite cell activation process, and therefore it indicates 
differentiation state. In the in vivo experimentation part o f this work, plasmid vectors 
were injected into the right TA muscles o f both young and old animals. Plasmid 
vectors contained either cDNAs o f MGF or IGF-I Ea, or empty vector (for control 
group). The injections might cause some damage to muscle tissues. Therefore, the 
damage might decrease MyoD and myogenin expressions for a while in all animals in 
all groups. However, expression might be increased again a while later due to effects 
of intrinsic and extrinsic signalling factors. Furthermore, in old mdx group, because 
the satellite cell pools decrease in advanced age, there might be not enough quiescent 
satellite cells to proliferate and then differentiate and therefore to express MyoD and 
myogenin. As a result, due to the damage, MyoD and myogenin expression in IGF-Ea 
and empty vector injected muscle samples in old animals might be decreased. On the 
other hand, because MGF stimulated the activated satellite cell markers (MyoD and 
myogenin), both expression might be increased again. The data in this study and the 
figures 4.19, 4.20, 4.21 and 4.22 confirm this observation. MGF data for myogenin 
expressions were statistically significant for both young and old animals (p: 0.009 and 
0.044 respectively).
A recent publication suggests that plasmid distribution in muscle tissue drops by the 
15th day (Coelho-Castelo et al, 2006). The same researchers also suggest that plasmid
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/ naked DNA (pcDNA) distribution is dose dependent, and the distribution time 
decreases in lower doses (Coelho-Castelo et al, 2006). Plasmid DNA doses introduced 
into animals in this study was 1 pg/g. The average weight o f old mdx mice was 26 g, 
therefore, less than 30 pg p f plasmid DNAs were transferred into TA muscles o f each 
old animal. According to Coelho-Castelo et al, this amount o f plasmid DNA is low. 
Therefore, along with reduced satellite number and activation process, plasmid DNA 
distribution might be ended after 21 days, and RNA extracted from them for 
investigating MyoD and myogenin expression by RT-PCR. Therefore, on the day, on 
which the tissues samples were taken, cDNAs o f IGF-I splice variants might be 
stopped or decreased, and thus satellite cell activation might be ended. As a result, the 
doses and time point used in the in vivo gene transfer part o f this study might cause 
the low effects o f MGF in satellite cell activation.
On the other hand, the data for MyoD expression o f both young and old mdx mice 
were not significant statistically. As explained before, firstly, MyoD is expressed in 
satellite cell activation process and then myogenin is expressed. MyoD also indicates 
myogenin expression. Therefore, on the day, on which the tissues samples were taken, 
the effect o f MGF might be stopped or decreased, and thus MyoD expression by MGF 
might be ended.
As can be seen from Figures 4.19 to 4.22, it is observed that, the data were very 
variable, particularly in old animals,. Because the expression levels for all three genes 
(MyoD, myogenin and beta-actin) largely varied, the error bars for all groups were 
high. Particularly in old mdx mice, all animals were in different ages, and some of
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them were too old (some o f them were 26 months old) and as a result, they were too 
weak. This age differences can be a reason for high error bars for old animals.
In addition, in this part o f the study, an internal control / reference / housekeeping 
gene (p-actin) was used to normalise target mRNA expressions. The P-actin mRNA 
was amplified to ensure equal quantities o f starting RNA before performing RT-PCR. 
Then, each o f the calculated copy numbers for either MyoD or myogenin was 
normalized against the corresponding p-actin copy numbers by dividing them to the 
absolute gene copy number o f p-actin. The p-actin expressions in all samples had very 
large variation. Many publications suggest that transcription levels o f P-actin can vary 
widely in response to experimental manipulation in different human and animal cells 
(Bustin, 2000). In addition, after large volume liquid delivery to muscle cells, p-actin 
variations widely increase in muscle cells (Prof G. Goldspink, May 2007, personal 
communication). In this study, P-actin expression varied widely in injected muscle 
samples when compared them to injected control ones. In order to normalise them the 
corresponding internal reference / housekeeping gene, absolute copy numbers of 
MyoD (and those o f myogenin) were divided to the absolute gene copy number o f P- 
actin. The ratios varied widely and therefore, error bars were very high. Another 
reason of non-significant states o f MyoD data for MGF group might be this p-actin 
variation.
Hill and Goldspink previously showed that MGF activated quiescent satellite cells in 
wild type rats (Hill and Goldspink, 2003, Hill et al, 2003). This study indicated that 
MGF also activated satellite cells in mdx mice. MGF initiates the activation o f muscle
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satellite (stem) cells, as well as up regulating protein synthesis. The action o f MGF is 
more specific than that o f systemic IGF-I Ea.
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5 General Discussion
Numerous publications have so far shown that IGF-I is involved in several cellular 
processes, including proliferation, differentiation, repair and maintenance. For some 
time, it has been also known that alternative splicing o f the IGF-I gene within human 
skeletal muscle tissue occurs leading to isoforms that have different E domains, 
including pro-IGF-IEa, pro-IGF-IEb, and pro-IGF-IEc (MGF) (Goldspink and Yang, 
2004). For a long time, it has been proposed that E peptide o f these pro-IGF-I 
precursors may act as independent growth factors (Siegfried et al, 1992; Yang and 
Goldspink, 2002; Goldspink and Yang, 2004).
In recent years, the physiological effects o f two main splice variants o f the IGF-I gene 
in muscle cells were studied and it has been shown that one o f these variants (MGF) 
significantly increased myoblast proliferation in some vertebrates, including rabbits 
and mice (Yang et al, 1997; Yang and Goldspink, 2002). However, the physiological 
functions o f the splice variants o f the gene on human muscle in in vitro culture models 
have not been previously elucidated. Therefore, this study has, for the first time ever, 
investigated the E domain in a human in vitro cell culture model.
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This study has strongly showed that MGF has a remarkable effect in muscle cell 
proliferation. The MGF dramatically increased myoblast proliferation in vitro in both 
animals and humans (in mouse C2C12 myoblast cell lines and human primary 
myoblasts). In humans, MGF increased myoblast proliferation in all muscle-derived 
cell cultures studied, including muscles with different embryological origins, and the 
cells from muscles o f patients with degenerative diseases.
This study showed that MGF has a significant effect on mouse myoblast proliferation. 
The study also showed that the proliferation effect o f MGF on C2C12 was dose 
dependent, and the effect was not high in lower doses. This study clearly showed that 
the effect o f MGF was higher than the systemic form of IGF-I, IGF-I Ea. Four years 
ago, Yang and Goldspink suggested that MGF increased mouse C2C12 myoblast 
proliferation, and its effect was higher than IGF-I Ea (Yang and Goldspink, 2002). 
This study confirmed their suggestion.
The study also showed that the MGF did not affect myoblast proliferation in rat 
myoblast cell lines (L6 E9). Rosen et al suggests that IGF-I expression is very low or 
nonexistent in the neonatal rat L6 cell line (Rosen et al, 1993). On the other hand, 
Braun et al suggests that L6 cells are restricted in their expression o f myogenic factors 
(Braun et al, 1989), and MyoD is not expressed in L6 cells (Braun et al, 1989; Rhodes 
and Konieczny, 1989). MyoD is vital for myogenesis, and myoblast proliferation 
cannot start without MyoD. Therefore, MGF might be stimulating L6 E9 cells, but the 
proliferation could not occur due to lack o f MyoD expression.
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This study showed that two IGF-I isoforms, IGF-I Ea and MGF, have antagonist 
affect in muscle differentiation. The data in this study showed that MGF had not any 
effect on myoblast differentiation (myotube formation) although it remarkably 
stimulated myoblast proliferation. Whereas, the systemic form o f IGF-I (IGF-I Ea) 
had a huge effect on myotube formation while having limited stimulation on myoblast 
proliferation. IGF-I Ea might be taking desmin positive cells out o f stem cell pool into 
myogenic differentiation.
The study also showed that MGF had reduced the effect o f IGF-I Ea on myoblast 
differentiation. When E peptide o f MGF was added to long r3 IGF-I, the effect o f long 
r3 IGF-I on myotube formation were decreased. The preventative effect o f E domain 
o f MGF on myoblast differentiation was dose dependent, and the effect o f IGF-I Ea 
decreased more when MGF was added to IGF-I Ea in higher doses.
Previous studies have used BrdU or Alamar Blue, particularly those that claim IGF-I 
causes satellite cell replication. However, these studies have often not used markers to 
distinguish cells at different stages o f the lineage pathway. This study found that a 
satellite cell activation marker, desmin, to be suitable to distinguish the muscle 
progenitor cell for other myoblasts. It demonstrated that the E peptide o f MGF 
induces progenitor cell proliferation significantly in primary muscle culture from 
patients with CMD, FSHD and ALS as well as healthy individuals. Additionally, 
MGF did not affect myotube formation, a process that IGF-I accelerates significantly. 
The present work therefore demonstrated that the MGF E domain had a distinct 
biological activity compared to long r3 IGF-I. It caused the monocleate progenitor
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(satellite) cells to replicate but it has no effect on myotube formation. In contrast, long 
r3 IGF-I had a marked effect on such formation. Therefore the data in this study 
confirmed that, MGF and long r3 IGF-I had different cellular actions: MGF increased 
myoblast proliferation whilst systemic IGF-I Ea induced myotube differentiation and 
was in accord with that o f Yang and Goldspink’s (2002), and Mouly and Butler- 
Browne’s data (Yang and Goldspink, 2002; Mouly and Butler-Browne, unpublished 
data).
In this study, as mentioned above, MGF did not have any effect in proliferation in rat 
myoblast cell lines (L6 E9). Whereas it increased myoblast proliferation 2 fold (more 
than 100 percent) in C2C12: 38.2 percent increase for healthy primary cultured 
craniofacial myoblasts; 50.6 percent for healthy primary cultured limb muscle 
myoblasts. It was observed in this study that C2C12 cells grow quiet easily and 
rapidly in high levels. Therefore, a more than 100 percent o f increase in MGF E 
Domain treated proliferating cells was not surprising. Again, it was observed in this 
study that human primary cultured muscle cells grew more slowly.
Gillian Butler-Brown and Vincent Mouly suggest that systemic IGF-I starts signalling 
by Akt pathway after fusion competent myoblasts fuse to myotubes, not before 
(Unpublished data by Butler-Brown and Mouly) (this significant information was 
obtained by Prof Goldspink from Drs Gillian Butler - Brown and Vincent Mouly 
during a private communication in Myores meeting, held in Rome, in November, 16th 
-19 , 2005). The results o f this study clearly confirm these findings: MGF increase 
myoblast proliferation by activating o f the quiescent satellite cells, whilst systemic
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IGF-I induces differentiation. On the other hand, a while ago, it has been suggested 
that MGF is expressed before systemic IGF-I following muscle damage (Yang and 
Goldspink, 2002; Haddad and Adams, 2002; Goldspink and Yang, 2004). This study 
indicated that MGF stimulated myoblast proliferation and IGF-I Ea stimulates 
myoblast differentiation (myotube formations). Proliferation stage is earlier stage of 
myogenesis than differentiation. Therefore, the findings o f this study also support 
above information.
In this study, differentiation experimentation in human degenerative muscle cells was 
unsuccessful. Degenerative myoblasts did not fuse and myotube formation was not 
observed despite all efforts. Thus, differentiation state was only determined in healthy 
human muscles. In this study, it was observed that the ratios o f degenerative 
myoblasts were very low (between 5 and 12 percents) compare to those o f healthy 
cells (between 38 and 50 percents). Inhibition o f calcineurin may play an important 
role in degenerative muscle pathophysiology (Stupka et al, 2004). Calcineurin also is 
a mediator o f the IGF-I signalling pathway (Musaro et al, 1999). Thus, Shavlakadze et 
al propose that muscle degeneration could be due to a lack o f IGF-I signalling 
(Shavlakadze et al, 2004). As a result, because o f decreasing activated satellite cells / 
myoblasts number; lack of IGF-I, particularly MGF, signalling; insufficiency o f 
mechanotransduction, etc, myotube formation might not be occurred.
For a long time, it has been known that, IGF-I is a neurotrophic factor and possesses 
potential clinical applications, in neurodegenerative disorders, particularly in ALS 
(Wilczak and Keyser, 2005). To date, systemic delivery o f human recombinant IGF-I
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has been used to treat ALS (Wilczak and Keyser, 2005). Most recently, Kasper et al 
(2005) found that exercise, when combined with IGF-I gene therapy by AAV2 vector, 
have some synergistic effects in treatment o f ALS (Kaspar et al, 2005). The findings 
o f Kaspar et al support the findings o f this study, because MGF is expressed only in 
response to mechanical stimuli, including exercise.
This study demonstrated that different actions o f different IGF-I isoforms were 
probably mediated via different receptors. The data concerning the blocking o f the 
IGF-I receptor in this study provided sufficient evidence that MGF increases myoblast 
proliferation via a different signalling pathway, and MGF does not stimulate 
proliferation thraw IGF1R. Therefore, MGF might be bound to different receptor or 
receptors other than IGF1R. Thus, it seems that E domain o f MGF is an independent 
growth factor to systemic form o f IGF-I, despite both are splice variants o f the same 
IGF-I gene.
Muscle satellite cells were one of the first tissue specific stem cells to be studied (for 
review see Dhawan and Rando, 2005). However, many studies have been carried out 
on transformed cells because of the availability o f muscle cell lines and little work has 
been carried out using primary human muscle culture. In human muscle, the lineage 
and signalling associated with the activation process from quiescent, mononucleated 
to progenitor cells has been studied. Muscle satellite (stem) cells appear to be residual 
myoblasts that have not fused to form myotubes/muscle fibers. These are seen in 
juxtaposition with the muscle fibers following embryological differentiation o f the 
tissue. Although, residual myoblasts are believed to be the main source o f muscle
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satellite cells, myoblast is a generic term for any cell that gives rise to muscle, and in 
primary cell cultures, all mononucleated cells are not satellite cells. There is a need 
therefore to have a marker to denote the stage in the progenitor cell lineage such as 
desmin (Sinanan et al, 2004; Dhawan and Rando, 2005).
Muscle loss is one o f the main causes o f death in patients with certain neuromuscular 
diseases. Goldspink and Yang suggested that in some cases, the muscle loss can be 
linked to the inability to express MGF (Goldspink and Yang, 2001; Goldspink, 2005), 
and they observed that muscles o f mdx dystrophic mice, a model o f human Duchenne 
Muscular Dystrophy, are unable to express MGF even during mechanical stimuli 
(Goldspink and Yang, 2001; Goldspink and Yang, 2004; Goldspink, 2005). De Bari et 
al observed that, when mesenchymal stem cells were introduced into dystrophic 
muscles o f mdx mouse, the sarcolemmal expression o f dystrophin and also that MGF 
are restored (De Bari et al, 2003). Therefore, it seems that MGF is required for 
activation o f stem cell lineage.
In addition, Stupka et al suggest that calcineurin has an important role in the 
pathophysiology o f degenerative muscle (in dystrophic mdx mouse) (Stupka et al,
2004). Inhibition o f calcineurin resulted in 300 -  400 % more necrotic myofibers and 
reduced regeneration (Stupka et al, 2004). It has been known that the calcineurin is a 
mediator o f IGF-I signalling pathway (Musaro et al, 1999). Therefore, Shavlakadze et 
al propose that muscle degeneration in dystrophic mdx mouse can be due to the lack 
of IGF-I signalling (Shavlakadze et al, 2004). Furthermore, Prof G. Goldspink 
suggests that the production o f MGF may involve some type o f mechanotransduction
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mechanism (Goldspink, 2005). According to this study, it seems that both 
mechanisms, insufficiency o f satellite cells and inability to express MGF, have some 
role in the occurrence o f defective muscles mechanism.
This study found that cDNAs o f MGF, which were transferred in a plasmid vector, 
significantly increased muscle growth o f dystrophic mdx mice both in strength and 
mass, and that this was much more effective in younger animals.
The data in this study shows that MGF increases muscle force slightly in old mdx 
mice. The ratio o f the increase o f MGF was 10.6 %, and IGF-I increases 9.5 %. 
Comparing this observe to the effect o f MGF in young animals, it can be said that the 
effects o f cDNAs o f  MGF in muscle growth o f old mice is not high when comparing 
it to those o f IGF-I Ea one. This is in accord with the findings o f Wells and Goldspink 
who reported that the age significantly influenced the level o f expression o f the 
injected plasmid DNA (Wells and Goldspink, 1992). They found that the highest 
levels of plasmid DNA expression were obtained in the 4-6 weeks age young mice, 
significantly higher than in mice older than 10 weeks (Wells and Goldspink, 1992). In 
this study, young mdx group was age o f 4-8 weeks, whereas, the age o f the older mice 
were between 15-26 months.
It has been known that the ageing process causes a reduction in the regenerative 
capacity o f skeletal muscles eventually leading to reduced muscle strength, and to 
take place muscle weakness and also wasting (sarcopenia). On the other hand, satellite 
cells are the primary source o f regenerating muscle fibers, and satellite cells must first
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be activated from quiescent state to produce myoblast progeny and to start 
regeneration (Zammit et al, 2006). The mechanisms causing the impaired regenerative 
response to injury or degeneration observed in skeletal muscle o f aged animals are not 
known yet. So far, different hypothesis have been proposed. For instance, Jejurikar et 
al, suggests that apoptosis may be a mechanism responsible for the depletion of 
satellite cells in old animals and then impairing the regenerative response (Jejurikar et 
al, 2006). The same researchers therefore proposes that aging increases the 
susceptibility o f skeletal muscle derived satellite cells to apoptosis (Jejurikar et al, 
2006). On the other hand, it is known that satellite cell activation is controlled by the 
Notch signalling pathway that is initiated by the rapid increase in expression o f the 
Notch ligand, Delta, following injury. Conboy and Rando suggest that this up- 
regulation o f Delta is blunt and thus satellite cell activation is remarkably reduced in 
old skeletal muscles (Conboy and Rando, 2005). Again, Hameed et al found that 
MGF expression in elderly women and men dropped significantly (Hameed et al, 
2002; Hameed et al, 2003; Harridge, 2003; Hameed et al, 2004).
As a result, degenerative skeletal muscle, including that o f DMD, states motor nerve 
innervation; satellite cell numbers and proliferative potential significantly decrease in 
advanced age; regenerative capacity and contractility o f skeletal muscle exhaust in 
degenerative muscles o f neuromuscular diseases, particularly in DMD (Jejurikar and 
Kuzon, 2003; Shi and Garry, 2006). On the other hand, plasmid distribution decreases 
in advanced age. The lower effect o f cDNAs o f MGF in muscle growth in old mdx 
mice can be explain under all these negative conditions.
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For many years, it has been broadly known that the satellite cells in skeletal muscle 
provide the extra nuclei for post-natal growth. (Moss and Leblond, 1971; Schultz, 
1976; Zammit et al, 2006). The satellite cells are the primary stem cells in adult 
skeletal muscle; they are responsible for postnatal muscle growth, regeneration, repair 
and hypertrophy (Dhawan and Rando, 2005, Zammit et al, 2006). Therefore, the 
satellite cells are also called muscle stem cells (Collins and Partridge, 2005).
The mononucleated / activated satellite cells express M-Cadherin and CD 34. When 
the satellite cells are activated, they commence to co-express c-met, MyoD, myf5, 
Desmin, Pax-3, Pax-7 and later myogenin, and become intermediate progenitors and 
fusion competent myoblasts, subsequently they fuse and differentiate to myotubes 
(Dhawan and Rando, 2005). Two families o f myogenic basic helix-loop-helix (bHLH) 
transcription factors regulate above biochemical differentiation: (a) the myogenic 
regulatory factors (MRFs) including MyoD, myogenin, Myf-5 and MRF4, and (b) 
myocyte enhancer factor 2 (MEF) proteins, and other transcription factors such as 
Pax-3 and Pax-7. MyoD and myogenin are among the most important factors o f those 
regulatory factors. Therefore, the levels o f mRNA transcripts o f such markers 
demonstrated satellite cell activation in this study.
Since quantitative real-time RT-PCR technique was first developed by Higuchi et al 
in 1993 (Higuchi et al, 1993), the technique has being increasingly used for the 
quantification o f specific mRNA expression. The quantitative real-time RT-PCR 
technique with SYBR Green I fluorescent dye is highly sensitive and it allows 
quantification o f transcripts even in very low abundance.
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This study demonstrated that both MyoD and myogenin transcript levels were higher 
in MGF treated young mdx mice muscle tissues compared to uninjected control 
muscles of the same animals. In this way, the study showed that MGF activated 
muscle satellite cells o f mdx mice, particularly in young animals. In contrary, transfer 
o f IGF-I did not stimulated the expression o f satellite cell markers. The effectiveness 
o f MGF was apparently in the satellite cell activation. Hill and Goldspink also showed 
this effect in rats. Hill and Goldspink’s data showed that MGF clearly activated 
quiescent satellite cells (Hill and Goldspink, 2003a, Hill et al, 2003b). This study 
indicated that MGF initiates the activation o f muscle satellite (stem) cells. The study 
also showed that the effect o f MGF in satellite cell activation by investigating satellite 
cell markers expression in young mdx mice was higher and / or clearer than those of 
old animals.
In summary, this study found that MGF significantly increased myoblast proliferation 
in animal myoblast cell lines and primary cultured human myoblast, in both healthy 
and degenerative muscles from CMD, FSHD and ALS. The study also found MGF 
probably have another signalling pathway, and it used another receptor rather than 
type 1 IGF receptor. The study showed again that MGF increased muscle growth by 
gene transfer way, and also increased satellite cell activation. The hypothesis o f in 
vitro part of this study was that the E domain o f MGF, in comparison with IGF-I 
mature peptide, influences cell proliferation and prevents myogenic differentiation in 
primary cultured muscle cells from patients with CMD, FSHD and ALS, and rodent 
muscle cell lines. In vitro data o f this study confirmed this hypothesis.
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On the other hand, second hypothesis was that the coding sequence o f MGF, in 
comparison to the coding sequence o f IGF-I Ea, improves the maximum tetanic 
contractile force o f muscles by activating satellite cells in the mdx mouse. In vivo data 
of this study also confirmed this hypothesis.
Consequently, one aims o f this study was to find a way to treat degenerative muscles 
in neuromuscular disorders. This study showed that MGF has a potential as a 
therapeutic agent to treat muscle degeneration in neuromuscular disorders, such as 
DMD, CMD, FSHD and also ALS.
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Chapter 6:
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Chapter 6 -  Part 1:
6.1 Conclusion
6.1 Conclusion
Skeletal muscle is highly regenerative tissue, and for a while, it has become main 
target for gene therapy applications. This study also attempted to develop a novel 
gene therapy application to treat muscle degenerating in neuromuscular disorders 
using IGF-I splice variants. For this aim, the effects of IGF-I splice variants (IGF-I Ea 
and MGF) were investigated in animal and human skeletal muscles in vitro and in 
vivo. In order to study the effects o f the splice variants of the gene in vitro, along with 
rodent myoblast cell lines, primary cultured healthy and degenerative human muscle 
cells were investigated. This study found that MGF had a dramatic effect on myoblast 
proliferation, both in mouse and human muscles. MGF increased myoblast 
proliferation significantly in both healthy and degenerative muscles from CMD, 
FSHD and ALS patients. The study also demonstrated that MGF and IGF-I have 
antagonist effect. IGF-I Ea increased myoblast differentiation (myotube formation), 
whilst MGF increased myoblast proliferation and prevent the differentiation. 
Moreover, the study showed that MGF had a different signalling pathway than 
systemic / liver type IGF-I variant. In addition, the study found that the ratios of
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myoblast o f degenerative muscles were very low when compare them to those of 
healthy muscles.
The effects o f such splice variants were also investigated in in vivo animal model of 
most common neuromuscular disorder, DMD, which was mdx mouse. After cDNAs 
of MGF and IGF-I Ea were introduced into skeletal muscles o f young and old mdx 
mice in plasmid / naked DNA, which is the main non-viral gene delivery system, the 
roles o f the variants, particularly that o f MGF were studied in muscle growth in 
strength and mass and satellite cell activation. The study showed that MGF 
dramatically increased muscle strength, particularly in young animals. MGF also 
increased satellite cell activation. In conclusion, the study firmly proposes that MGF 
has a potential as a therapeutic agent to treat muscle degeneration in neuromuscular 
disorders, such as DMD, CMD, FSHD and also ALS. Thus, gene therapy applications 
using MGF transfer into muscle can be an effective technique.
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Chapter 6 -  Part 2:
6.2 Suggestions for Future Investigations
In this study, the effects o f MGF were investigated only in muscle cells and tissues. 
However, recent data shows that MGF has also similar effects on different tissues and 
organs, including damage to cardiac muscles (G. Goldspink and S. Y. Yang, 
unpublished data; Dr Paul Goldspink o f Department o f Physiology and Biophysics, 
University o f Illinois College o f Medicine at Chicago -  USA, unpublished data) the 
CNS (Dluzniewska, 2005), periphery nerves (S. Y. Yang, unpublished data), 
endometrium (Prof Goldspink group, unpublished data), tendons and ligaments 
(Olesan et al 2006; Heinemeier et al, 2007). Recent years, MGF has become regarded 
as a general tissue repair factor. However, the data about the action o f MGF on 
different tissues and organs are still very limited. Therefore, in vitro and in vivo 
actions o f MGF on such tissues and organs with certain conditions should be 
investigated.
Recent investigations found that MGF also has some neurotrophic effects, and it 
significantly increases motor neuron survival (Aperghis et al, 2004; Dluzniewska,
2005). The in vitro data in this study was also supported these findings. MGF 
dramatically increased activated mononucleated satellite cell proliferation in primary
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muscle cell from ALS patients. These effects should be investigated in vivo animal 
models of ALS, such as SOD1 mouse. The MGF expression in ALS might be also 
investigated in resting and mechanically stimulated muscle and neuron cells from both 
human and animals with and without ALS.
This study demonstrated that MGF probably has a different receptor-mediated 
pathway to the systemic liver type IGF-I (IGF-I Ea). The pathways o f MGF (both 
receptor-mediated and signalling pathways) are unknown. In order to learn 
effectiveness mechanism o f MGF, to investigates MGF pathways therefore vital.
Up to date, E domains o f IGF-I peptides, including MGF, has not been demonstrated 
in blood circulation. Only mature IGF-I peptide has been seen in circulation. 
However, it is known that the level o f mature IGF-I peptide increases after heavy 
exercise, and major IGF-I supply tissue is skeletal muscle during exercise. However, 
this has binding proteins which bind the IGF-I domain which stabilize it and act as a 
time release mechanism. It seems that during exercise, MGF expression significantly 
increases in skeletal muscle during heavy exercise and then, E domain o f MGF are 
probably cleaved at specific sites by some proteases and this may stay within the basal 
lamina o f the fibres. The mature peptide o f MGF may leave the cell and enter the 
blood circulation whilst the E domain o f MGF probably goes to only a little further to 
activate the satellite cells that are within basal lamina of each fibre. These 
mechanisms should also be investigated.
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It appears that MGF signalling is different to IGF-I Ea; there is much work needed to 
investigate their different cellular mechanisms. Because o f their therapeutic potential 
for treating muscle wasting, this effort would be worthwhile.
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Appendix -1 :  Additives for MCGM (Muscle Cell Growth Medium)
ADDITIVES STOCK SOLUTIONS FINAL SOLUTIONS
EGF 20 pg/ml 10 ng/ml
bFGF 2 pg/ml 2 ng/ml
Low Insulin 100 pg/ml 5 ng/ml
Dexamethasone 390 pg/ml 390 ng/ml
Feutin 50 mg/ml 50 pg/ml
Vitamin E (Trolox) 25 mg/ml 25 pg/ml
Vitamin C 100 mg/ml 50 pg/ml
Vitamin H (D-Biotin) 100 mg/ml 250 ng/ml
Transferrin 5 mg/ml 5 pg/ml
Sodium Selenite 100 pg/ml 5 ng/ml
Albumax-1 20 % sol. (200 mg/ml) 500 pg/ml
Penicillin / Streptomycin 10 000 U/ml or (50 mg/ml) 500 pg/ml
Long r3 IGF-I 2 mg/ ml various
MGF 1 mg/ml various
DMEM Serum free medium -
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Appendix -  2: In Vitro Primary Cell Culture Data
HEALTHY
CRANIOFACIAL
MUSCLE Cont
Cont + 
Ab-I MGF
MGF + 
Ab-1 IGF-I
MGF + 
IGF-I
53.09735 52.58621 70.12448 76.99531 55.88235 60.43478
50.93633 49.79079 72.58065 77.19298 52.17391 56.50558
52.22672 50.36765 71.21951 75 58.41121 58.54701
45.89372 47.44526 70.12448 62.67281 63.30645 56.84647
47.34513 41.12554 66.26506 69.41581 59.82143 61.70213
49.37238 42.22222 69.09722 65.38462 66.28352 60.96491
50.2439 67.17557 59.07173 61.27451
50.93633 66.51584 58.59031
48.0198 59.03084 54.43548
69.62617 55.81395
73.55769
65.91928
73.23232
HEALTHY 
LIMB MUSCLE Control (%) MGF (10) ("/•) IGF-I (10) (%)
MGF (10) + IGF-I 
(10) (%)
35.55556 55.14019 43.63636 38.68613
39.86486 59.00621 52.43902 38.28125
40.41096 54 48.40183 39.49045
41.04046 60.37736 43.18182
39.24051 55.26316 46.26866
35.06494 61.70213 48.6911
41.08108 55.05051
35.20408 62.56983
38.38384 57.79221
CMD Cont (•/•)
Cont+Ab-I
(•/.) MGF (%)
MGF + 
Ab-1 (%) IGF-I (%)
MGF + 
IGF-I (%)
9.615385 10.52632 19.71831 16.39344 11.66667 12.69841
13.33333 8.62069 17.1875 14.51613 13.11475 12.90323
9.433962 10.16949 15.71429 18.84058 15.87302 11.47541
9.803922 10.34483 16.39344 17.1875 13.46154 14
11.53846 10.14493 18.42105 11.76471 14.58333
8.695652 11.11111
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ALS Cont (%)
Cont + 
Ab-1 (%) MGF (•/•)
MGF + 
Ab-1 (•/•) IGF-I (%)
MGF + 
IGF-I (%)
6.5 5 7 7 3 5
5 7 8 6 3 5
3 3 7 6 5 3
4 5 8 6 5 5
5 5 6 6 6 6
5 6 7 8 6 6
6 8 6 6
4 8 5 6
5 6 5
FSHD Control (*/•) MGF (10) (%) IGF-I (10) (%) MGF + IGF-I (•/.)
12 22 14 13
12 22 15 14
13 23 15 13
10 21 16 15
13 19 12 16
12 17 15 16
10 19 12
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Appendix -  3: TA Muscle Force Measurements after Gene Transfer 
Young mdx muscle force measurements
I V ector -  only group |  IGF-I Ea group |  MGF group |
Untreated
(control)
Treated
(Exp)
Untreated
(control)
Treated
(Exp)
Untreated
(control)
Treated
(Exp)
1 170.6097 155.176 48.5282 41.02167 100.3291 95.99235
2 46.50255 81.57908 50.65128 36.95866 86.42602 90.3801
3 134.0026 104.4107 24.36758 38.93613 106.1964 117.676
4 129.5383 70.99235 32.66584 43.32933 69.46173 115.5077
5 96.375 125.7117 42.48676 41.51977 95.60969 112.574
6 68.95153 80.30357 40.89591 55.22658 114.2321 178.773
7 77.625 80.04847 50.46212 48.79844 71.375 135.1505
8 35.1604 65.28537 72.14031 137.3189
Mean 103.3721 99.74599 40.65226 46.38449 89.4713 122.9216
Inc (%) - 3.63% 14.10% 37.38%
p val. (NS) 0.783 (NS) 0.292 (S) 0.014
Old mdx muscle force measurements
| V ector -  only group | IGF-I Ea group j MGF group
Untreated
(control)
Treated
(Exp)
Untreated
(control)
Treated
(Exp)
Untreated
(control)
Treated
(Exp)
1 24.11499 38.04082 63.56138 69.46647 59.78204 66.63198
2 52.22341 59.30957 57.18371 62.85267 62.61654 69.46643
3 62.85264 60.96906 47.57806 63.79747 69.23028 64.97724
4 45.84587 46.08208 65.92334 62.61645 62.38033 68.28546
5 60.72684 80.10179 90.48305 81.27668 12.77804 20.09949
6 78.28647 47.45061 58.60106 85.05608 64.01909 72.99375
7 56.71138 59.07347 59.54579 69.21746
8 62.75821 66.39575
Mean 54.00837 55.32565 62.85002 68.81688 55.76459 61.6674
Inc (%) 2.44% 9.49% 10.58%
p val. (NS) 0.862 (NS) 0.211 (S) 0.015
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Appendix -  4: Mdx TA Muscles Weights after Gene Transfer
Young Mdx TA Muscles Weights
VECTOR-ONLY IGF-I Ea MGF
Cont. (mg) Exp. (mg) Cont. (mg) Exp. (mg) Cont. (mg) Exp. (mg)
1 40 40 48 48 36 43
2 30 39 48 55 46 56
3 28 29 49 55 32 33
4 34 32 53 53 36 33
5 47 43 55 61 41 48
6 23 29 48 57 29 29
7 37 37 76 80 34 46
8 44 41 65 60 43 46
Mean 35.4 36.2 55.2 58.6 37.1 41.7
Inc (%) 100 102 100 106 100 113
p val. (NS) 0.598 (NS) 0.079 (S) 0.040
Old Mdx TA Muscles Weights
VECTOR-ON LY IGF-I Ea MGF
Cont. (mg) Exp. (mg)
Cont.
(mg) Exp. (mg)
Cont.
(mg) Exp. (mg)
1 59 61 91 92 88 90
2 85 70 89 95 91 95
3 75 64 88 92 92 99
4 78 79 88 87 76 86
5 87 90 80 81 65 70
6 75 74 80 80 70 80
7 92 94 89 89
8
Mean 76.5 73 86.8 88.7 81.6 87
% 100 95 100 102 100 107
p val. (NS) 0.309 (NS) 0.087 (S) 0.009
324
Appendix -  5: Expression of Satellite Cell Markers after Gene Transfer
Young Mdx MyoD Expression Data by RT-PCR 
(MyoD copy number / 0-actin copy number ratios)
L Vector-only I IGF-I Ea I MGF
ll ntreated Treated | Untreated Treated | Untreated Treated |
1 9.95E-01 2.57E-01 1 5.63E-01 2.63E-01 1 3.99E-01 3.86E+01
2 4.41 E-01 5.88E-01 2 6 .44 E-01 6.62E-01 2 6.36E+00 9.38E+00
3 8.09E+00 1.11E+00 3 2.43E-01 4.27E-01 3 4.56E-02 5.12E+01
4 2.03E+00 5.10E+00 4 7.34E-01 2.08E-01 4 4.43E-02 6.27E-01
5 3.75E-02 2.30E-03 5 2.43E-01 1.70E-01 5 5.27E-01 6.91 E-01
6 2.04E+00 1.77E+01 6 2.44E-01 2.72E-01 6 3.38E-01 4.28E+00
7 3.62E-01 3.68E-03 7 6.10E-01 2.90E-01 7 4.24E-01 1.98E+00
8 8 4.47 E-01 6.08E-01 8 2.04E-02 1.02E+00
Mean 2.00E+00 3.54E+00 4.66E-01 3.62E-01 1.02E+00 1.35E+01
St Err 1.06E+00 2.46E+00 7.11E-02 6.52E-02 7.66E-01 7.03E+00
m i ­ (NS) 0.578 (NS)0.285 (NS)0.125
Young Mdx Myogenin Expression Data by RT-PCR 
(Myogenin copy number / p-actin copy number ratios)
| Vector-onl^ | IGF-I^Ea I MGF
Untreated Treated | Untreated Treated | Untreated Treated |
1 1.52E-01 3.94E-02 1 2.08E-01 1.03E+00 1 2.23E-01 1.60E+01
2 4.41 E-04 1.00E+00 2 1.90E+00 7.67E+00 2 2.04E+00 1.29E+01
3 2.82E-01 1.90 E-01 3 1.11 E-01 2.14E+00 3 5.51 E-02 4.68E+00
4 2.60E+00 1.71 E+00 4 4.51 E+00 2.31 E+00 4 7.68E-02 1.79E+00
5 3.69E-02 1.13E+00 5 4.10E+00 2.31 E+00 5 1.02E-01 1.57E+00
6 9.86E-01 5.72E-03 6 3.28E-01 1.79E-01 6 4.40E-01 5.43E+00
7 1.53E-01 1.60E+00 7 3.30E-01 1.81 E-01 7 1.71 E-01 2.31 E+01
8 8 2.02E+00 5.73E-01 8 7.98E-02 1.33E+01
Mean 6.01 E-01 8.11 E-01 1.69E+00 2.05E+00 3.98E-01 9.84E+00
St Err 3.56E-01 2.76E-01 6.31 E-01 8.66E-01 2.38E-01 2.72E+00
p val. (NS) 0.59 (NS) 0.707 (S) 0.009
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Old Mdx MyoD Expression Data by RT-PCR 
(MyoD copy number / p-actin copy number ratios)
Vector-only IGF-I Ea MGF
Untreated Treated Untreated Treated T Untreated Treated
1 1.07E+02 5.15E+01 1 1.26E+01 2.05E-02 1 1.08E-01 2.63E+00
2 4.69E-01 3.23E+00 2 1.17E-02 3.00 E-02 2 1.12E-01 2.91 E-01
3 1.13E-01 8.32E-02 3 1.36E-02 6.53E-01 3 1.20E-01 1 22E-02
4 8.76E-01 1.12E-02 4 5.61 E-02 1.09E-02 4 2.56E-01 6.33E-01
5 2.16E-01 2.34E-02 5 1.24E-02 2.20E-01 5 1.55E+00 7.67E+00
6 6 1.65E-02 1.47 E-02 6 5.78E-01 1.41 E+00
7 7 9.77E-03 1.69E-01 7 3.12E-01 9.48 E-01
Mean 2.17E+01 1.10E+01 1.81 E+00 1.60E-01 4.33E-01 1.94E+00
St Err 2.12E+01 1.02E+01 1.79E+00 8.81 E-02 1.09E+01 3.34E-01
p val. (NS) 0.391 (NS) 0.398 (NS) 0.12
Old Mdx Myogenin Expression Data by RT-PCR 
(Myogenin copy number / p-actin copy number ratios)
Untreated Treated | Untreated Treated | Untreated Treated |
1 9.36E+00 1.14E+00 1 5.77E+00 2.87E-02 1 2.07E-03 4.30E-01
2 1.59E-01 4.31 E+00 2 7.02 E-02 8.20E-02 2 1.27E-01 3.55E-01
3 1.31 E-01 1.31 E-01 3 3.93E-02 3.14E-01 3 4.46E-03 1.89E-01
4 1.08E+00 8.41 E-02 4 1.04 E-01 8.11 E-02 4 2.03E-01 2.73E-01
5 1.05E+00 1.50 E-02 5 6.17E-02 2.03E-01 5 1.59E+00 3.12E+00
6 6 6.35E-02 3.31 E-03 6 1.55E-01 4.99E-01
7 7 6.96E-02 1.56E-01 7 4.13E-02 5.40E-01
Mean 2.35E+00 1.14E+00 8.83E-01 1.24E-01 3.04E-01 7.72E-01
St Err 1.76E+00 8.20E-01 8.15E-01 4.10E-02 2.17E-01 3.94E-01
p val. (NS) 0.573 (NS) 0.396 (S) 0.044
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Appendix -  6: List of Publications
Peer reviewed papers:
1- Kenan Ates, Shi Yu Yang, Richard W. Orrell, Andrea C. M. Sinanan, Paul Simons,
Andrew Solomon, Steven Beech, Geoffrey Goldspink and Mark P. Lewis. IGF-I splice 
variant, (MGF) increases progenitor cells in ALS, dystrophic and normal muscle. FEBS 
Letters (in press).
2- Ates, K., Yang, S. Y., Lewis, M., and Goldspink, G. Changes in muscle regulatory factors 
in mdx murine skeletal muscle following intramuscular transfer of the cDNA of the IGF-IEa 
and MGF splice variants of the IGF-I gene. Journal o f Physiology (submitted, under 
consideration).
3- Yang, S. Y. *, Ates, K. *, Beech., S., and Goldspink, G. Increased contractile force in mdx 
murine skeletal muscle following intramuscular transfer of the cDNA of two splice variants of 
IGF-I. Journal o f Physiology (submitted, under consideration).
(* both authors made an equal contribution)
Published abstracts:
1- G. Goldspink, K. Ates, S. Y. Yang, R. T. Jaspers, J. Weaden R. W. Orrell. (2005) MGF (a 
splice variant of IGF-I) increases satellite cell number and kick starts the hypertrophy process 
in normal and atrophic muscle. FASEB Summer Research Conference 2005,4rd International 
Conference on Skeletal Muscle Satellite and Stem Cells, Omni Tucson National Golf Resort 
& Spa, Tucson, AZ, US (June 11-16, 2005)
2- K. Ates, S. Yang, A. Sinanan, G. Goldspink and M. Lewis. (2006) Effects of MGF on 
human muscle stem cell proliferation in dystrophic, ALS and healthy human muscle, FEBS 
Journal. 273 (si), 128. 31. International FEBS Congress on Molecules in Health and 
Disease, Istanbul, Turkey (24-29 June 2006)
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